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EXECUTIVE
SUMMARY
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Introduction Cervical cancer poses a serious health threat to
sexually active women, especially in low and middle income coun-
tries (LMIC) where screening opportunities are often low and treat-
ment remains inaccessible for most of the affected women. Primary
prevention through human papillomavirus (HPV) vaccination may
therefore provide a turning point in the battle against cervical can-
cer. However, prior to implementing large-scale vaccination pro-
grammes, several knowledge gaps need to be addressed. There-
fore, formative research has been conducted measuring (hypothet-
ical) acceptability and identifying potential barriers to successful
implementation. In general, the vaccine is well accepted, with main
reported barriers costs and fear of side effects.
The introduction of the HPV vaccine gave indeed rise to many
studies gauging the public's perspectives, often applying health be-
haviour theories such as the Health Belief Model (HBM) to identify
determinants of acceptability (i.e. susceptibility and severity of cer-
vical cancer, barriers and benefits of the vaccine, self-efficacy, and
cues to action). However, most of these studies took place in in-
dustrialized regions and did not measure HPV vaccine uptake. As
such, several questions arise: 1) Is the HPV vaccine acceptable in
low-income countries, where they can have most impact, and are
the determinants similar? - 2) Does high acceptability always lead
to high HPV vaccine uptake, i.e. the true outcome of interest? In
order to answer them, a study with three objectives was set up.
Objectives
• Objective 1: To determine the acceptability and subsequent
uptake of the HPV vaccine in the context of an HPV pilot
vaccination programme in Eldoret, Kenya.
• Objective 2: To ascertain whether health behaviour theories
can be effectively applied to predict HPV vaccination in El-
doret, Kenya.
• Objective 3: To identify factors that influence successful intro-
duction of an HPV vaccination programme in Eldoret, Kenya.
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Study design A longitudinal study was rolled-out, with baseline
and follow-up taking place before and after the implementation of
an HPV vaccination effort. The programme freely offered the HPV
vaccine to girl pupils of primary schools in Eldoret: the vaccine
was administered in the referral hospital but promotion was done
at school by teachers. A cohort of randomly selected mothers of
these eligible girls was set up and invited to participate twice in a
quantitative interview regarding cervical cancer prevention. HPV
vaccine acceptability was measured at baseline while uptake got re-
ported at follow-up. This design allowed studying acceptability and
uptake, including the relation between these two main outcomes.
In addition, a qualitative component was implemented at follow-up,
evaluating the programme from the perspective of key-informants.
Results The HPV vaccination programme took place from May
2012 until March 2013. Baseline and follow-up data were collected
two months before and after the programme, in March 2012 and
May 2013, respectively. Of the 287 women interviewed in 2012, 89.2
percent (256/287) agreed to be interviewed again the next year. Also
focus group discussions were organized in May 2013, with fathers (3),
teachers (4) and vaccinators (1).
While acceptability of the HPV vaccine among the mothers was
very high at baseline (88 percent accepted), only 31 percent had
eventually vaccinated their daughter, and 51 percent reported that
they had wanted to vaccinate but had missed the opportunity. Res-
ults showed that among this latter group, 55 percent had not re-
ceived information regarding the whereabouts of the programme.
Finally, among those who had actively decided not to vaccinate (18
percent), 42 percent mentioned fear of side effects as barrier and 31
percent said the partner opposed to vaccinating the daughter against
cervical cancer. In general, the majority of the participants reported
that unknown side effects made them doubt about HPV vaccination
and that they needed more information in order to make an informed
decision.
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No strong relation was found between HPV vaccine acceptabil-
ity and vaccination. Also with regard to the applicability of the
Health Belief Model (HBM), no associations were found between
the constructs and uptake, except for self-efficacy which positively
influenced vaccination. The predictive value of the model did in-
crease after adding a variable reporting whether or not the mother
had received adequate information; being well-informed led to higher
vaccine uptake.
The qualitative data revealed that teachers and fathers had poor
knowledge regarding cervical cancer and felt rather uncomfortable
sharing information about it. This had also led to poor communic-
ation regarding the vaccination programme. Teachers also missed
support of health care providers to address the questions of the par-
ents as well as their own doubts. In general, HPV vaccination was
not considered important given that cervical cancer was perceived
as a consequence of a modern lifestyle with which the participants
did not feel related. Finally, distrust towards (new) vaccines also
hampered uptake: some thought it was an experiment while others
had lost faith in vaccines during previous vaccination experiences.
Suspicion did however fade away after a couple of months, once the
community was convinced about the safety of the vaccine.
Discussion HPV vaccine acceptability was not a strong predictor
of vaccine uptake. The translation of intention into behaviour was
mainly hampered because information about the vaccination pro-
gramme did not reach all parents. Limited knowledge regarding
HPV and cancer and cultural taboo made it difficult for teachers
and parents to discuss HPV vaccination. Therefore, direct commu-
nication of health care providers with caregivers seems crucial as
the former is better posted to discuss such topics. Moreover, fail-
ure of achieving such a contact moment did not only lead to poor
uptake but also allowed the spread of rumours and doubts. Future
programmes will need to have more attention for two-way commu-
nication, to address misbeliefs, as opposed to the top-down approach
usually used.
5
So while HPV vaccine uptake was lower than expected, mainly
due to organizational reasons, HPV vaccine acceptability reported
at baseline might have been overestimated because of several factors.
First of all, given that awareness regarding cervical cancer and HPV
vaccination is generally low in Kenya, some participants were prob-
ably overtaken by the new information which interfered with their
estimation of intention, tending to overvalue (also partly due to so-
cial desirability). In addition, people may overestimate their inten-
tions - especially for new behaviours barriers are hard to predict -
or express a desire rather than a true plan of action. Finally, given
the novelty of HPV vaccination, it is not always clear who will take
the final decision and as reported by the women in the quantitative
study, in the end many fathers had an important role in the decision-
making. As a result, women were not in control of the behaviour
meaning that their intentions were no longer relevant as predictor
for the vaccination status of the daughter.
Taken all together, the poor vaccine uptake, due to promotional
flaws, combined with the high reported acceptability led to an im-
balance in the relation acceptability-uptake which was mainly driven
by low acceptability leading to non-uptake, rather than by acceptors
fulfilling their own reported objectives.
Similar to acceptability, also the HBM constructs were poor de-
terminants of uptake. Given that these measurements only assess
personal beliefs and attitudes, and given the above-mentioned im-
portance of programmatic strategies, adding variables beyond the
personal perspective, at the organizational level, might improve the
predictive value of the theory. In addition, also the value of each
of the constructs can be questioned. Regarding the absence of a
correlation of uptake with severity and susceptibility, this is not so
surprising given the Kenyan context: access to high quality care is
limited and diseases often remain untreated which makes them more
life-threatening. Especially (cervical) cancer is considered deadly.
As such, perceiving cervical cancer as a threat is common and, con-
sequently, does not distinguish those who vaccinate against HPV
and those who don't. With regard to foreseen benefits and barriers,
one can wonder how reliable people's estimates can be regarding the
advantages and disadvantages of a new, unknown vaccine. By meas-
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uring users' and non-users' perspectives, more realistic determinants
might be identified. Also trust in the vaccine or in the health sys-
tem might be a stronger predictor, given that people rely on past,
medical experiences. Also self-efficacy, which was positively associ-
ated with vaccine uptake, can be considered as trust, in oneself, to
perform the desired behaviour.
By focussing promotion on increasing trust, but also by choosing
a delivery platform that instils confidence and convenience, vaccine
uptake could thus potentially increase. A carefully designed pro-
gramme should indeed take into account vaccine confidence, compla-
cency and convenience and address them by both tailored promotion
and adequate vaccine delivery. In the context of the HPV vaccina-
tion programme in Eldoret however, none of the three C's seemed
to be properly fulfilled: some people distrusted the vaccine and the
health providers in the referral hospital, cervical cancer was not al-
ways seen as a threat (whereas the vaccine had potential side effects)
and offering the vaccine in a health centre was not considered the
most convenient approach. School-based vaccination seemed more
preferred but good cooperation between health staff and the teachers
corpse will be crucial to obtain good coverage.
Conclusion Measuring HPV vaccine acceptability and its determ-
inants is not sufficient to predict uptake. More attention should
go to other important factors such as vaccine confidence or more
broadly, vaccine hesitancy. In addition, variables beyond personal
control contribute significantly to vaccine uptake pointing out the
need to complement formative research - mostly conducted prior to
implementation and based on personal health behaviour theories 
with monitoring vaccination programmes and assessing users' and
non-users' perspectives.
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Deel II
SAMENVATTING
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Inleiding Baarmoederhalskanker vormt een ernstig gezondheidsri-
sico voor seksueel actieve vrouwen, in het bijzonder in ontwikkelings-
landen waar de mogelijkheden tot opsporing ervan vaak beperkt zijn
en waar de meeste vrouwen geen toegang hebben tot behandeling.
Primaire preventie door middel van vaccinatie tegen het humaan pa-
pillomavirus (HPV) kan daarom een kantelpunt vormen in de strijd
tegen baarmoederhalskanker. Vooraleer er echter grootschalige vac-
cinatieprogramma's kunnen worden opgezet, dienen er wel een aan-
tal kennishiaten weggewerkt worden. Met het oog hierop wordt er
formatief onderzoek gevoerd om naar de (hypothetische) aanvaard-
baarheid te peilen en om potentiële barrières voor een succesvolle
implementatie te identificeren. Daaruit blijkt dat het vaccin in het
algemeen goed aanvaard wordt en dat de kosten en de vrees voor
bijwerkingen de vaakst gerapporteerde barrières zijn.
De introductie van het HPV vaccin leidde dus tot veel studies die
de publieke opinie ten opzichte van het vaccin willen meten. Derge-
lijke studies maken vaak gebruik van het Health Belief Model (HBM)
om determinanten van aanvaarding na te gaan (nl. vatbaarheid voor
en ernst van baarmoederhalskanker, de voor- en nadelen van HPV-
vaccinatie, eigen-effectiviteit en prikkels of `cues' die aanzetten tot
actie). De meeste van deze studies vonden echter plaats in ontwik-
kelde regio's en omvatten geen informatie omtrent de opname van
het HPV-vaccin. Dit leidt tot meerdere vragen : 1) Is het HPV-
vaccin ook aanvaardbaar in lage-loonlanden, waar het de grootste
impact kan genereren, en zijn de determinanten vergelijkbaar? -
2) Leidt een hoge aanvaarding altijd tot een hoge opname van het
HPV-vaccin, wat uiteindelijk de werkelijk beoogde uitkomst is? Om
deze vragen te kunnen beantwoorden, is een studie opgezet, die drie
doelstellingen omvat.
Doelstellingen
• Doelstelling 1: Bepalen van de aanvaardbaarheid en de daar-
opvolgende opname van het HPV-vaccin in de context van een
HPV-piloot-vaccinatieprogramma in Eldoret, Kenia.
• Doelstelling 2: Nagaan of theorieën omtrent gezondheidsge-
drag effectief kunnen toegepast worden om HPV-vaccinatie in
Eldoret, Kenia, te voorspellen.
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• Doelstelling 3: Identificeren van factoren die een invloed heb-
ben op een succesvolle introductie van een HPV-vaccinatie-
programma in Eldoret, Kenia.
Opzet van de studie Een longitudinale studie werd opgezet, met
baseline en opvolging net voor en na de implementatie van een HPV-
vaccinatieprogramma. Het programma bood gratis HPV-vaccinatie
aan meisjes leerlingen van basisscholen in Eldoret: het vaccin werd
toegediend in het referentieziekenhuis, maar de promotie gebeurde
op de scholen, door leerkrachten. Via willekeurige selectie werd een
cohorte opgezet van moeders van de meisjes die in aanmerking kwa-
men voor het vaccin. De moeders werden tweemaal uitgenodigd om
deel te nemen aan een kwantitatief interview over preventie van baar-
moederhalskanker. De aanvaardbaarheid van het HPV-vaccin werd
gemeten op baseline, en de vaccinatiestatus werd gerapporteerd bij
de vervolgmeting na afloop van het programma. Deze aanpak liet toe
om aanvaarding en opname van het HPV-vaccin te bestuderen, als-
ook de relatie tussen deze twee eindvariabelen. Daarnaast werd een
kwalitatieve component toegevoegd aan de opvolgingsstudie, waarbij
het programma werd geëvalueerd door sleutelfinformanten.
Resultaten Het HPV-vaccinatieprogramma vond plaats van mei
2012 tot en met maart 2013. Baseline- en opvolgingsdata wer-
den verzameld, respectievelijk twee maanden voor en na het pro-
gramma. Van de 287 vrouwen geïnterviewd in 2012, ging 89,2 per-
cent (256/287) het jaar nadien akkoord om opnieuw geïnterviewd te
worden. Daarnaast werden focusgroepdiscussies georganiseerd met
vaders (3), leraars (4) en vaccinatoren (1).
Waar de aanvaarding van het HPV-vaccin bij de moeders op ba-
seline zeer hoog was (88 percent), liet uiteindelijk slechts 31 percent
hun dochter vaccineren; 51 percent rapporteerde dat ze haar hadden
willen laten vaccineren, maar de kans daartoe toch gemist hadden.
De resultaten toonden aan dat bij deze laatste groep, 55 percent geen
praktische informatie had ontvangen over het programma. Bij dege-
nen die bewust beslist hadden niet te vaccineren (18 percent), had
42 percent angst voor bijwerkingen en gaf 31 percent aan dat hun
partner zich had verzet tegen het vaccineren van hun dochter. In het
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algemeen gaf de meerderheid van de deelnemers aan dat ongekende
bijwerkingen hen hadden doen twijfelen over HPV-vaccinatie en dat
ze meer informatie nodig hadden om een doordachte beslissing te
kunnen nemen.
Er werd geen sterk verband gevonden tussen aanvaarding van het
HPV-vaccin en vaccinatiegedrag. Wat betreft het HBM, werden er
evenmin verbanden gevonden tussen de constructen en opname van
het vaccin, behalve voor zelf-effectiviteit, wat een positieve invloed
had op vaccinatie. De voorspellende waarde van het model ver-
hoogde wel nadat een variabele werd toegevoegd die aangaf of de
moeder al dan niet adequate informatie had ontvangen; goed geïn-
formeerd zijn leidde tot een hogere vaccin opname.
De kwalitatieve data toonden aan dat leerkrachten en vaders een
zwakke kennis hadden over baarmoederhalskanker en zich niet com-
fortabel voelden bij het delen van informatie daaromtrent. Dit had
ook geleid tot beperkte communicatie omtrent het vaccinatiepro-
gramma. Voor leraars ontbrak het ook aan steun van gezondheids-
werkers om een antwoord te kunnen bieden op vragen van ouders,
en om hun eigen twijfels weg te nemen. In het algemeen werd HPV-
vaccinatie niet belangrijk geacht, gezien baarmoederhalskanker werd
beschouwd als een gevolg van een moderne levensstijl die, volgens
de deelnemers, niet van toepassing was op hen. Tot slot werd op-
name van het vaccin ook gehinderd door wantrouwen ten opzichte
van (nieuwe) vaccins: sommigen dachten dat het om een experiment
ging, terwijl anderen hun vertrouwen in vaccins reeds verloren had-
den bij vorige ervaringen met vaccinatie. Na een paar maand werd
die achterdocht echter minder, eens de gemeenschap overtuigd was
van de veiligheid van het vaccin.
Discussie Aanvaarding van het HPV-vaccin leidde niet steeds tot
vaccinatie. De omzetting van intentie naar gedrag werd voornamelijk
gehinderd doordat de informatie over het vaccinatieprogramma niet
alle ouders bereikte. De communicatie over HPV-vaccinatie tussen
leerkrachten en ouders werd bemoeilijkt door de gebrekkige kennis
over HPV en kanker en door het culturele taboe. Directe communi-
catie tussen een gezondheidswerker en de ouders lijkt daarom cru-
ciaal, gezien de gezondheidswerker beter geplaatst is om dergelijke
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onderwerpen te bespreken. Het niet verwezenlijken van een derge-
lijk contactmoment, leidde niet alleen tot een lage opname, maar
liet ook toe dat er geruchten en twijfels omtrent HPV-vaccinatie
verspreid werden. Toekomstige programma's zullen meer aandacht
moeten geven aan tweerichtingscommunicatie, ten opzichte van de
gebruikelijke top-down benadering.
Terwijl de opname van het HPV-vaccin lager was dan verwacht,
vooral omwille van organisatorische redenen, is het ook mogelijk
dat de aanvaardbaarheid van het vaccin, gerapporteerd op baseline,
te hoog werd ingeschat omwille van diverse factoren. Ten eerste,
sommige deelnemers werden wellicht overweldigd door nieuwe in-
formatie, gezien de kennis omtrent baarmoederhalskanker en HPV
over het algemeen vrij laag is in Kenia. Dit beïnvloedde hun eigen
inschatting van intentie waarbij ze geneigd waren om een hogere
intentie te rapporteren (ten dele ook te wijten aan het geven van
sociaal wenselijke antwoorden). Daarnaast werden eigen intenties
misschien overschat omdat het moeilijk is om barrières voor nieuw
gedrag te voorspellen, of misschien werd er eerder een wens dan
een werkelijk actieplan gerapporteerd. Uiteindelijk is het bij nieuw
gedrag ook niet steeds duidelijk wie de uiteindelijke beslissing zal ne-
men. Uit de kwantitatieve studie met de moeders bleek inderdaad
dat het de vaders waren die vaccinatie soms hadden tegengehouden.
Gezien vrouwen dus niet steeds de controle hadden over het al dan
niet vaccineren van de dochter, kunnen hun intentieverklaringen als
minder relevant beschouwd worden voor de uiteindelijke vaccinatie-
status van de dochter.
Men kan dus stellen dat de lage opname van het vaccin, om-
wille van falende promotie, gecombineerd met hoge gerapporteerde
aanvaarding, leidde tot een onevenwicht in de relatie aanvaarding-
opname. Die relatie werd namelijk voornamelijk gestuwd door niet-
aanvaarding die tot niet-opname leidde, eerder dan door aanvaarders
die hun eigen gerapporteerde doelstellingen verwezenlijkten.
Net zoals aanvaarding, bleken ook de variabelen van het HBM
zwakke determinanten van vaccinatie te zijn. Gezien deze facto-
ren enkel persoonlijke overtuigingen en attitudes weerspiegelen, en
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gezien het hogervermelde belang van programmatische strategieën,
zou de voorspellende waarde van de theorie verhoogd kunnen wor-
den door het toevoegen van variabelen op hogere niveaus dan het
persoonlijke perspectief. Daarnaast kan ook de waarde van elk van
de factoren van de theorie in vraag gesteld worden. Zo is de afwezig-
heid van een correlatie tussen opname van het vaccin, en vatbaarheid
en ernst niet echt verrassend, rekening houdend met de Keniaanse
context: toegang tot een kwalitatieve gezondheidszorg is beperkt, en
aandoeningen worden vaak niet behandeld, zodat ze meer levensbe-
dreigend worden. Zeker (baarmoederhals)kanker wordt als dodelijk
beschouwd. Baarmoederhalskanker als een bedreiging beschouwen
is dus een algemene manier van denken en maakt bijgevolg geen
onderscheid tussen diegenen die vaccineren tegen HPV en diegenen
die dat niet doen. Wat betreft de voorziene voordelen en barrières,
men kan zich afvragen hoe betrouwbaar iemands inschatting kan zijn
over de voor- en nadelen van een nieuw, ongekend vaccin. Door het
nagaan van de denkbeelden van gebruikers en niet-gebruikers, kun-
nen mogelijk meer realistische determinanten geïdentificeerd worden.
Ook vertrouwen, in het vaccin of in het gezondheidssysteem, zou
een sterkere voorspeller kunnen zijn, gezien mensen verder bouwen
op voorbije, gelijkaardige ervaringen met vaccinaties of met gezond-
heidszorg. Daarenboven kan ook zelf-effectiviteit, wat een positieve
determinant was van vaccinatie, beschouwd worden als vertrouwen,
in zichzelf, om het gewenste gedrag uit te voeren.
De opname van het vaccin zou verhoogd kunnen worden door
zowel via promotie als via een geschikt vaccinatieplatform het ver-
trouwen in vaccinatie te stimuleren en de toegankelijkheid te ver-
hogen. Een zorgvuldig ontworpen programma zou inderdaad ver-
trouwen en toegankelijkheid moeten garanderen, alsook de nadruk
leggen op de noodzaak van vaccineren. Binnen de context van het
HPV-vaccinatieprogramma in Eldoret, waren echter geen van deze
voorwaarden volledig vervuld: sommige mensen wantrouwden het
vaccin en de gezondheidswerkers in het referentieziekenhuis, baar-
moederhalskanker werd niet altijd als risico gezien (terwijl het vaccin
wel als potentieel gevaarlijk werd beschouwd) en het vaccin aanbie-
den in een ziekenhuis werd niet gezien als de meest geschikte, toe-
gankelijke benadering. Vaccinatie op school leek meer geprefereerd,
maar een goede samenwerking tussen gezondheidswerkers en het le-
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rarenkorps zal dan cruciaal zijn om een goede vaccinatiedekking te
bereiken.
Conclusie Het meten van HPV-vaccin aanvaarding en de deter-
minanten ervan is niet voldoende om opname van het vaccin te voor-
spellen. Meer aandacht dient te gaan naar andere belangrijke fac-
toren zoals vertrouwen in vaccins of, meer algemeen, een aarzelende
houding t.o.v. vaccineren. Gezien de vele variabelen die vaccinatie
beïnvloeden, maar die niet steeds onder de individuele controle val-
len, is het noodzakelijk om formatief onderzoek  dat veelal wordt
uitgevoerd vóór een vaccinatieprogramma van start gaat en geba-
seerd wordt op persoonlijke gedragstheorieën  aan te vullen met
het monitoren van vaccinatieprogramma's en het nagaan van de per-
spectieven van de gebruikers.
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Part III
INTRODUCTION
17
18
Chapter 1
HPV infections and the
burden of related diseases
Human papillomaviruses (HPV) cause a serious health threat to
men and women worldwide. Among the sexually transmitted in-
fections (STI), genital HPV infections are most common, hence the
heavy burden on global health. In this first chapter, HPV infections
will be discussed, more particularly their transmission mode and the
process from infection to malignant lesions such as cervical cancer.
Stipulating when most infections occur and which tend to be per-
sistent will also help clarifying the pathway of cancer development.
Secondly, cervical cancer incidence will be presented, with special
attention to the situation in Sub-Sahara Africa given that the study
presented in this thesis took place in Kenya. Finally, both secondary
and primary prevention techniques will be addressed, pointing out
their strengths and weaknesses.
1.1 Human Papillomavirus infections
Human papillomaviruses (HPV) are a group of small, non-enveloped,
double-stranded DNA viruses belonging to the family Papovaviridae.
There are over 150 different HPV types divided in five major HPV
genera: alphapapillomavirus, betapapillomavirus, gammapapilloma-
virus, mu papillomavirus and nu papillomavirus. They are perfectly
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adapted to invade oral mucosa or skin (representatives of all five
genera) or epithelial cells in genital mucosa (alphapapillomaviruses
only) [1].
While most of the HPV types are harmless, some types induce
malformations and even cancer. The causal link between these vir-
uses and cervical cancer was first established in 1991 by Harald
Zur Hausen, a German scientist [2], while more recent research also
provides evidence of their role in the pathogenic process of anogenital
cancers (vagina, vulva, anus and penis) and head and neck tumours,
including oropharyngeal malignancies. Furthermore, several benign
lesions of the skin are associated with HPV infections (warts, among
others) (figure 1.1) [3][8]. In this thesis, I will focus on genital HPV
infections, especially cervical ones.
Figure 1.1: HPV types: mucosal and cutaneous infections
source: The American Cancer Association 2014
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1.1.1 Transmission and risk factors
Genital HPV infections are primarily transmitted through sexual
contact, most commonly vaginal and anal intercourse (other routes
such as digital and oral genital contact are also seen, yet less fre-
quently). Simulations have suggested that HPV is more infectious
than the Human Immunodeficiency Virus (HIV) or herpes simplex 2,
with a median per-act transmission probability of 40 percent [9], [10].
Factors that enhance the risk of HPV acquisition are early sexual
onset - due to an enlarged transformation zone during puberty -
and having multiple partners; other STI are potentially cofactors as
opposed to just markers. In addition, immunodeficiency disorders
also increase the chance of HPV infections. More particularly, they
inhibit clearance and may thus lead to multiple infections and/or
speed up the progress of malignancy [10].
Studies have demonstrated a similar effect of smoking [11], [12]
yet others have failed to do so [10], [13], [14]. Smoking might thus
alter one's susceptibility for HPV infections or either be a proxy of
sexual risk behaviour. Likewise, the use of hormonal contraceptives
is linked with HPV infections but whether it is a causal relation or a
confounding effect remains unclear [10], [14], [15]. Finally, condom
use and male circumcision may significantly reduce HPV acquisition,
however, research results are not conclusive. Nevertheless, it is clear
that condoms will never provide full protection since HPV may still
infect the not-covered areas [10], [14], [16], [17].
1.1.2 Stages of cervical HPV infections
Cervical infections with HPV are very common and typically hap-
pen between the age of 15 and 20 years, i.e. the period of sexual
debut. Usually, incidence then steadily decreases although some
studies show a stabilization or even a second peak among middle-
aged women (figure 1.2). This observation is found all over the world
but seems to be more prominent in Africa and Central and South
America. Possible explanations for the occurrence of more HPV in-
fections in later life are reactivation of old, latent infections due to
hormonal changes or dropped immune defence. Additionally, the
peak might also originate from new, unprotected sexual relations
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(from the partner) at older age [10], [14], [18].
Up to 80 percent of all women worldwide will become infected
with high-risk HPV once in their lifetime but most of them clear
or suppress the infection naturally within one or two years. Only
persistent infections may lead eventually to malignant lesions, which
can take up to 10 years and more. Natural regression remains pos-
sible even after pre-malignant lesions are formed; only invasive ab-
normalities are a point of no return (figure 1.2). The risk of evolving
towards precancerous lesions and ultimately to cancer depends on
many factors: higher age and impaired immunity seem to increase
the risk of persistent infections. As mentioned above, also tobacco
use and hormonal family planning methods may interfere with one's
capacity to ward off a persistent infection. The most important
factor however, might be the type of HPV with which one is infec-
ted. HPV 16, for example, is known to progress rapidly [8], [10],
[14].
Figure 1.2: Progression of HPV infections
source: Trottier 2006
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1.1.3 Type distribution
As previously mentioned, HPV can induce several types of abnor-
malities but while there are over 150 types of human papillomavir-
uses, only a small subset is considered to be high-risk, with HPV 16
and 18 as most known oncogenic types (table 1.1)
Table 1.1: Risk classification of alpha HPV types
Risk level HPV types
High-risk or oncogenic 16, 18, 31, 33, 35, 39, 45, 51, 52,
56, 58, 59
Probable high-risk 26, 30, 34/64, 53, 66, 68, 67, 69,
70, 82, 85
Low-risk or non-oncogenic 6, 11, 40, 42, 43, 44, 54, 61, 70, 72,
81
source: Bzhalava 2013
Among women with normal cervical cytology, up to 11.7 percent
are HPV positive, with the highest prevalence found in Sub-Sahara
Africa (24.0 percent). HPV 16 and 18 are consistently in the top
three of most frequent infections in women without cytological ab-
normalities among all continents (worldwide prevalence of 3.2 per-
cent and 1.4 percent, respectively) [6], [19], [20].
With regard to HPV types detected in lesions, HPV 6 and 11
account for 90 percent of genital warts while HPV 16 and 18 are
found in over 70 percent of invasive cervical cancers worldwide. The
contribution of HPV 16 and 18 increases from low-grade cervical
lesions (16-32 percent), to high-grade (41-67 percent), up to invasive
cancer. Following HPV types cause another 25 percent of the cases:
31, 33, 35, 45, 51, 52 and 58 [21][23]. Similarly, HPV 16 and 18 are
predominantly found in penile and anogenital cancer (figure 1.3)[24],
[25].
Again there is little or no variation in the distribution of HPV
types in cervical cancer around the world. However, some stud-
ies do show small deviations, e.g. HPV 35, 45 and 52 have been
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more reported in invasive cervix cancers in Sub-Sahara Africa com-
pared with worldwide presence [26][29]. More research is needed
to confirm this yet there is already evidence that the current HIV
epidemic might be at the root of this deviation. HIV positive wo-
men have more often multiple HPV infections, including HPV types
less frequently detected in women with single infections [26], [27],
[30][32].
Figure 1.3: HPV types linked with warts and tumours
source: Kim 2008
1.2 Cervical cancer
1.2.1 Cervical cancer worldwide
Crude incidence rates show that cervical cancer is the fourth most
common cancer among women worldwide, with over 500,000 new
cases each year. Similarly, cervical cancer is the fourth most lethal
cancer in the world with an estimated 265,653 deaths in 2012. The
burden of disease differs however greatly among regions, depending
heavily on the level of development as can be seen in figure 1.4. In-
deed, around 70 percent of the yearly new cases occur in the low-
and middle income countries (LMIC) where age-standardized mor-
tality rates can rise up to 27.6/100,000 (East Africa) compared with
2/100,000 in Western Europe. The main reasons for this striking
health inequality are mainly the lack of screening and treatment
opportunities [24], [33].
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Figure 1.4: Age-standardized incidence of cervical cancer worldwide;
estimation for 2012
Rates per 100.000 women per year
source: Globocan 2012
1.2.2 Cervical cancer in Sub-Sahara Africa
The world's region most affected by cervical cancer is Sub-Sahara
Africa. With age-standardized incidence and mortality rates of
34.8/100,000 and 22.5/100,000 respectively, it is the cancer which
causes the highest health burden among women (figure 1.5)(crude
incidence of breast cancer is however slightly higher). In addition,
projections are not hopeful: due to the current population growth,
the number of yearly new cases may double by 2030 (from 93,225
cases in 2012 to 160,163 in 2030) [33]. Other competing health pri-
orities, such as HIV/AIDS, malaria and tuberculosis, have led to
lack of attention while poor cancer registries have led to an under-
estimation of the problem. Better cancer registration is needed to
obtain a more detailed understanding of the presence of the disease
in different regions [30].
Besides the aforementioned shortage of adequate health services to
detect and treat (precursors of) the disease, knowledge is often very
poor resulting in low screening coverage even if programmes are in
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place. Also, some of the risk factors, such as early age at first sexual
intercourse and pregnancy, or other STI infections are still far too
common in Sub-Sahara Africa and contribute substantially to the
high incidence of cervical cancer [27], [30], [31]. High mortality on
the other hand is also explained by poor general health (e.g. co-
morbidity with nutrition deficiencies, anaemia or malaria), delay in
presentation and abandonment of treatment due to poverty related
barriers [31].
Figure 1.5: Cancer among women in Sub-Sahara Africa: age-
standardized incidence and mortality rates; estimation for 2012
source: Globocan 2012
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Whether the current HIV epidemic has also influenced the number
of new cases of cervical cancer remains unclear as in some countries
there has been no increased incidence reported since the beginning
of the HIV outbreak. However, it is known that HIV positive wo-
men are more susceptible to HPV infections and seem to clear them
less easily due to their impaired immune system. Therefore, cervical
cancer is even more common among HIV positives in Sub-Sahara
Africa and since 1993 it is included in the list of AIDS-defining
clinical conditions (figure 1.6) [22], [27], [30], [31]. It is yet to be
seen if access to antiretroviral therapy (ART) will affect the current
epidemic: a longer life might provide the time needed to develop ma-
lignant lesions while a restored immune defence might help clearing
HPV infections [27], [30].
Figure 1.6: Age-standardized (world) incidence rates of cervical can-
cer and HIV prevalence in Africa
source: Louie 2009
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1.3 Prevention of cervical cancer
1.3.1 Screening: secondary prevention
Cervical cancer is sometimes called "the silent killer" given the
slow and often asymptomatic progression of lesions into malignant
abnormalities (figure 1.2). But because of this time-taking process,
malformations can be detected and treated or removed before the
disease becomes terminal. Cytological screening is based on this
principle and allows trained health providers to detect abnormal cell
formations: cervical cells are sampled by removing epithelial cells
with a brush and revised under the microscope (i.e. pap smear).
While the technique has limited sensitivity (59 percent), it has good
specificity (94 percent). However, due to the low negative predictive
value in the general population it needs to be repeated frequently.
Even though the technique itself is cheap, it is labour intensive and
requires high-trained staff and rigorous quality control [34][36].
Reduced cervical cancer incidence in industrialized countries is
mainly due to high screening coverage (63 percent on average), either
achieved by organized programmes or through opportunistic screen-
ing (figure 1.7). Women in LMIC are much less screened (13 percent)
hence the higher incidence rates (figure 1.8) [34], [37][40]. In the
past ten years, a lot of effort has been put into evaluating alternat-
ive screening methods to get around the above-mentioned barriers of
cytological screening. Approaching most-at-risk groups and target-
ing one or two screening episodes in a lifetime, are considered first
steps towards improved cervical cancer control. Furthermore, al-
ternative technologies have been assessed and pushed forward: VIA
and VILI (visual inspection with acetic acid and visual inspection
with Lugol's iodine, respectively) are feasible options to offer screen-
ing in regions where cytological screening is difficult to implement,
even though sensitivity and specificity are lower. Both techniques
rely on the fact that abnormal cells colour differently after applying
either acetic acid or iodine on the cervical epithelium. Additionally,
screen-and-treat programmes, using cryotherapy as immediate re-
lieve, are promoted in order to reduce the number of visits and thus
loss-of-follow-up [34], [35], [41][43].
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Figure 1.7: Age-standardized incidence of invasive cervical cancer
and coverage of screening, England, 1971-1995
source: Quinn 1999
Figure 1.8: Age specific incidence of cervical cancer in 2 countries
with and without centralized and widespread screening programmes
source: Bosch 2006
29
Finally, therapeutic vaccines and molecular tests are being de-
veloped [42], [44], [45]. Especially HPV DNA-tests are currently
under debate, in terms of quality but also with regard to practical
issues such as informing and follow-up of HPV positive patients [42].
In this discussion, also other sample types are considered, such as
self-sampled vaginal swaps. A meta-analysis by Arbyn et al. (2014)
showed that sensitivity and specificity of HPV testing on self-samples
was however lower compared with clinician-taken samples. Never-
theless, offering women the opportunity to screen by self-sampling
might be a good approach to include those who do not attend reg-
ular screening programmes [46]. Similarly, detecting HPV DNA in
(first void) urine has been proposed, based on the high correlation
that was found between urinary HPV DNA and infections of the
lower genital tract, including cervical infections. DNA detection in
urine is however conditional on correct sampling, good storage con-
ditions and sample preparations, and lab techniques used. But since
these steps can be optimized and standardized, detecting HPV in
urine offers a very valuable alternative for vaginal/cervical samples
given that it only requires an easy-to-collect, non-invasive sample.
Besides the fact that this might be again more acceptable in some
subgroups, it also creates the use of new viral endpoints for clinical
trials of HPV vaccines [47][50].
1.3.2 Vaccination: primary prevention
The vaccines
Since 2006-2007, two prophylactic HPV vaccines are on the mar-
ket. In 2006, the Committee for Medicinal Products for Human Use
(CHMP) of the European Medicines Agency (EMA) and the US
Food and Drug Administration (FDA) granted Gardasil (Merck)
marketing authorization. Later on Cervarix (GlaxoSmithKline Bio-
logicals S.A.) was also approved by the EMA and the FDA in 2007
and 2009, respectively. While Cervarix was designed to prevent
precancerous lesions in and cancer of the cervix only, Gardasil pro-
tects also against condylomata acuminata or genital warts. The
former is indeed a bivalent vaccine containing purified major capsid
(L1) L1 proteins for HPV 16 and 18, two highly oncogenic HPV
types, in contrast with the quadrivalent Gardasil which also includes
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L1 proteins for HPV 6 and 11, the causal agents of genital warts. At
the moment, Gardasil and Cervarix are also recognized as primary
prevention methods against HPV lesions of the vulva and the vagina.
In addition, Gardasil's protection against anal lesions and cancer is
also acknowledged (even though studies have indicated protection
offered by cervarix as well) [51][55].
Both vaccines are ideally administered before sexual onset, given
that efficacy is highest among HPV-naive people. Therefore young
adolescents are targeted but catch-up vaccination might be given
to older adolescents and young adults. It is also worth mentioning
that both vaccines induce higher antibody levels among young ad-
olescents versus adolescents and young adults [56], [57]. As a result,
the original administration schedules are adapted: upon approval,
vaccination consisted out of three doses within six months. After re-
evaluation, a two-dose schedule given six months apart to girls nine
to fourteen or nine to thirteen for Cervarix and Gardasil respect-
ively, has been approved [58][61]. Cervarix is only licensed to be
given to girls; Gardasil can be used among both males and females.
An important difference between the vaccines is the use of a
strong, novel adjuvant (adjuvant system 04, AS04) in Cervarix com-
pared to the aluminium salt adjuvant of Gardasil. This strong
adjuvant might be the reason why Cervarix clearly offers cross-
protection against non-vaccine HPV types (i.e. 31, 33, 45, 51) [62]
[65]. In terms of duration of protection, both vaccines sustain high
immunogenicity and efficacy up to 8 years [66][69]. However, some
studies show a decreased anti-HPV 18 titer after five years among
15-26 year old women vaccinated with Gardasil [68], [70], [71]. In
general, Cervarix tends to induce higher immune response which may
have consequences for the duration of protection against HPV 16 and
18 [72]. Whether this will have clinical implications or whether the
vaccines will also provide protection due to immune memory or low,
undetectable titers remains to be investigated through long-term
follow-up studies. Finally, none of the vaccines are currently linked
with serious adverse side effects (table 1.2) [67][69].
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Table 1.2: Prophylactic HPV vaccines
GARDASIL CERVARIX
HPV types HPV 6, 11, 16, 18 HPV 16, 18
Cross- HPV 31 HPV 31, 33, 45, 51
protection
Adjuvant aluminium AS04 - aluminium
hydroxyphosphate hydroxide and
sulphate 3-deacylated mono-
phosphoryl lipid A
Injection place Intramuscular Intramuscular
Schedule 0, 2, 6 months 0, 1, 6 months
Approved for Boys and girls, Girls,
nine years or above nine years or above
Storage 2◦C - 8◦C 2◦C - 8◦C
Impact and the way forward
Given the time it takes to develop cervical cancer and the fact
that the vaccines are less then ten years on the market, it is too
early to detect changes in incidence rates in vaccinated popula-
tions. Impact on other HPV-related endpoints are however docu-
mented, e.g. in Australia where many studies have reported the
impact on genital warts. While the national HPV vaccination pro-
gramme was launched in 2007, results were already noticed in 2009
by investigating trends in diagnoses of genital warts in 2004-2009.
A decline was noted for young women, not for older groups, and
evidence already hinted towards herd protection for young, hetero-
sexual men [73]. In 2013, boys were included in the programme
and later on, more studies showed the protective effect of the vac-
cine, either direct or through herd protection, by comparing pre-
and post-vaccination data on cases of genital wards. Besides de-
tecting large effects for young, heterosexual women and men, they
also confirmed that the reductions are similar for indigenous and
non-indigenous populations, and for people living in disadvantaged
versus less-disadvantaged areas [74][76]. In addition, a small de-
cline among men who have sex with men has been observed yet it is
not clear whether this could be attributed to HPV vaccination [77].
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Similar results are detected in a meta-analysis by Drolet et al.
(2015), including also data from other countries. A first tendency
described is a decrease in vaccine HPV-types (i.e. HPV 16 and 18)
and anogenital warts, both in populations with high and low vaccine
coverage (more or less than 50 percent uptake among girls younger
than twenty years of age, respectively). Furthermore, among the
populations with high uptake, results from clinical studies are con-
firmed: cross-protection against HPV 31, 33 and 45 is detected and
herd-effects are noted through a decrease of anogenital warts in older
women and men. These results need to be interpreted with caution
due to several biases, such as potentially more doctor visits for gen-
ital warts post-vaccination or lack of control for changes in sexual
behaviour after the vaccines were introduced. In addition, the pro-
tective effect of the vaccine might fade out over time if immuno-
genicity does not hold. On the other hand, vaccinated girls have
often not yet entered the age-period when HPV infections and ano-
genital lesions peak, offering the possibility to detect an even larger
impact in the upcoming years. Finally, given that the results are
drawn from studies in high-income countries (HIC), different HPV
epidemiology or sexual behaviour, or co-factors such as HIV preval-
ence might inhibit correct extrapolation to resource-limited regions
[78], [79].
Several studies have also noted a decrease in high-grade cervical
abnormalities, which are the closest surrogates for cervical cancer
[80][83]. Again in Australia, the incidence of high- and low grade
cervical abnormalities was compared before and after the introduc-
tion of the vaccine. A decrease in high-grade lesions was found
among girls younger than 18 years of age, which was significantly dif-
ferent from the trend before the onset of the vaccination programme
[81]. Also, when comparing vaccinated versus non-vaccinated wo-
men, a significant reduction in cervical abnormalities was detected
already five years after the start of the vaccination programme [80].
Further evaluation of the results of these studies is however war-
ranted. For example, some results are not controlled for screening
behaviour or are only applicable for younger women [81][83]. Simil-
arly, it is yet to be seen if the same protective effect will be registered
among subgroups such as HIV positive people or whether the vaccine
will be equally protective against HPV related cancers other than
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cervical tumours [84][86]. Also more research is needed to mon-
itor type replacement by nonvaccine types. Results from a Finnish
studies suggested a competitive advantage for HPV 33 among the
unvaccinated population [87].
In 2014, a nonavalent vaccine containing HPV 6, 11, 16, 18, 31,
33, 45, 52, and 58 antigens was licensed by the US FDA, followed
by the European Committee for Medicinal Products for Human Use
(CMPH) in 2015. Together, these nine HPV types cause almost
90 percent of cervical cancers [61], [88]. Again, results of clinical
trials are promising but close follow-up will be necessary to verify
the population based effect.
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Chapter 2
HPV vaccination
programmes worldwide
Several kinds of HPV vaccination programmes are currently imple-
mented all over the world, applying various designs, targeting entire
countries or just some localities, launched as a long-term component
or as a pilot project. The following sections will describe different
types of vaccination programmes that have been rolled out, as well
as the uptake rates that have been reached so far. More particularly,
the first section will address national HPV vaccination programmes,
describing the state of affairs in HIC and in low- and middle income
countries. A second section is dedicated to the pilot HPV vaccin-
ation programmes or 'demonstration programmes' that have been
implemented in LMIC as to prepare national roll-out, pointing out
some shortcomings of these small-scale vaccination projects.
2.1 National HPV vaccination programmes
Since the introduction of the HPV vaccines in 2006-2007, many
countries have incorporated cervical cancer vaccination in their im-
munization scheme and have implemented programmes. While in
2010 national programmes were still limited to Mexico, Panama and
most HIC (USA, Canada, Australia, New-Zealand and North- and
West-Europe), by 2015 most Latin-American countries had followed
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(figure 2.1) [89]. However, these reports need to be interpreted with
caution, e.g. while Suriname has a national programme, it is mainly
focussed on the capital-city, meaning that many people in rural areas
still have limited access. Similarly, the programme in South-Africa
offers HPV vaccination to girls in public schools only, leaving behind
those in private institutions and non-school going girls [90].
Figure 2.1: Implementation of HPV vaccination programmes, Feb-
ruary 2015
source: Cervical Cancer Action
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2.1.1 High-income countries
Uptake of the HPV vaccine varies among countries and regions.
In Europe, reported three dose coverage ranges from over 75 per-
cent in Belgium-Flanders (2012), Denmark (2011), Portugal (2011)
and the UK (2015), to less than 30 percent (Belgium-Wallonia-2015,
France-2008 and Luxembourg-2009) [91][98]. Also outside Europe
discrepancies are found, even within countries: in the USA uptake
can vary between 15 and 70 percent [94], [95], [99][103] and also in
Canada differences are found (80 to 85 percent in eastern provinces
against 59 percent in Ontario (2010)) [94], [104]. In Australia, a
country that has been one of the pioneers in HPV vaccination, cov-
erage of around 70 percent is reported consistently from 2009 to
2013 [95], [105]. Finally, it is important to mention that studies in
various countries have showed that people of low economic status or
ethnic minorities report less uptake compared to the general popula-
tion, lowering the potential of the vaccine to reduce health inequality
[100], [101], [103], [106][112].
Organizational factors that have been identified to influence HPV
uptake are mainly the delivery platform and the financing methods.
In general, school-based vaccination is more successful than health
centre-located programmes [113], [114] and, given the high cost of the
vaccines, publicly funded programmes or societies with high medical
insurance coverage are more likely to reach high uptake [91], [95],
[100], [101].
2.1.2 Low- and middle-income countries
As can be seen in figure 2.1, national programmes in LMIC are
mainly located in Latin America, with some exceptions in Asia (e.g.
Singapore and Bhutan) and Africa (e.g. Rwanda and South-Africa).
Good results have been achieved through various implementation
schemes and delivery platforms. In Mexico for example, a gradual
roll-out, starting with mobile health clinics in the most deprived
communities in 2008, has grown into a nationwide programme in
2012, applying an adapted scheme of 2 doses in 6 months and a
booster dose 5 years later. In 2009, a coverage of 67 percent was
reached for the second dose. Panama on the other hand uses a mixed
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approach of both clinic and school based vaccination, reaching a 67
percent coverage for the third dose in 2010 [94].
Especially the high cost of the vaccines (up to more than 100 USD
per dose in HIC) is a major barrier for LMIC to organize large-scale
HPV vaccination programmes. Rwanda and Bhutan were able to
do so thanks to multi-year donations from Merck [94]. In Rwanda,
a combination of school-based vaccination and community involve-
ment to identify out-of-school girls led to a successful three dose
uptake of 93 percent in 2011 [115]. Other countries can obtain HPV
vaccines at reduced prices thanks to the Pan American Health Or-
ganization's Revolving Fund (14 USD a dose) or the Global Alliance
for Vaccines and Immunization (GAVI; 4.5 USD a dose). The latter
committed itself in 2011 to offer HPV vaccines to eligible countries,
i.e. countries with a DTP3 threshold of 70 percent national coverage,
and that can demonstrate the ability to deliver HPV vaccine to ad-
olescent girls. Demonstrated ability is defined as "prior experience in
delivering multi-dose vaccines to at least 50 percent of a target pop-
ulation of 9-13 year old girls in an average-sized district". Currently,
Rwanda, Lesotho and Uganda are the only African countries eligible
for national HPV vaccine introduction support. Nations lacking ex-
perience can apply for support to conduct small-scale demonstration
projects in order to gain the experience necessary to apply for na-
tional roll-out [94], [116][120].
2.2 Demonstration programmes
At this moment, most experience regarding HPV vaccination in
LMIC comes from demonstration projects, i.e. the pilot programmes
conditional to become eligible for GAVI support for national roll-
out (see above). Nepal, Vietnam, Peru and Uganda were the first
countries to implement small-scale HPV vaccination efforts with the
guidance of Path, an American NGO (2008-2010). Vaccines were
provided to Path by Merck (USA) and GlaxoSmithKline (UK). Dif-
ferent delivery platforms were tested among the different countries
and districts: school-based (selection of eligible girls either by age
or grade), health centre-based, incorporation of HPV vaccination
in an existing programme (i.e. the Child Days Plus Programme
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in Uganda), or a mixed approach. All countries showed positive
results: with exception of the district in Uganda where HPV vaccin-
ation was incorporated in the Child Days Plus Programme (uptake
was not higher than 61 percent), coverages were mainly above 80
percent (ranging from 68 to 98 percent). [120], [121].
After these four initial pilots, many more demonstration projects
have followed or are currently ongoing [122][127]. Especially in
East-Africa efforts are made to gradually introduce the HPV vac-
cines (figure 2.1). Given the large burden of disease in this region,
this is extremely urgent. Regarding the success rates of such pro-
grammes, a review by Ladner et al. (2014) provided insight in uptake
rates of 21 Gardasil Access Programs (pilot programmes made pos-
sible through donations of Merck). Between 2009-2013, these pilots,
taking place in 14 countries and using different delivery methods, all
achieved high coverage (minimum 69 percent) [122].
In contrast with these successful demonstration projects, one pi-
lot programme did however not end well: in India, a demonstra-
tion programme of Path was suspended after various human rights
groups, women's groups and academics asked for a re-evaluation of
the vaccine's safety and efficacy. Besides questioning the vaccine it-
self, people were not convinced about the need or priority given to
introduce (an expensive) vaccine against cervical cancer. Finally, the
vulnerability of the potential participants led to fear for exploitation.
The non-responsiveness of the government on these concerns resul-
ted in more pressure and ultimately suspension of the programme
[128], [129].
2.2.1 Limitations of demonstration projects
While results are encouraging - high uptake of the HPV vaccine
in LMIC seems possible - it is not always entirely clear how this
was achieved. Only some countries have thoroughly reported on
how demonstration projects were carried out and what their im-
pact was in terms of HPV vaccine uptake, acceptability and know-
ledge (the Path projects in Uganda, Peru, Nepal and Vietnam are
well described) [115], [121][127], [130][142]. For example, few pro-
grammes have documented how promotion took place or what types
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of messages were spread through what media. Nonetheless, those
studies that did investigate factors influencing uptake showed that
knowledge is an important predictor [133], [136] or found that ex-
posure to community influencers was of great importance and highly
related to vaccination [134]. Also, in Tanzania and Vietnam, vac-
cine refusers reported side-effects as one of the main reasons for
not vaccinating against cervical cancer, indicating the need for more
(convincing) sensitization [130], [132].
Besides community outreach and mobilization, Tsu et al. (2014)
also identified service delivery operations as defining for the success
rate of a programme, referring to types of vaccination platforms or
venues used, definition of the target group (eligibility criteria) and
timing of vaccination. [138]. Understanding the advantages and
disadvantages of different delivery strategies is of course crucial to
improve or maintain high uptake of the HPV vaccine yet projects
usually don't report more than the venue where vaccination took
place.
More efforts are thus needed in documenting HPV vaccination
programmes with respect to different service delivery operations and
promotional strategies in order to provide lessons learned and good
practices. In addition, such results may shed light on whether or
not it will be possible to scale-up pilot programmes into national
vaccination efforts: is the used design feasible nationwide and can it
lead to similar or more successful results? Indeed, for many countries
the sustainability of and the possibility to expand the demonstration
projects remain unclear [118].
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Chapter 3
Conceptual frameworks
to understand
vaccination behaviour
With the introduction of new methods comes along formative re-
search to evaluate the health system's capacity to include the newly
developed tool. Besides assessing whether the health system can
offer high quality health services, also the population's readiness to
take up the new behaviour is generally measured. To do so, ac-
ceptability studies are carried out to identify factors that hamper
uptake and to determine strategies to maximize coverage. This is
not different for the HPV vaccine: given the potential health benefit
that high coverage of the vaccine may offer, a lot of efforts goes to
studying whether the vaccine is well-received and if not, what causes
its rejection.
The following chapter will thus describe HPV vaccine acceptab-
ility studies. Extra attention will go to 1) determinants of vaccine
acceptability that are often investigated or discussed, 2) the state
of the art regarding acceptability studies in Sub-Sahara Africa, and
3) the health behaviour theories used to study vaccine acceptability
and uptake. Furthermore, a critical evaluation of HPV vaccine ac-
ceptability studies is presented as to identify points of improvement.
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Finally, the more recently introduced concept of 'vaccine hesitancy'
- as opposed to vaccine acceptability - is presented, describing the
different definitions and forms of usage of the last couple of years.
3.1 HPV vaccine acceptability studies
HPV vaccine acceptability is often determined by using the word
'would' in questions like "Would you agree to vaccinate..." or "Would
you accept..." or "How likely would you vaccinate..." [143]. These
type of questions are in a large majority of the acceptability studies
directed to (young) women, given that they are presumably the main
decision-takers when it comes to vaccination against cervical cancer
(being part of the target group or in their role as (future) mother).
Indeed, during early adolescence, most children remain dependent
on their parents for basic needs such as transportation and they have
not yet begun to test the authority of their parents and other adults.
Consequently, young adolescents may be most likely to comply with
parental advice regarding vaccination [144]. In addition, a care-
giver's consent is often required prior to vaccination.
In general, (childhood) vaccines are broadly accepted and also
many HPV vaccine acceptability studies report that the vaccine is
received positively by many people. The primary driver for vaccina-
tion is protection against cervical cancer. Health care professionals
are considered the most trusted person to advice on HPV vaccin-
ation, therefore, their recommendation is crucial and helps coun-
teracting doubts while stressing the importance of cervical cancer
prevention [95], [100], [101], [145].
Nonetheless, studies have showed that willingness-to-vaccinate should
not be taken for granted and might vary strongly among different
(sub)populations [95], [146][149]. In the Netherlands for example,
Protestants were less likely to accept the vaccine as opposed to Ro-
man Catholics or people without religion [150], [151]. It is known
that Orthodox Protestants, living in the so called Dutch Bible Belt,
are suspicious about vaccination; combined with a more traditional
lifestyle, rejection of the HPV vaccine is not truly surprising. In
Canada on the other hand, in-school HPV vaccination was refused
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by Catholic schools in Calgary. They banned the vaccine inspired by
the Roman Catholic bishop of Alberta who objected because "the
vaccine implies that early sexual intercourse is allowed" [152]. So
Roman Catholics in the Netherlands and Canada held up a different
point of view with regard to HPV vaccination. 'Religious' reasons
of vaccine refusal are often not more than a reflection of personal
concerns shared by a certain community [153]. For example, con-
servative wings in the USA have boycotted HPV vaccination, based
on moral concerns (they believe the vaccine promotes risky sexual
behaviour) [154], [155].
In addition, variance in acceptability has been documented among
ethnic groups. Non-Caucasians had lower awareness and a less pos-
itive attitude towards the vaccines than Caucasians in Canada [156],
while in the UK, Marlow et al. (2009) found that ethnicity and reli-
gion were highly associated with acceptability: white women repor-
ted higher acceptability compared to African, Caribbean or South
Asian, and Muslims accepted less as opposed to those with no re-
ligion [157]. These results clearly demonstrate that cultural factors
and underlying concerns influence people's intentions to vaccinate
their daughter [153]. By studying acceptability and its determin-
ants researchers try to find pathways to increase acceptability, if
needed, and eventually HPV vaccine uptake.
3.1.1 Determinants of acceptability
As stated, measured HPV vaccine acceptability is often high but,
as with most vaccines, concerns related to safety and efficacy do ex-
ist. Especially fear of side effects seems to lower vaccine uptake rates
[91], [95], [101]. Concerns may arise from the fact that the vaccine
is newly developed (or newly introduced) and that it prevents an
STI by targeting young adolescent girls prior to sexual debut [146],
[158][161]. Also practical issues can temper willingness to vaccin-
ate, such as the high cost of the vaccine or the time and effort it
takes to accompany the daughter, up to three times, to the health
care provider. Finally, awareness of cervical cancer is low in certain
communities meaning that people may doubt the usefulness of the
vaccine [160], [161]. These and other determinants are discussed in
the following paragraphs.
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Awareness as primary condition
Being aware of cervical cancer and the possibility to vaccinate
against it is a first condition to accept the HPV vaccine. More
in-depth knowledge often increases acceptability [112], [148], [154],
[162][165] yet not all studies confirm this [149], [158], [166], while
others even show that also without detailed knowledge acceptability
can be high [165], [167][184]. In any way, since the vaccines were
introduced in 2006-2007, public awareness regarding cervical cancer
and HPV has improved thanks to promotional campaigns and me-
dia attention [149], [185][187]. Unfortunately, knowledge remains
generally inadequate: worldwide, the causal link between HPV and
cervical cancer is still poorly understood and the vaccine remains
rather unknown. In addition, information received is not always
complete or correct and as a result people might reject the vaccine,
e.g. when pilot vaccination programmes are considered as part of
a clinical trial, the vaccine's safety will obviously be an issue [148],
[162], [188].
If interest fades away, knowledge and awareness might even more
decrease. A systematic review by Trim et al. (2012) showed indeed
a slight drop in 2010 after an increase in 2008 and 2009 [185]. In
addition, knowledge varies greatly, both in country and between
countries [95], [112], [147], [149], [188] and worrisome, under-served
or disadvantaged groups are more likely to have limited knowledge
[146], [154], [161], [189].
More information is frequently requested by participants of ac-
ceptability studies as to enable them to make an informed decision
[163]. Given that lack of information or misunderstandings also allow
instigation of doubts and impinges the ability to feel confident about
a decision, it is clearly important for vaccination programme design-
ers to answer this request and to transfer information correctly and
convincingly. Surprisingly, few studies have evaluated the impact
of promotional campaigns and those that did do not always show
improved knowledge [133], [190]. Various reasons might cause this
failure, going from organizational factors, poorly tailored messages
or lack of capacity among the target group to correctly interpret in-
formation. As such, health literacy might be an important factor to
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take into account, however, until now it has not been a major point
of discussion in HPV vaccine related research. This might be partly
due to a poor understanding of the concept.
Table 3.1: Matrix with four dimensions of health literacy applied to
three health domains
Health Disease Health
care prevention promotion
Obtain
health in-
formation
Ability to access
information on
medical or clinical
issues
Ability to access
information on
risk factors
Ability to update
oneself on determ-
inants of health
Understand
health in-
formation
Ability to under-
stand medical in-
formation and de-
rive meaning
Ability to under-
stand information
on risk factors and
derive meaning
Ability to under-
stand information
on determinants of
health and derive
meaning
Process
health in-
formation
Ability to inter-
pret and evaluate
medical informa-
tion
Ability to inter-
pret and evalu-
ate information on
risk factors
Ability to inter-
pret and evaluate
information on
determinants of
health
Apply
health in-
formation
Ability to make
informed decisions
on medical issues
Ability to make
informed decisions
on risk factors
Ability to make
informed decisions
on health determ-
inants
source: Sorensen 2009
The concept of health literacy has greatly evolved during the last
years: while the original, more narrow interpretation indicated the
ability to handle words, terms and numbers in the context of medical
care, it has broadened up to a set of skills which enables people to use
health information in decision making and carrying out the preferred
action. Sorensen et al. (2012) introduced a new definition, based on
a review of all definitions and frameworks that have been used in the
past: "Health literacy is linked to literacy and entails people's know-
ledge, motivation and competences to access, understand, appraise
and apply health information in order to make judgements and take
decisions in everyday life concerning healthcare, disease prevention
and health promotion to maintain or improve quality of life during
the life course". With this definition, twelve dimensions are intro-
duced, formed out of four competences (access, understanding, pro-
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cessing and applying information) and three domains (health care,
prevention and promotion) (table 3.1) ([191]). When it comes to
decisions regarding preventive actions such as HPV vaccination, ob-
taining and rightly evaluating information on especially risk factors
seem to be important skills in the process of decision-making, as
opposed to the more traditionally evaluated factors such as 'having
heard of', in this case cervical cancer, HPV and the HPV vaccine.
Safety and efficacy
Thanks to the success of childhood vaccinations, vaccines are con-
sidered some of the most effective methods to prevent diseases by
health policy makers and providers but also by the general pub-
lic. Therefore, a lot of people have faith in the HPV vaccine when
it comes to safety and efficacy, but others do worry: doubts are
mostly related to the novelty of the vaccines, i.e. can we exclude
already long-term side-effects and will the induced protection be
long-lasting? Such fears are known to have a negative effect on
HPV vaccine acceptability [146], [154], [163].
Some people are particularly worried about the HPV vaccine's
potential interference with fertility. Specially in more traditional or
patriarchal communities targeting only girls against an STI raises ex-
tra concerns [146]. In these settings, vaccinating both boys and girls
might boost the vaccine's credibility. Also, given the faith people
put in physician's advice, they are in place to counteract doubts
and provide correct information [95], [100], [101], [145].
Influence on sexual behaviour
Due to the sexual nature of cervical cancer, the HPV vaccine is
also believed to encourage early sexual onset, promiscuity or unsafe
sex according to some societies [95], [112], [146][149], [154], [159],
[160], [162], [182], [183], [185]. Offering protection against an STI
could be interpreted by the targeted young girls as an approval to
become sexually active or could result in risk compensation. In Den-
mark, for instance, young women mentioned that due to the vaccine
a false sense of security might be created among vaccinated people,
which could lead to more high-risk sexual behaviour [192]. In gen-
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eral however, these concerns are only reported by a minority, often
concentrated among conservative, religious affiliations. Nonetheless,
it does jeopardize acceptability and subsequently coverage and herd
immunity. Until this moment, a number of studies have shown no
increase in sexual activity among those vaccinated [193], [194].
Related to this is that some people worry about stigmatization:
vaccinating against an STI is openly saying that the girl is or will
soon become sexually active. This might be the reason that accept-
ability tends to rise if the vaccines are offered to older girls. Seem-
ingly, for some people it is more acceptable to vaccinate adolescent
girls and young women against cervical cancer as opposed to young
adolescents [95], [112], [147], [149], [154], [159], [183], [185].
Practical barriers
Time and money constraints obviously also interfere with HPV
vaccination intentions. Especially the latter barrier is often men-
tioned, which is of great concern: the capacity of the vaccine to
close the gap of health inequality when it comes to cervical can-
cer, is jeopardized when people refuse to vaccinate based on cost or
insurance status. Both in high- and low-income countries, cervical
cancer will remain `a disease of the poor' when the vaccine is not
(sufficiently) subsidized [95], [146], [160], [195]. Acceptability and
subsequent uptake of the vaccine will thus highly depend on pro-
grammatic decisions reducing investments to be made by the target
group, such as transport, both financial and in terms of time. Also,
different vaccination schedules, and more particularly reducing the
need for several doses, can significantly lessen the burden and thus
help increasing willingness to vaccinate [168].
Similarly, and linked with the above-mentioned importance of
awareness, acceptability of the HPV vaccine is highly influenced by
health professionals' recommendation. As such, access to health
care and contact moments to discuss HPV vaccination with a physi-
cian are identified as important determinants [95], [100], [101], [145].
While this is of course strongly related to the quality and coverage
of the local health care system, willingness to invest personal time
to visit a health centre will again play a role. Additionally, in order
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to reach the target group with crucial information regarding cervical
cancer and HPV vaccination, as well as to inform them on practical
issues such as cost, possible reimbursements or the whereabouts of
the vaccination effort, other promotional activities than face-to-face
client-provider visits could also enhance the flow of information.
3.1.2 HPV vaccine acceptability studies in Sub-
Sahara Africa
Several HPV vaccine acceptability studies were implemented in
HIC even before the vaccines were approved. The bulk of stud-
ies is still carried out in industrialized regions but over the last five
years, LMIC and more importantly countries with high cervical can-
cer incidence are also studying their population's readiness towards
HPV vaccination [121], [126], [146], [168][184], [196][205]. While
the main results are similar - high acceptability is reported as well
as fear of side effects - some context specific factors emerge. An
important conclusion is that general awareness is even lower and
the aetiology of cervical cancer is practically unknown. Although
this does not always impede high acceptability, it does contribute to
myths and rumours. Terminology issues - e.g. cervix is not always
translatable in the local languages - add to this problem [178], [181].
In addition, in Sub-Sahara African communities, distrust towards
the vaccines might not only originate from the novelty of the vaccine
but also from a generally more suspicious attitude towards the health
system. According to formative research in low-resource settings
(Vietnam, Peru, Uganda and India), people question the vaccinators'
ability to safely administer the vaccines, doubt they will use clean
needles or are afraid expired vaccines will be used. Additionally,
vaccines are believed from lower quality than those used in HIC or,
people tend to believe that Western companies use their communities
to experiment with unapproved medicines [146]. Again it is yet to
be seen if this can be overcome or if this will hamper vaccination
behaviour eventually.
Another factor that might be more pronounced in Sub-Sahara
African studies is the difference in involvement or attitude of men
and women regarding HPV vaccination. While women tend to know
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more about cervical cancer - are more targeted in sensitization pro-
grammes - and are often hold responsible for the health of family
members, they might lack decisive power or financial liberty [169],
[180], [184], [206]. In addition, women in Uganda have reported a
non-supportive role of their partners when it comes to vaccination
[206].
Finally, HPV vaccine refusal based on fear for sexual inhibition
or fertility interference might be more present in African settings,
where perceptions are often traditional and diverse and a moral-
istic or paternalistic approach towards young girls is common. Also
stronger religious convictions might play a role here. Some studies
have indeed already reported concerns related to vaccinating young
girls against an STI but it is not clear if this will actually inhibit
vaccine uptake [170], [176].
However, while these factors can lead to lower HPV vaccine ac-
ceptability, there might also be an extra driver in Sub-Sahara Africa
compared with HIC. People are still more conscious about the im-
pact of vaccines on child health as opposed to people in HIC who
have not experienced the threat of childhood diseases [206]. As such,
African communities can value more the benefit of prevention over
treatment.
3.1.3 Theoretical frameworks: Health behaviour
theories
The Health Belief Model
The main interest of acceptability studies is to find predictors
and barriers for acceptability and consequently for behaviour. Fre-
quently these studies apply health behaviour constructs that include
a variety of psychological factors (e.g. attitudes, beliefs, perceived
barriers) to associate them with acceptability. A proven health be-
haviour theory to predict vaccination is the Health Belief Model
(HBM) (table 3.2) [207], [208], which is also commonly used in HPV
vaccine acceptability studies [143], [158], [183]. The authentic HBM
indicates that for an individual to take action (e.g. to have one's
daughter vaccinated), this person would have to (1) perceive the
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disease at least as moderately severe; (2) perceive a susceptibility or
vulnerability by the disease; (3) believe that there are benefits in tak-
ing the preventive action; (4) not perceive major barriers obstructing
the action. Self-efficacy (one's perceived ability to undertake the ac-
tion) and cues-to-action (triggers such as multimedia advertisement
or a physician's recommendation) were added later in order to im-
prove the theoretical model [209].
Table 3.2: Constructs of the Health Belief model
BELIEF DEFINITION
Perceived sus-
ceptibility
What chance individuals believe they have of
getting a specific health condition
Perceived sever-
ity
How seriously individuals believe a certain
condition will affect their life situation
Perceived bene-
fits
The benefits individuals believe there are in
taking action to address the health condition
Perceived barri-
ers
The road blocks or threats individuals anticip-
ate in trying to address the health condition
Cue to action External of internal factors that stimulate in-
dividuals to act (based on their perceptions)
Self-efficacy The level of confidence individuals have in
their ability to act
Brewer et al. (2007) and Cunningham et al. (2014) have reviewed
HPV vaccine acceptability studies focussing on the HBM constructs
in the USA and Africa respectively [158], [183]. The former review
included twenty eight studies, the latter fourteen (among ten coun-
tries). Perceived susceptibility reported in African studies was not
always high which might have been caused by misunderstandings
such as believing the disease is inherited. In general, own risk was
considered lower than a daughter's risk of HPV infection or cervical
cancer. While studies in the USA revealed a positive relation with
acceptability [158], Cunningham et al. (2014) reported either no cor-
relation [169] or also a positive one ([170], [183]). Among all studies,
the majority of the participants agreed that cervical cancer is a ser-
ious illness (perceived severity) [158], [183]. While two studies, in
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Botswana and Ghana [169], [170], detected an association between
HPV vaccine acceptability and perceived severity, the other studies
were not conclusive [158], [183]. Perceived effectiveness of the HPV
vaccine was the main benefit investigated while in terms of barriers
cost and safety concerns were discussed, among others. The link
with acceptability remains again unclear for both constructs: repor-
ted barriers do not necessarily deter acceptability and trusting the
vaccine's efficacy does not always lead to higher willingness to vaccin-
ate [158], [183]. Finally, cues to action indicated by American studies
included physician's recommendation and school requirement, and
although this was only reported by few studies, a positive association
with acceptability was found [158]. In the African studies, cues to
action also enclosed endorsement from the government and acknow-
ledgement by community members (associations with acceptability
were not investigated) [183].
The indecisiveness of the mixed results reported above induces the
idea that the HBM is not always applicable in the context of HPV
vaccine acceptability. Given that the reviews are based on studies
in different countries and settings (rural, urban, clinics) and include
different participants (adolescents, young women, students and par-
ents), it might however be that the model only predicts HPV vaccine
acceptability in certain situations. In addition, the constructs used
are not standardized and are thus measured in different ways which
may also affect the predictive value of the model in each study.
Finally, and more importantly, the original HBM stipulates associ-
ations of constructs with a certain action, and not with acceptability
or any other precursor of behaviour. A theory that does include an
antecedent such as acceptability is the Theory of Planned Be-
haviour. This other well-known model estimates the occurrence of
a certain action under the assumption that the action was inten-
tional: the three main constructs (attitude, subjective norms and
perceived behavioural control) are correlated with intention, which
is considered the final predictor of the actual behaviour. Some stud-
ies, applying the TPB, did indeed find a relation between intention
and vaccination behaviour, or support for the TPB in general [210]
[212].
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So although the HBM constructs were not originally thought of
as determinants of precursors, many researchers do verify their cor-
relations with acceptability or willingness to vaccinate similar to the
idea of the TPB that actions are preceded by intentions. Thor-
oughly investigating whether the HBM constructs actually predict
acceptability and/or HPV vaccine uptake seems necessary in order
to justify the use of the model in HPV vaccine acceptability studies.
3.1.4 Limitations of acceptability studies
As mentioned above, HPV vaccine acceptability studies are mainly
carried out in Western settings, while research in LMIC, i.e. where
the vaccines can have the greatest impact, is still scarce. Further-
more, due to convenience sampling, the majority of the studies fo-
cus mainly on white, Caucasian people in urban settings. Parti-
cipants are often recruited at colleges or health centres and very few
studies have tried to identify cultural variations [103], [143], [158].
Acceptability studies in resource limited regions or targeting differ-
ent groups of populations might give new insights on the vaccine
decision-making process.
The results of HPV vaccine acceptability studies are also limited
due to methodological issues. For example, the context in which
HPV vaccine acceptability is measured, i.e. whether the vaccine is
already accessible, will influence the measurement greatly. In addi-
tion, the cross-sectional character of most studies inhibits investig-
ating the entire pathway of decision making, i.e. the translation of
acceptability into actual behaviour. Furthermore, the majority of
the studies only gauge personal opinions - sometimes driven by 'tra-
ditional' cognitive health behaviour theories at that level - exclud-
ing many other important determinants related to vaccine uptake.
These major limitations and possible solutions are further discussed
below.
Acceptability as precursor of behaviour
By measuring acceptability one obtains an estimate of the poten-
tial coverage rate that could be reached with an ideal implement-
ation design. However, various acceptability studies were conduc-
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ted before the HPV vaccine was actually on the market, gauging
acceptability, barriers and attitudes in a purely hypothetical situ-
ation. As such, actual behaviour and encountered hindrances might
be different from those foreseen. But also in situations where the
HPV vaccine is not yet widely available or accessible for the general
population, participants might report fairly conjecturally given the
novelty of the vaccine and the little experience they have with it.
Consequently, assessed willingness to vaccinate might be a poor pre-
dictor for subsequent behaviour; once the opportunity to vaccinate
against cervical cancer actually occurs, people can react differently
or can be influenced by experiences (from thirds) [213]. Indeed, a
review by Trim et al. (2012) showed that in HIC reported inten-
tion was highest in 2005, i.e. before the vaccines were licensed, then
dropped a bit, to rise again until 2008 and from then on decline on-
wards [185]. Introduction of the HPV vaccine may have caused these
shifts in measured acceptability. Therefore, extra attention should
go to users' perspectives, exploring how people choose and gather-
ing feedback on how they experienced vaccination, rather than solely
trying to gauge acceptability at a certain moment in time [213].
Another step would be to implement longitudinal studies, to as-
sess both the precursor and the actual action itself, and to invest-
igate to what extent the precursor truly estimates the behaviour
[214]. Unfortunately, the majority of the HPV vaccine acceptabil-
ity studies now are cross-sectional, measuring acceptability through
quantitative or qualitative research methods, and do not implement
a follow-up round to assess actual uptake. To our knowledge, very
few studies - and all in HIC - have compared expressed acceptab-
ility and/or intention to vaccinate to actual HPV vaccine uptake
through longitudinal surveys and those that did found contradict-
ory results regarding the correlation between the antecedent and the
actual vaccination behaviour [210], [211], [215][219]. More longit-
udinal research is necessary to get a better understanding of the
link between HPV vaccine acceptability and behaviour in different
contexts.
A last remark regarding the methodology used in quantitative
acceptability studies, is that they often rely on (univariate) correla-
tions to investigate determinants of acceptability. While these asso-
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ciations are often wrongly interpreted as causal links, they also don't
take into account the more complex pathway of decision-making.
Mediating analysis such as structural equation modelling should be
considered in order to better understand underlying mechanism of
behaviour [220].
Acceptability versus structural factors
While acceptability might be a first step towards HPV vaccination,
there are of course several factors that may impede the intention
and thus the translation towards behaviour. Many of these variables
might be related to community or organizational characteristics. For
example, the importance of community influencers to reach high
uptake reported in the post-vaccination studies of the demonstration
projects in Uganda and Vietnam imply that people reach out to
others in order to make a decision [121], [130]. Refusal of community
chiefs might thus hamper vaccination regardless of one's own (initial)
intention. Also, as mentioned above, even if HPV vaccination is
accepted and considered a priority, programmatic design can impose
too much when it comes to time and financial investments. As such,
studies which only take into account personal drivers and barriers
are limited and might oversee important organizational hindrances
[121]. Unfortunately, the majority of the HPV vaccine acceptability
studies don't investigate factors other than at individual level.
Also the application of health behaviour theories often encourages
the use of personal factors only: while theories provide a framework
for guiding the study and help researchers putting the problem in
a certain perspective, directing the design of the study in line with
this perspective, they also might blind the researcher for important
determinants other than the constructs. In the case of applying the
Health Belief Model in the context of HPV vaccination, indeed only
personal attitudes are investigated.
Although it is possible that in certain contexts personal opinions
are indeed the main components of action, this might be different
in other situations. By reviewing evaluations of HPV vaccination
programmes in LMIC and interviewing key informants, Wigle et al.
(2013) found that besides sociocultural barriers, health systems and
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political barriers are at least as important [118]. So besides study-
ing acceptability, attention should also go to those factors beyond
personal opinion.
Finally, rigorous testing of behavioural theories in several (cul-
tural) contexts regarding different preventive techniques is seldom
done [214], [220]. Since the development of many theories is West-
ern based and validation has also mainly been carried out in HIC,
one can question the applicability of behavioural theories in other
settings. The findings that health system barriers might be more
important than sociocultural barriers with regard to HPV vaccine
uptake in LMIC [118], indicate that theories at a personal level might
not be that applicable in settings were the quality of the health ser-
vices is not guaranteed. It is therefore important to test and compare
constructs and health behaviour theories in order to understand the
efficacy of these theories in predicting health behaviour in different
settings.
3.2 Vaccine hesitancy
During the past few years, the term vaccine hesitancy has popped
up in vaccination literature regarding reluctance towards immun-
ization, which is documented in both LMIC and HIC. However,
definition and usage - as attitude, behaviour or decision making
process - were not always consistent. Therefore, the WHO Strategic
Advisory Group of Experts (SAGE) established a Working Group
on Vaccine Hesitancy in 2012 to define and review vaccine hesitancy.
In the following years, reports and publications showed the results
of their work, among which following definition and determinants of
vaccine hesitancy: [221][223].
VACCINE HESITANCY "Vaccine hesitancy refers to delay
in acceptance or refusal of vaccination despite availability of vaccin-
ation services. Vaccine hesitancy is complex and context specific,
varying across time, place and vaccines." [223].
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3.2.1 Determinants of vaccine hesitancy
Contextual, individual and group, and vaccine/vaccination
specific influences
In terms of determinants of vaccine hesitancy, the SAGE Work-
ing Group proposed two models. A first model they developed is a
more complex model arranging identified determinants in three cat-
egories: contextual, individual and group, and vaccine/vaccination
specific influences (figure 3.1). While doing so, they reviewed liter-
ature and noticed that, like in HPV vaccine acceptability research,
determinants are often linked with the core constructs of popular so-
cial cognitive models, which are however limited and miss important
factors [221], [222], [224][226].
Figure 3.1: SAGE Working Group Determinants of Vaccine Hesit-
ancy Matrix
source: SAGE Working Group 2014
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Vaccine confidence, complacency and convenience
A second model that was identified was a framework that was
actually introduced by the WHO EURO Vaccine Communications
Working Group in 2011, presenting the "three C's", which stand
for vaccine confidence, complacency and convenience, as influencing
factors of vaccine hesitancy.
VACCINE CONFIDENCE "Trust in the effectiveness and
safety of vaccines and in the system that delivers them, including
the reliability and competence of the health services and health pro-
fessionals and having trust in the motivations of the policy makers
who decide which vaccines are needed and when they are needed.
Vaccination confidence exists on a continuum, ranging from zero
to 100 percent confidence. Vaccination confidence is only one of a
number of factors that affect an individual's decision to accept a vac-
cine." [221]
VACCINE COMPLACENCY "Vaccine complacency exists
where perceived risks of vaccine preventable diseases are low and
vaccination is not deemed a necessary preventive action. Besides
perceptions of the threat of disease severity and/or transmission,
complacency about a particular vaccine or about vaccination in gen-
eral can be influenced by under-appreciation of the value of vaccine
(effectiveness and/or safety profile) or lack of knowledge. Immuniz-
ation programme success may result in complacency and ultimately,
hesitancy, as individuals weigh risks of vaccines against risks of dis-
eases that are no longer common as a result of immunization." [221])
VACCINE CONVENIENCE "The quality of the service (real
and/or perceived) and the degree to which vaccination services are
delivered at a time and place and in a way that is considered appeal-
ing, affordable, convenient and comfortable, also affects the decision
to vaccinate. Vaccination convenience and complacency are also de-
termined by the priority that an individual places on vaccination."
[221]
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Vaccine confidence is probably by far the most documented de-
terminant. Especially in the last decade, several vaccine boycotts
have increased the interest in trust in vaccines, in particularly in
vaccine safety and effectiveness. In Nigeria, for example, the polio
vaccine was brought in discredit in 2003-2004, leading to outbreaks
across three continents. Similarly, the H1N1 vaccine caused a lot of
disturbance during the pandemic in 2009-2010, while more recently,
the HPV vaccine was rejected in Spain, Greece, the Netherlands,
Cameroon, India and Japan. In all countries, a drop in HPV vac-
cine acceptability and uptake was seen after incomplete messages re-
garding non-associated adverse effects were circulated by the media
[127], [128], [150], [227][231]. In the latter country, where the gov-
ernment stopped actively recommending the vaccine, coverage rates
even dropped from 70 percent to 5 percent. In addition, rumours
were rapidly picked up by media from other countries resulting there
also in confidence loss (figure 3.2) [128], [230], [231].
Figure 3.2: Global transmission of HPV related reports and rumours
from and towards Japan in 2014
source: Larson 2014
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Also anti-vaccination groups - who believe that vaccines hamper
(the development of) the immune system, cause diseases such as
autism and autoimmune disorders, and are introduced out of finan-
cial interest of the pharmacy - spread their messages quickly and
far-out by (social) media. Research showed that the majority of
Youtube videos regarding HPV vaccination were negative in tone
and that videos disapproving the vaccines were more viewed [232].
Through these channels they can directly influence people's beliefs
about vaccines and consequently vaccination coverage. Generally,
(social) media tend to publish more over-simplified, negative mes-
sages which endangers vaccine trust and induces loss in confidence
and thus vaccine hesitancy [194], [233], [234].
In general, both models - the matrix and the three C's - include
many factors that are traditionally addressed in vaccine acceptability
studies, such as fear for side effects or perceived severity. This is not
entirely surprising given that vaccine hesitancy can be defined as a
continuum between full acceptance and outright refusal of a vaccine.
3.2.2 Vaccine hesitancy as a decision-making pro-
cess
Peretti-Watel et al. (2015) further elaborated on the work of the
SAGEWorking Group and developed a theoretical framework to fur-
ther minimize ambiguous notions. They argued that while vaccine
hesitancy is often conceived as a temporary attitude of individuals
who are situated in an anti/pro continuum, this does not imply that
they are against or in favour of vaccination in general, but rather
that they endorse intermediate feelings regarding one or more vac-
cines in particular. As such, it might be more appropriate to define
vaccine hesitancy as a decision-making process. This process can
be simple (without hesitancy), for people with strong pro-vaccine or
anti-vaccine convictions, or difficult (with hesitancy) for those with
doubts. Additionally, there is a third group, namely people who
have little interest in the vaccine. So while this latter group shares
the same behaviour as those who are doubting, i.e. delaying vaccin-
ation, and while they are also positioned in the intermediate of the
anti/pro continuum, they are not committed to look for information
to make a balanced decision [235]. Defining vaccine hesitancy as a
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process rather than an attitude, i.e. a position on a pro/anti vaccin-
ation continuum, thus shifts the focus from an outcome of interest,
i.e. vaccine uptake, delay or refusal, towards the pathway by which
this behaviour is reached.
Finally, Peretti-Watel et al. (2015) created a framework in which
four groups are identified - passive conformism, passive hesitancy,
enlightened conformism and rationalized hesitancy - by combining
two major factors of vaccine hesitancy: trust in authorities, and
risk/culture and healthism, i.e. exerting autonomy over and super-
valuing health (figure 3.3). People with low trust might thus shift,
for example after being exposed to promotion, from passive to ra-
tionalized hesitancy; lately this is observed in some high-educated
subgroups, merely in HIC [235]. This approach clearly allows for
more differentiation than more traditional divisions of vaccinated
vs. non-vaccinated, or acceptors vs. non-acceptors of vaccines.
Figure 3.3: Vaccine hesitancy along two axes: commitment to risk
culture/healthism (horizontal) and distrust/trust toward health au-
thorities
source: Peretti-Watel et al. 2015
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3.3 Rationale
Cervical cancer imposes a huge health threat on women in Sub-
Sahara Africa and the burden will only increase - due to the current
demographic explosion - if no extra effort is undertaken. The de-
velopment of primary prevention techniques, i.e. HPV vaccines, can
however induce a turning point in the process of eradicating HPV
infections and the associated cancers.
Prior to introducing the HPV vaccine in national immunization
programmes, acceptability studies are encouraged in order to estim-
ate a population's readiness for this new preventive method. How-
ever, even though a lot of effort is put into measuring HPV vaccine
acceptability, it is not guaranteed that
• from a public health perspective it is justified to measure ac-
ceptability: is acceptability a major determinant of uptake or
not?
• we use the correct theories to identify determinants of vaccine
acceptability and uptake.
• acceptability studies cover the most important factors leading
to successful vaccination programmes.
Few studies have indeed investigated whether high HPV vaccine
acceptability really leads to high uptake. Similarly, pilot vaccination
projects provide limited insight in how they reached good coverage:
to what extent are personal believes important and at what point
do organizational decisions play a role in achieving high uptake?
In order to inform countries on how to introduce HPV vaccination
successfully, a critical reflection on the usefulness of acceptability
studies is necessary, as well as evidence based lessons learned from
demonstration projects.
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Part IV
OBJECTIVES
63
64
General objective
The general objective of this doctoral research is to con-
tribute to the understanding of factors influencing HPV
vaccine introduction.
Specific objectives and research ques-
tions
Objective 1: To determine the acceptability and subsequent
uptake of the HPV vaccine in the context of an HPV pilot
vaccination programme in Eldoret, Kenya.
1. What are determinants of HPV vaccine acceptability and up-
take - is acceptability a predictor for uptake?
2. Which barriers to vaccinate do people foresee and which are
eventually encountered during a vaccination programme?
Hypotheses: Acceptability will be high yet uptake will be some-
what less: both outcomes will be related to each other, but pre-
cursors of behaviour such as acceptability are not always translated
into action. Knowledge will be associated with acceptability and
uptake, but HPV vaccination will also be influenced by practical
barriers. Finally, fear for side effects will be a major reason for
refusing the vaccine as opposed to conservative attitudes towards
vaccinating young girls against an STI; for many, protection against
cervical cancer will be the convincing driver.
Objective 2: To ascertain whether health behaviour
theories can be effectively applied to predict HPV
vaccination in Eldoret, Kenya.
1. Do the constructs of the Health Belief Model predict uptake?
2. Do the constructs of the Health Belief Model predict accept-
ability?
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3. What is the added value of a precursor of behaviour, such as
acceptability or intention, in the Health Belief Model?
4. What is the added value of mediating and moderating personal
characteristics?
Hypotheses: Most constructs of the Health Belief Model will pre-
dict uptake but associations with acceptability will be higher. As
such, adding a precursor of behaviour will increase the predictive
value of the theory. Socio-demographic factors will have a substan-
tial, direct impact on behaviour and will hence improve the model.
Objective 3: To identify factors that influence successful
introduction of an HPV vaccination programme in
Eldoret, Kenya.
1. How were people mobilized - which factors defined the success
of the promotional strategy, taking into account determinants
of vaccine hesitancy (figure 3.1):
• Contextual influences, such as the communication envir-
onment and religious or cultural characteristics?
• Individual and/or group influences, such as knowledge
and beliefs about cervical cancer, vaccine related experi-
ences and health literacy?
• Vaccine/vaccination-specific issues, such as health care
providers' capacities to promote, and attitude towards
the vaccine and the programme?
2. Did people have a good understanding of HPV and cervical
cancer after the programme had finished?
3. How did the service delivery operations, i.e. the vaccination
strategy, influence vaccine uptake, taking into account determ-
inants of vaccine hesitancy (figure 3.1):
• Contextual influences, such as socio-economic or logistic
barriers?
• Individual and/or group influences, such as trust in the
health system?
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• Vaccine/vaccination-specific issues, such as the adminis-
tration schedule or novelty and reliability of the vaccine?
Hypotheses: Awareness will improve but correct understanding
of HPV and cervical cancer will still be limited; this will not influence
vaccine uptake. Programmatic design, such as assuring absence of lo-
gistic barriers and clear communication regarding the availability of
the vaccine will be strong determinants of vaccine uptake. Therefore,
direct communication and recommendations of health care providers
with the caregivers of the girls will be crucial. Failure of achieving
such contact moments will lead to poor uptake and will allow the
spread of rumours. In addition, given the novelty of the HPV vac-
cine, hesitancy towards the vaccine will be common, mainly due to
lack of confidence.
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Part V
STUDY SETTING AND
METHODOLOGY
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Chapter 4
Study setting
4.1 HPV infections and the burden of cer-
vical cancer in Kenya
4.1.1 Cervical cancer
Kenya has one of the highest incidence rates in the world for cer-
vical cancer. With a crude incidence of 22.4/100,000 a year and age-
standardized of 40.1/100,000, it is the most common female cancer
in Kenya, leaving even breast cancer behind. Likewise, cervical can-
cer is also the most lethal cancer among Kenyan women (mortality
of 11.5/100.000 a year; age-standardized 21.8/100,000) (see figure
4.1). Age specific incidence and mortality rates are similar to those
of other Eastern African countries and of course far above the world
averages (figures 4.2 and 4.3) [236].
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Figure 4.1: Cancer incidence and mortality among women in Kenya;
estimations for 2012
source: Globocan 2012
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Figure 4.2: Age specific incidence rates of cervical cancer in Kenya,
Eastern Africa and the world; estimations for 2012
Figure 4.3: Age specific mortality rates of cervical cancer in Kenya,
Eastern Africa and the world; estimations for 2012
source: Human Papillomavirus and Related Diseases Report - KENYA -
2015
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As a result of the high incidence and the poor prognosis of most
patients, cervical cancer poses a high burden on the Kenyan health
system. The low survival chances are often due to late detection and
limited prevention and treatment options. Data on cervical cancer
screening is scarce but clearly shows inadequate usage. According to
the WHO Household survey of 2002, only 4 percent of urban women
and 2.6 percent of rural women had been screened in the last ten
years [236]. A more recent study (2007-2009) by Rositch et al. (2012)
in Nairobi measured that 14 percent of the female participants had
ever had a pap smear and only 18 percent recognized screening as
the most conventional method to prevent cervical cancer [237]. In
Kisumu, on the other hand, only 6 percent of the women visiting
health facilities reported to be screened previously (2007) [238].
Also, while the disease is highly prevalent and has a devastating
impact on the reproductive health of many women, knowledge re-
mains low in Kenya. For example, a study among women in health
facilities near Kisumu showed that only 22 (15 percent) of them had
ever heard of cervical cancer [168]. Older studies also present low
knowledge rates and one study showed that even among cervical can-
cer patients only 52 percent had heard about the disease (2003-2005)
[239], [240].
In addition to low awareness and limited health services, which in-
hibits people to look for preventive medicine, there are many more
factors that stimulate the expansion of this epidemic. Onset of
sexual activity at young age and unsafe sexual practices, both re-
cognized as risk factors for cervical cancer, are rather common in
the Kenyan community. According to the latest Demographic and
Health Survey, 12 percent of women age 20-49 years had their sexual
debut before the age of 15 and about half of them before they were
18 years old. Regarding safe sex, only 24 percent of women reported
condom use at first sexual encounter, and among the sexually active
women age 15-24, 33 percent had engaged in higher-risk intercourse
during the last 12 months [241].
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4.1.2 HPV infections
In Kenya, various studies have defined the prevalence of HPV. A
study in Mombasa showed a prevalence of 42.3 percent of infection
with any type of HPV. Of those infected, 46 percent had a mul-
tiple infection and the most prevalent types were HPV 58, 16, 53,
18 and 6 (decreasing order) [242]. Another study in Nairobi found
44.3 percent of cervical samples positive, with HPV 52, 16, 35 and
66 as most present types (decreasing order). HPV 16, 52 and 35
were frequently detected in high-grade lesions [243]. Among HIV
negative and HIV positive women with invasive cervical cancer, the
same distribution of HPV types is reported for both groups: HPV
16 and/or 18 were found in over 60 percent of the cancers. Mul-
tiple infections were, as expected, also more present among the HIV
positive women [244]. Finally, in a study among female sex work-
ers in Mombasa, HPV 16 and/or 18 did not seem the most present
types: of the screened women, 22.8 percent was positive for HPV
16 and/or 18 while almost 50 percent was infected with other HPV
types. Of all women, 35.2 percent was HIV infected and co-infection
with HPV was seen among one fourth of them. Among the HIV
positive women, cervical abnormalities were more present [245].
In conclusion, even though not all studies detected HPV 16 and
18 as most present HPV types, both viruses clearly contribute to the
spread of cervical cancer in Kenya. Therefore, we can conclude that
the application of the HPV vaccines would have a major impact if
adequate coverage rates is reached.
4.2 The HPV vaccination demonstration
project in Eldoret, Kenya
Through the GARDASIL Access Program (GAP), the Moi Re-
ferral and Teaching Hospital was granted 9,000 doses of the quad-
rivalent vaccine to vaccinate young girls in Eldoret, Kenya. The vac-
cines were used to pilot HPV vaccination focusing both on comple-
tion of the scheme (three doses in six months) and safety. Hospital-
based vaccination was chosen to reduce the costs of the programme.
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In order to avoid excess demand, promotion of the programme
was originally restricted to a limited number of government primary
schools. Only schools within the Eldoret Municipality were con-
sidered to avoid non-uptake due to transport issues. Up to ten
schools (out of forty-two) were randomly selected until a total of
about 4,000 eligible girls was reached, expecting a coverage of around
75 percent (3000/4000). However, if eligible girls who were not en-
rolled in these schools showed up at the vaccination site (i.e. the
hospital), they were not refused.
The vaccines were offered to girls in classes 4 to 8, approximately
9 to 14 years old. The teachers were sensitized by health staff and
through providing leaflets, and were subsequently asked to instruct
students and parents. To do so, some schools organized parent meet-
ings, other schools distributed letters while others just asked the
students to inform their parents about the upcoming vaccination
programme.
Vaccination took place on Saturdays and Wednesdays, from May
2012 to March 2013. After consent was obtained from an adult care-
giver, nurses from the hospital vaccinated the girls for free. Given
that a three dose schedule was planned, a vaccination card with a
next appointment was given after the first and second dose. Addi-
tionally, nurses called the caregiver to remind them about the second
and third dose if they had not showed up on the scheduled day.
Because of the low response during the first three months of the
programme, other schools in the County, government and private,
were also invited to participate from August 2012 onwards, and a
local radio announced the vaccination opportunity as well. Con-
sequently, sufficient demand was created and in September 2012,
the programme stopped administering the first dose after reaching
3,000 girls in order to guarantee sufficient vaccines for the following
doses.
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Chapter 5
Study design
A mixed-method approach was chosen: quantitative data was col-
lected, primarily to address the research questions related to spe-
cific objectives one and two (studying the gap between acceptability
and uptake, and testing the HBM). A qualitative component, more
specifically focus group discussions (FGD) with key stakeholders,
was organized to answer the research questions of specific object-
ive three (identifying factors that influenced the success rate of the
programme).
5.1 The quantitative component: a lon-
gitudinal study
Given the dearth of longitudinal studies measuring HPV vaccine
acceptability and uptake, a cohort study was set up. The study par-
ticipants were mothers from eligible girl pupils who were enrolled in
one of the ten initially selected schools of the HPV vaccination pro-
gramme in Eldoret. The women were interviewed before the onset of
the programme, assessing HPV vaccine acceptability (March 2012)
and once it was finished, recording reported HPV vaccine uptake
(May 2013). Through including mothers of eligible girls in the tar-
geted schools, we assured that all participants would have had the
option, in theory, to fully vaccinate their daughter against cervical
cancer through the demonstration programme.
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5.1.1 Recruitment of participants
Baseline After obtaining permission of the head teachers of the
ten initially included schools, girls were randomly selected from the
class lists of classes 4-8: the number of selected girls per school
was proportional to the total number of girls in standard 4-8 of the
ten selected schools, and the number of selected girls per class was
proportional to the total numbers of girls in the classes 4-8 of that
particular school. A short informative talk was given to teachers
present, and in all schools leaflets were left behind to inform all
teachers about the longitudinal study and the upcoming vaccination
programme. Teachers were asked to hand out invitation letters to
the selected girls. Through these letters, directed to the mother
or female guardian, potential participants were invited to attend
a face-to-face, informative session and interview regarding cervical
cancer prevention, the next Saturday at school. If they were not
able to make it but were willing to participate, they could return
the invitation letter leaving us their telephone number so that we
could reach out to them and schedule another appointment. They
were given the choice to be interviewed at school or any other place
they would prefer. Given the study context, all participants were
mothers/guardians of young, teenage girls, living in an urban/semi-
urban area.
Follow-up At the start of the baseline interview, it was made
clear to the invited women that we intended to contact them again
one year later, to ask for their final decision and actions regarding
vaccinating their daughter against cervical cancer. Once agreed on,
contact information was collected, including telephone numbers of
the participant and people close to them, as well as a description of
how to reach their house. These data were used to contact and invite
the same women the year after for the follow-up interview. Again,
interviews took place at school, at home or any other place of their
choice. If women were unable to attend a face-to-face interview,
some key questions regarding the uptake of the HPV vaccine were
asked over the phone.
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Sample size calculation To estimate the relation between baseline
acceptability and vaccine uptake reported at follow-up, sample size
for comparing two proportions was calculated, expecting acceptab-
ility among 75 percent of the participants and uptake among 60
percent of the non-acceptors and among 80 percent of the accept-
ors (power 80 percent). Anticipating non-participation and loss to
follow-up, we doubled the required sample size of 234, thus aiming
at distributing 468 invitation letters for the baseline study.
5.1.2 Procedures and measurements
Baseline A structured questionnaire was developed, using the HBM
and the TPB as main frameworks to assess HPV vaccine acceptabil-
ity, intention to vaccinate, and attitudes towards cervical cancer and
HPV vaccination. In addition, socio-demographics and knowledge
and awareness were assessed. Furthermore, the baseline interview
included an informative session in order to allow the interviewee
to make informed decisions about HPV vaccination. Leaflets with
comprehensive facts and pictures about cervical cancer and HPV
vaccination assisted the interviewer during these talks and assured
consistency. Also the upcoming HPV vaccination programme was
mentioned during this informative moment in order to ensure that
women understood that the vaccine would soon be freely available at
the hospital. Information was shared after gauging knowledge and
awareness but before assessing willingness to vaccinate and theory
related constructs.
Follow-up During the follow-up interview, participants were asked
whether or not their daughter had received the HPV vaccine and
if yes (i.e. had received at least one dose), what difficulties they
had encountered in doing so. Women who had not vaccinated their
daughter were asked to explain what had stopped them or why they
had actively refused the HPV vaccine for their daughter. Finally,
also the promotion of the programme was evaluated, i.e. whether
or not the women had received information about HPV vaccination
and the whereabouts of the programme - other than what they had
received during the baseline interview - and whether this information
had been useful to them.
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5.1.3 Data management and analysis
In a first step of the analysis, determinants of HPV vaccine accept-
ability and uptake were identified using bivariate and subsequently
multivariate logistic regression. While doing so, also the relation
between these two outcome variables was investigated. Given the
survey design, adjusted odds ratios were calculated taking into ac-
count the schools as primary sampling unit and using weights to
adjust for discrepancies between the sample and the population.
This post-stratification corrected for differences in the distribution
of women invited per school compared with the proportion of girls in
classes 4 to 8 of each school on the total number of girl pupils in these
classes among the ten schools. In addition, a descriptive analysis of
the follow-up data was carried out to gain insight in the barriers
women had encountered while trying to vaccinate their daughter or
reasons why they had refused to do so.
Secondly, the HBM was tested applying structural equation mod-
elling. This pathway analysis allowed to verify the mediating and/or
moderating effect of the constructs on HPV vaccine uptake as well
as of socio-demographic variables. The predictive value of the model
expanded with willingness to vaccinate, as precursor of vaccine up-
take, was also measured.
5.2 The qualitative component: focus group
discussions
At follow-up, the quantitative data was complemented with FGD
with key stakeholders. More particularly, fathers of eligible girls
were invited as to understand the perspective of the male guardian
related to HPV vaccination of young girls. Furthermore, teachers
and vaccinators were included to obtain their view on the HPV vac-
cination programme and to evaluate their tasks, i.e. promoting HPV
vaccination and administering the vaccines respectively. The FGD
were coded and analysed openly and subsequently the results were
shared with the programme coordinator as to obtain his view on the
course and the evaluation of the programme.
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5.2.1 Recruitment of participants
Fathers of eligible girls were contacted using the contact inform-
ation of themselves and their partners gathered during the baseline
study. Teachers were invited by visiting the schools and, after ob-
taining approval of the head teacher, addressing them and schedul-
ing a FGD. In addition, leaflets with invitations were left behind for
those teachers who were not present at the moment of the research
team's visit. Finally, the vaccinators were notified of the FGD by the
head nurse of the hospital who also had been in charge of organizing
the work of the vaccinators during the vaccination programme.
5.2.2 Measurements
Both fathers' and teachers' knowledge regarding cervical cancer
and HPV prevention was assessed, as well as their attitudes towards
the HPV vaccine. In all FGD, awareness regarding the HPV vac-
cination programme that had taken place was evaluated, while also
the strengths and weaknesses of the programme were discussed and
possibilities on how to improve future programmes were explored.
Also the course of the programme was discussed, mainly with the
vaccinators and the programme coordinator.
5.3 Research ethics
Ethical approval was obtained for both baseline and follow-up
study, and the FGD by the ethical boards of Ghent University, Bel-
gium, and Moi University, Kenya. Written and oral informed con-
sent was obtained from the participants of the longitudinal study
for the baseline and follow-up surveys, respectively. With exception
of the women who were interviewed by phone, all interviewees of
the follow-up survey received 200 KES (approximately 1.5 euro). In
addition, signed consent forms were requested from all participants
of the FGD and all received 200 KES (approximately 1.5 euro).
All field workers who assisted in this study were trained concern-
ing three aspects: 1) basic knowledge and understanding of cervical
cancer and HPV vaccination, 2) apprehension of the questionnaire
or interview guide, and 3) awareness of the rights of, and skills to
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approach (potentially vulnerable) participants. As such, interview-
ers were prepared to provide information when necessary and to
explain potential participants that participation was voluntary and
independent from their view regarding HPV vaccination.
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Part VI
RESULTS
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Outline
The results section is divided into three parts, following the ob-
jectives of the thesis. Each objective and its corresponding research
questions are mainly addressed in one paper, although some are
answered throughout the papers.
paper 1: published Vermandere H, Naanyu V, Mabeya H, Vanden
Broeck D, Michielsen K, Degomme O. Determinants of Acceptance
and Subsequent Uptake of the HPV Vaccine in a Cohort in Eldoret,
Kenya. PLoS One. 2014;9(10):e109353. doi:10.1371/journal.pone.0109353.
paper 2: submitted - currently under review Vermandere
H, van Stam MA, Naanyu V, Michielsen K, Degomme O, Oort F.
Uptake of the Human Papillomavirus Vaccine in Kenya: testing the
Health Belief Model through structural equation modeling on Cohort
Data. Globalization and Health.
paper 3: published Vermandere H, Naanyu V, Degomme O,
Michielsen K. Implementation of an HPV vaccination program in
Eldoret, Kenya: results from a qualitative assessment by key stake-
holders. BMC Public Health. 2015;15(1):875. doi:10.1186/s12889-
015-2219-y.
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Chapter 6
Determinants of
Acceptability and
Subsequent Uptake of the
HPV Vaccine in a Cohort
in Eldoret, Kenya
Paper 1: HPV vaccine acceptability and uptake In this first
paper, the results of the longitudinal study are presented, i.e. HPV
vaccine acceptability at baseline and HPV vaccine uptake at follow-
up. While there are many acceptability studies - and the number is
still growing, definitely in LMIC - only few have been able to also re-
port the subsequent behaviour, i.e. vaccination. To our knowledge,
this is the first cohort study in Sub-Sahara Africa covering determ-
inants of both acceptability and uptake of the HPV vaccine, and the
relation between these two outcome variables. At the same time,
the paper reports on the perspectives of female caregivers of young
girls towards the HPV vaccine and the demonstration programme,
more particularly the barriers they foresaw and encountered.
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Participation rates in the cohort study
Table 6.1 gives an overview on how invitations and subsequent par-
ticipation rates led to the final study cohort: Aiming at 468 in-
vitations, we eventually invited 472 mothers of girls in standard
4-8 of the ten schools initially targeted by the programme. Among
these, 287 (60.81 percent) and 256 (89.20 percent) participated in
the baseline and follow-up study respectively.
Table 6.1: Participation rates per school (10) and weights applied
to adjust for the survey design
Girls in
school
(propor-
tion)
Girls
invited
(propor-
tion)
Baseline
parti-
cipation
(rate)
Weights
adjust-
ing diff.
part.
rates*
Post-
stratifi-
cation
weights**
Follow-
up
parti-
cipation
(rate)
1 778 57 38 21.61 1.14 37
(0.14) (0.12) (66.67) (97.37)
2 617 63 41 17.95 0.82 33
(0.11) (0.13) (65.08) (80.49)
3 278 28 9 15.72 0.83 9
(0.05) (0.06) (32.14) (100.00)
4 527 43 32 11.23 1.02 25
(0.09) (0.09) (74.42) (78.13)
5 608 52 37 14.61 0.97 33
(0.11) (0.11) (71.15) (89.19)
6 291 24 16 8.08 1.01 13
(0.05) (0.05) (66.67) (81.25)
7 470 41 25 15.28 0.96 24
(0.08) (0.09) (60.98) (96.00)
8 1087 93 44 47.72 0.97 42
(0.19) (0.20) (47.31) (95.45)
9 240 20 15 5.00 1.00 14
(0.04) (0.04) (75.00) (93.33)
10 769 51 30 26.38 1.26 26
(0.14) (0.11) (58.82) (86.67)
Total 5665 472 287 - - 256
(1.00) (1.00) (60.81) (89.20)
* proportion girls in school/proportion girls invited)*(nr of girls invited - baseline
participation
** Weights adjusting for difference in proportions 'number of girls in school' and
'number of girls invited' (proportion girls in school/proportion girls invited)
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Abstract
The development of Human Papillomavirus (HPV) vaccines provides new opportunities in the fight against cervical cancer.
Many acceptability studies have revealed high interest in these vaccines, but acceptance is only a precursor of behavior, and
many factors, at personal, community and provider level, may inhibit the translation of willingness to vaccinate into actual
uptake. Through a longitudinal study in Eldoret, Kenya, HPV vaccine acceptability was measured before a vaccination
program (n = 287) and vaccine uptake, as reported by mothers, once the program was finished (n = 256). In between
baseline and follow-up, a pilot HPV vaccination program was implemented via the GARDASIL Access Program, in which
parents could have their daughter vaccinated for free at the referral hospital. The program was promoted at schools: Health
staff informed teachers who were then asked to inform students and parents. Even though baseline acceptance was very
high (88.1%), only 31.1% of the women reported at follow-up that their daughter had been vaccinated. The vaccine was
declined by 17.7%, while another 51.2% had wanted the vaccination but were obstructed by practical barriers. Being well-
informed about the program and baseline awareness of cervical cancer were independently associated with vaccine uptake,
while baseline acceptance was correlated in bivariate analysis. Side effects were of great concern, even among those whose
daughter was vaccinated. Possible partner disapproval lowered acceptance at baseline, and women indeed reported at
follow-up that they had encountered his opposition. In Kenya, women prove to be very willing to have their daughter
vaccinated against cervical cancer. However, in this study, uptake was more determined by program awareness than by HPV
vaccine acceptance. School-based vaccination might improve coverage since it reduces operational problems for parents. In
addition, future HPV vaccination campaigns should address concerns about side effects, targeting men and women, given
both their involvement in HPV vaccination decision-making.
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Introduction
Cervical cancer, caused by the oncogenic Human Papilloma-
virus (HPV), continues to be life- threatening for women
worldwide. Especially in resource-limited settings, where screening
is rare and high-quality treatment is either unavailable or
unaffordable, health outcomes for infected women are poor. As
a result, 85% of the 530,000 new cases annually occur in
developing countries. Kenya is no exception and has one of the
highest incidence and mortality rates associated with cervical
cancer across the globe. [1–3]
With the introduction of HPV vaccines, primary prevention
against HPV 16 and 18 has become a possibility. Given that the
vaccines are most effective in HPV-naı¨ve populations, young girls
are the primary target group, with the aim of vaccinating before
sexual debut and as such avoiding potential infections. [4–7]
Before implementing large-scale vaccination programs, however,
various knowledge gaps need to be addressed [8]: in Kenya, for
example, little is known about people’s attitudes towards the
vaccines and different vaccination strategies should be tested.
[9,10]
Acceptability studies, primarily conducted in Western countries
and some, more recently, in low- and middle-income countries
(LMICs), generally indicate a high interest in these vaccines, but
safety, cost and certain socio-cultural factors are often identified as
obstructions. These concerns arise from the fact that the vaccines
are relatively new and that it may be considered inappropriate to
target young adolescent girls to prevent infection with a sexually
transmittable virus. [11–16] Sub-Saharan African studies found
similar results although cervical cancer awareness and knowledge
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is often very poor. [9,10,15–29] A study in Ghana also reported a
high willingness to vaccinate; yet, many participants were
concerned about side effects, such as influencing the girls’ fertility
and unsafe administration of the vaccine (i.e. using unclean
needles). [16] In Kisumu, West-Kenya, Becker-Dreps et al.
initially found high acceptance (95%), but this rate dropped when
mentioning that vaccination requires three shots (31%). [9]
Moreover, acceptance has been suggested to vary among ethnic,
religious and socio-economic groups. [30–32]
A recent review by Wigle et al. showed that in LMICs, health
system and political barriers may impede the development of
sustainable, successful programs more than socio-cultural obstacles
do. For example, reaching the target population has proved to be
challenging. [33] Adolescent care is often lacking or not prioritized
in health centers, and while school-based delivery is mostly
successful, it remains conditional on high attendance. [33,34] In
addition, post-vaccination studies have revealed that vaccine
uptake can be affected by program-related issues, such as
community sensitization and involvement of the government.
[35–38] Research should therefore go beyond the study of
hypothetical acceptability and explore the entire pathway leading
to vaccine uptake.
To this end, this longitudinal study aims to survey the
acceptability, subsequent uptake and encountered barriers from
the perspective of the mothers of young girls, in the context of a
pilot HPV vaccination program in Eldoret, Kenya. This design
enables us 1) to determine demographic predictors of baseline
acceptability and uptake at follow-up, 2) to investigate to what
extent acceptance itself is a predictor of behavior, and 3) to identify
the barriers that were actually encountered as opposed to those
foreseen. To our knowledge, this is the first longitudinal study
measuring HPV vaccine acceptance and subsequent uptake in
Africa.
Methods
The GARDASIL Access Program
This longitudinal study took place before and after the
implementation of a pilot vaccination program. Through the
GARDASIL Access Program (GAP), the Moi Referral and
Teaching Hospital was granted 9,000 doses of the quadrivalent
vaccine to vaccinate young girls in Eldoret, Kenya. [39] In order
to avoid excess demand, promotion of the program was restricted
to a number of randomly selected government primary schools,
although other girls from the community were not refused if they
showed up at the vaccination site (i.e. the hospital). A hospital-
based vaccination was chosen to reduce the costs of the program.
In order to avoid non-uptake due to transport issues, only schools
within the Eldoret Municipality were considered.
The vaccines were offered to girls in classes 4 to 8,
approximately 9 to 14 years old, from ten primary schools in
Eldoret Municipality. These schools were randomly selected until
a total of about 4,000 eligible girls was reached, expecting a
coverage of around 75% (3000/4000). [38,40–42] The teachers
were sensitized by health staff and through providing leaflets, and
were subsequently asked to instruct students and parents.
Vaccination took place on Saturdays and Wednesdays, from
May 2012 to March 2013. After consent was obtained from an
adult caregiver, nurses from the hospital vaccinated the girls for
free. Given that a three dose schedule was planned, a vaccination
card with a next appointment was given after the first and second
dose. Additionally, nurses called the caregiver to remind them
about the second and third dose if they had not showed up on the
scheduled day.
Because of the low response during the first 3 months of the
program, other schools in the County, government and private,
were also invited to participate from August 2012 onwards, and a
local radio announced the vaccination program as well. In
September 2012, the program stopped administering the first
dose after reaching 3,000 girls in order to guarantee sufficient
vaccines for the following doses.
Recruitment of study participants
Two months before the start of the vaccination program (March
2012), a random selection of mothers from girls in classes 4 to 8
from the ten selected schools were invited for a face-to-face
interview: after randomly selecting girls from class lists in each
school, invitation letters for the baseline interview, addressed to
their mothers, were given to the girls. The number of invitation
letters per school was proportional to the total number of girls in
classes 4 to 8 of the ten schools. Two months after the vaccination
program was closed (May 2013), the same mothers were invited
for a follow-up interview by using the contact information they
had provided during the baseline interview. If women were unable
to participate again, yet reachable by phone, they were asked to
answer a few key questions regarding uptake over the phone.
To estimate the relation between baseline acceptance and
vaccine uptake reported at follow-up, sample size for comparing
two proportions was calculated, expecting acceptance among 75%
of the participants and uptake among 60% of the non-acceptors
and among 80% of the acceptors (power 80%). Anticipating non-
participation and loss to follow-up, we doubled the required
sample size of 234, thus aiming at distributing 468 invitation letters
for the baseline study.
Procedures
The interviews were conducted in Swahili or English, according
to the interviewee’s preference, and took place at school, work or
home, again as chosen by the participant. To verify clarity and
correct wording of the questionnaire, pilot tests were performed
for the baseline and follow-up surveys (n = 4, n = 9, respectively).
During the baseline interview, all women separately received basic
information from the interviewer regarding cervical cancer,
screening and HPV vaccination. Leaflets with comprehensive
facts and pictures were used to assure consistency. In addition, the
participants were also informed about the upcoming vaccination
program and were made aware of the fact that they would be
invited for a follow-up interview once the vaccination program was
finished. Interviewers emphasized that participation in the baseline
and follow-up study, should not affect the decision to have their
daughter vaccinated.
Measures at baseline
Before the participants were provided with basic information as
mentioned above, socio-demographic characteristics were col-
lected, and their awareness concerning cervical cancer was
assessed. Once the participants had been informed, their attitudes
towards the HPV vaccine were investigated: 1) Acceptability was
evaluated by asking the participants to score the question ‘would
you vaccinate your daughter against cervical cancer?’ on a 5-point
Likert scale, and 2) Perceived barriers, were assessed by first using
an open question and subsequently giving reasons why not to
vaccinate with which the participants could agree or disagree (5-
point Likert scale). Acceptance was defined as ‘(very) likely to
vaccinate your daughter’ (scores 4–5). Potential barriers, derived
from literature [9,16,29,30,43,44], comprised a lack of informa-
tion, concerns about efficacy, side effects, infertility and unsafe
administration (i.e. using unclean needles), worries about encour-
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aging unsafe sexual activity, a perception of the daughter as too
young, disapproval by the partner, time constraints and the
inconvenience of three doses.
Measures at follow-up
The vaccination status of the daughter was verified by asking
the mother. Participants whose daughter was not vaccinated were
asked, regardless of their reported baseline acceptance, whether
they had actively decided not to vaccinate (refusers) or whether
they had wanted to vaccinate but had failed to do so. Initiation of
vaccination (i.e. having received at least one dose) was considered
as ‘being vaccinated’ in further analysis. Additionally, participants
were asked whether they had received information regarding the
HPV vaccination program.
In terms of barriers, all problems encountered were document-
ed: mothers from vaccinated girls were asked which difficulties
they had had to overcome (open and closed yes/no questions),
while the others were asked why they had refused the vaccine
(open question) or why they had not managed to have their
daughter vaccinated as they had intended (open, and closed yes/
no questions). Closed questions measuring reasons for not
vaccinating included lack of time, transport costs, disapproval of
somebody, refusal of daughter, fear of side effects and not knowing
where and when to go for vaccination, and were obtained from
literature. [35,38,45,46]
Analysis
In the analysis of the surveys, answers to open questions were
grouped, and emerging themes were identified. The baseline
characteristics and attitudes of non-respondents and respondents
from the follow-up study were compared based on the Mann-
Whitney-Wilcoxon test and chi-square analysis. For this purpose,
perceived barriers were converted from a 5- into a 3-point scale,
combining scores 1-2 and 4-5. In logistic regressions, baseline
barriers were entered as continuous variables.
We used bivariate logistic regressions to examine correlates of
baseline HPV vaccine acceptance and vaccination status. Given
the small variation in baseline participation rate per school,
adjusted odds ratios were calculated: weights were applied to take
into account the missing observations. Additionally, schools were
considered as a primary sampling unit; thus, we corrected for
clustering at school level.
For each outcome variable (i.e. acceptance and uptake), three
multivariate logistic regression models were developed with
baseline variables. In the first model, the participants’ character-
istics were included, whereas in the second, all perceived barriers
were incorporated. Independent items measuring the same barrier
were grouped together - conditional on high internal consistency
(i.e. Cronbach’s alpha. 0.75) - to avoid multicollinearity. Lastly,
the third model comprised baseline variables which were selected
through backward stepwise regression. For the outcome variable
uptake, an additional model was created by adding acceptance
Figure 1. Flow diagram of participation in a longitudinal study, measuring baseline acceptance and subsequent uptake of the HPV
vaccine.
doi:10.1371/journal.pone.0109353.g001
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Table 1. Baseline characteristics, perceived barriers and acceptance of the HPV vaccine; comparing respondents and non-
respondents of the follow-up study.
TOTAL BASELINE
(n =287)
FOLLOW-UP RESPONDENTS
(n=256) NON-RESPONDENTS (n =31)
BASELINE CHARACTERISTICS
Median (IQR) Median (IQR) Median (IQR) p-value
Participant age at baseline 35 (32–40) 35 (32–40) 35 (39–40) 0.43
Range (years) 21 – 59 21 – 59 23 – 56
Age of daughter at baseline 12 (11–14) 12 (11–14) 12 (11–13) 0.68
Range (years) 8 – 18 8 – 18 8 – 17
Years of education of participant 8 (7–12) 8 (7–12) 8 (6–11) 0.35
Range (years)* 0 – 13+ 0 – 13+ 0 – 13+
Housing characteristics** 5 (4–5) 5 (4–5) 5 (4–6) 0.04
Range 1 – 7 2 – 7 3 – 7
n (%) n (%) n (%) p-value
Marital status of participant 0.85
With partner 217 (75.6) 194 (75.8) 23 (74.2)
Without partner 70 (24.4) 62 (24.2) 8 (25.8)
Religious affiliation of participant 0.48
Protestant 226 (79.3) 204 (80.3) 22 (71.0)
Catholic 46 (16.1) 39 (15.3) 7 (22.6)
Muslim 13 (4.6) 11 (4.3) 2 (6.4)
Origin of participant*** 0.98
urban 171 (60.2) 153 (60.2) 18 (60.0)
rural - outside Kenya 113 (39.8) 101 (39.8) 12 (40.0)
Ever heard of cervical cancer? 0.37
No – don’t know 117 (40.9) 102 (40.0) 15 (48.4)
Yes 169 (59.1) 153 (60.0) 16 (51.6)
BASELINE BARRIERS: if you would decide not to vaccinate, why would that be?
Need more information? 0.40
(strongly) disagree 98 (34.6) 84 (33.3) 14 (45.2)
neutral 17 (6.0) 15 (5.9) 2 (6.4)
(strongly) agree 168 (59.4) 153 (60.7) 15 (48.4)
Doubt the vaccine works? 0.36
(strongly) disagree 197 (70.1) 174 (69.6) 23 (74.2)
neutral 24 (8.5) 20 (8.0) 4 (12.9)
(strongly) agree 60 (21.3) 56 (22.4) 4 (12.9)
Fear of side effects? 0.26
(strongly) disagree 149 (52.5) 129 (51.0) 20 (64.5)
neutral 27 (9.5) 26 (10.3 1 (3.2)
(strongly) agree 108 (38.0) 98 (38.7) 10 (32.3)
Fear of interference with fertility? 0.43
(strongly) disagree 171 (60.4) 149 (59.1) 22 (71.0)
neutral 45 (15.9) 41 (16.3) 4 (12.9)
(strongly) agree 67 (23.7) 62 (24.6) 5 (16.1)
Afraid of unsafe administration? 0.07
(strongly) disagree 203 (71.7) 177 (70.2) 26 (83.9)
neutral 17 (6.0) 14 (5.6) (9.7)
(strongly) agree 63 (22.3) 61 (24.2) 2 (6.4)
It might encourage unsafe sex 0.94
(strongly) disagree 238 (84.7) 212 (84.8) 26 (83.9)
neutral 23 (8.2) 20 (8.0) 3 (9.7)
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and being well-informed about the HPV vaccination program to
the third model. The adjusted F-Wald test was used to measure
goodness-of-fit. Potential interactions among the variables in these
models were explored.
Ethics statement
The study was approved by the ethical boards of Ghent
University, Belgium, and Moi University, Kenya. Written and oral
informed consent from all participants were obtained for the
baseline and follow-up surveys respectively. With exception of the
participants who were interviewed by phone, all interviewees of
the follow-up survey received 200 KES (approximately 1.5J). The
ethics committees of Ghent University (Belgium) and Moi
University (Kenya) approved this consent procedure.
Results
Preliminary analysis
Of the 472 women invited, 287 agreed to participate (60.8%), of
which 256 (89.2%) were interviewed during follow-up (figure 1).
There were no differences between those who did and those who
did not participate in the follow-up study, except for the quality of
their housing (Table 1).
A strong correlation was identified between four baseline
barriers inherent to vaccination (i.e. doubting efficacy, fear of side
effects, of infertility and of unsafe administration; alpha = 0.90).
In addition, two baseline barriers related with time constraints
were also correlated (i.e. vaccination takes time, and three doses
are inconvenient; alpha = 0.79). Therefore, average Likert scale
scores were calculated, creating two new variables used in
multivariate analysis.
Baseline acceptance and perceived barriers
Among all participants (n = 287), 60.3% and 27.9% said it was
respectively ‘very likely’ and ‘likely’ that they would have their
daughter vaccinated. Up to 59.4% considered a lack of
information as potentially preventing them from vaccinating their
daughter. Concerns about side effects were expressed by 38.0%
(interference with fertility was indicated by 23.7%), and almost one
out of four was afraid that the vaccine would not be administered
safely. In addition, over one-fifth of the participants doubted the
efficacy of the vaccine (Table 1).
Table 1. Cont.
TOTAL BASELINE
(n =287)
FOLLOW-UP RESPONDENTS
(n=256) NON-RESPONDENTS (n =31)
(strongly) agree 20 (7.1) 18 (7.2) 2 (6.4)
Daughter is too young for vaccine 0.91
against an STI?
(strongly) disagree 250 (88.3) 222 (88.1) 28 (90.3)
neutral 9 (3.2) 8 (3.2) 1 (3.2)
(strongly) agree 24 (8.5) 22 (8.7) 2 (6.4)
Partner won’t approve? 0.70
(strongly) disagree **** 221 (78.4) 196 (78.1) 25 (80.6)
neutral 30 (10.6) 28 (11.2) 2 (6.4)
(strongly) agree 31 (11.0) 27 (10.8) 4 (12.9)
Vaccination takes a lot of time 0.75
(strongly) disagree 275 (96.8) 245 (96.8) 30 (96.8)
neutral 6 (2.1) 5 (2.0) 1 (3.2)
(strongly) agree 3 (1.1) 3 (1.2) 0 (0.00)
Inconvenience of 3 doses needed 0.08
(strongly) disagree 265 (96.0) 236 (96.3) 29 (93.5)
neutral 6 (2.2) 6 (2.4) 0 (0.0)
(strongly) agree 5 (1.8) 3 (1.2) 2 (6.4)
BASELINE ACCEPTANCE
Would you vaccinate your daughter 0.69
against cervical cancer?
very unlikely 6 (2.1) 6 (2.3) 0 (0.0)
unlikely 3 (1.0) 3 (1.2) 0 (0.0)
neutral 25 (8.7) 21 (8.2) 4 (12.9)
likely 80 (27.9) 73 (28.5) 7 (22.6)
very likely 173 (60.3) 153 (59.8) 20 (64.5)
IQR = interquartile range.
*13+: those who studied in higher education i.e. college (middle level) and/or university.
**housing: continuous variable constructed by scoring aspects of the living place: material of the roof, walls and floors, and toilet and water facilities.
*** women were asked where they had lived for most of the time up to 12 years of age.
**** includes participants without a relationship.
doi:10.1371/journal.pone.0109353.t001
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Few women refused the vaccine thinking that it would
encourage their daughter to have unprotected sex (7.1%) or that
she was too young (8.5%). Considering vaccination as time-
consuming or perceiving three doses as inconvenient was hardly
mentioned (1.1% and 1.8% respectively)), but 11.0% of the
women believed that the partner would not approve of the HPV
vaccination (Table 1). The open questions did not reveal other
barriers than those probed for with closed questions.
Determinants of baseline acceptance
From all baseline characteristics of the participants, only age
was correlated with acceptance in bivariate analysis, with older
women more likely to accept. Regarding the barriers perceived at
baseline, those referring to negative health consequences (i.e. side
effects, infertility and unsafe administration of the vaccine) lowered
acceptance, as did doubting the efficacy of the vaccine. ‘Consid-
ering the daughter too young’ and ‘thinking the partner would not
approve’ were also negatively correlated with acceptability
(Table 2).
Through multivariate analysis (Table 3), both acceptance and
uptake were predicted 1) by the baseline characteristics of the
participants (model 1) and 2) by the baseline barriers (model 2). In
these models, acceptance was higher among older participants
while negatively correlated with perceiving the partner as a
potential barrier and with religion (Muslims accepted less).
Backward stepwise regression with all variables led to the selection
of three predictors of acceptance (model 3): the barriers ‘foreseeing
the partner’s disapproval’ and ‘considering the daughter too
young’, and baseline cervical cancer awareness. In this final model,
the aforementioned barriers had a negative impact on vaccine
acceptance.
HPV vaccine uptake
Only 31.1% of the girls initiated vaccination during the pilot
program (n = 254), of which 70.9% received three doses. Among
the women whose daughter did not receive the vaccine (176/254),
45 had refused (17.7%), and 130 (51.2%) said that, although they
had wanted to, their daughter was not vaccinated (Table 4 –
figure 1).
Of the participants who did not accept the vaccine at baseline,
none of the daughters received the vaccine, although two women
(22.2%) claimed that in the end they had wanted to have their
daughter vaccinated. Of the acceptors, 52.7% failed to have their
daughter vaccinated, and 14.3% changed their mind and were no
longer interested when the was program rolled out. Of those who
were indecisive at baseline, 23.8% had their daughter vaccinated,
28.6% chose not to, while the majority (47.6%) missed out even
though they had decided to accept the vaccine (Table 4).
Determinants of HPV vaccine uptake
In bivariate logistic analysis, acceptance was associated with
uptake (AOR:2.57), but being well-informed about the program
(62.5%; 147/235) increased the odds of vaccination even more
(AOR:6.37). Few baseline characteristics of the participants were
correlated with uptake: having heard of cervical cancer at baseline
predicted uptake, and Catholic participants had higher vaccina-
tion rates than Protestants. None of the barriers had any predictive
value for uptake (Table 2).
In multivariate analyses, these results were confirmed as uptake
was positively associated with ‘ever heard of cervical cancer’
(model 1), but with none of the baseline barriers (model 2). For
both models, the adjusted Wald test showed a poor fit. Through
backward stepwise regression, three predictors of uptake were
identified and included in the third model: having heard of
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cervical cancer before the study increased the odds of having a
vaccinated daughter, and women who grew up in urban areas
reported more uptake than those with a rural background. The
third factor, disapproval by the partner, was negatively associated
at the 0.1 level (p = 0.09). Adding acceptance and being well-
informed to this model caused this last correlation to disappear
while being well-informed became the strongest correlate.
Acceptance was positively associated with uptake at the 0.1 level
(p = 0.09) (model 4) (Table 3).
Encountered difficulties and reasons for non-uptake of
the HPV vaccine
As can been seen in Table 5, not receiving information
regarding where and when the vaccination took place was the
most important barrier and was reported by 54.6% of those who
wanted yet failed to have their daughter vaccinated. The second
most important barrier was fear of side effects, mentioned mostly
by mothers who either had a vaccinated daughter or refused the
vaccine, followed by a lack of time, which was reported by those
who had their daughter vaccinated and by those who wanted to
but had missed out, but not by refusers. Transport costs were not a
concern among refusers, but were mainly mentioned by mothers
whose daughter had received the vaccine. Other problems raised
were a lack of information about the vaccine and other people
opposing the vaccine, among whom the partner and the daughter
herself. ‘Not being in town’ or simply ‘forgetting the vaccination’
were never mentioned by refusers and hardly by women with
vaccinated daughters, but were quite frequently reported by
participants who had failed to have their daughter vaccinated.
Finally, nine refusers claimed that they had never considered
vaccinating their daughter against cervical cancer.
Discussion
This longitudinal study measured HPV vaccine acceptance and
subsequent uptake in Eldoret, Kenya. At baseline, 88.1% of the
participants accepted the vaccine, but only 31.1% reported
initiation of vaccination at follow-up. While similar acceptance
rates have been found in other studies [9,10,16,18–28], the
proportion of vaccinated girls was below expectations: most
demonstration projects show a coverage of over 75% and
Rwanda’s national program even reached 93.2%. [38,40–42,47]
However, uptake could have been much higher considering that
Table 4. Baseline acceptance and subsequent decisions regarding uptake of the HPV vaccine.
BASELINE ACCEPTANCE Follow-up: Follow-up: Follow-up: TOTAL
(would you vaccinate your daughter?)
Decided not to
vaccinate (n(%))
Wanted to vaccinate
but missed out (n(%))
Vaccinated
(1–3 doses) (n(%))
(very) unlikely 7 (77.8) 2 (22.2) 0 (0.0) 9 (100.0)
neutral 6 (28.6) 10 (47.6) 5 (23.8) 21 (100.0)
(very) likely 32 (14.3) 118 (52.7) 74 (33.0) 224 (100.0)
TOTAL 45 (17.7) 130 (51.2) 79 (31.1) 254 (100.0)
doi:10.1371/journal.pone.0109353.t004
Table 5. Encountered difficulties and reasons for non-uptake of the HPV vaccine.
FOLLOW-UP SURVEY
Decided not to vaccinate
(n =45)
Wanted to vaccinate but
missed out (n =130) Vaccinated TOTAL (n=254)
(1–3 doses) (n = 79)
Reasons for non-uptake*
(n (%))
Reasons for non-uptake**
(n (%))
Encountered difficulties**
(n (%))
Not knowing/finding out
where & when to go
0 (0.0) 71 (54.6) 2 (2.5) 73 (29.8)
Fear of side effects 15 (41.7) 12 (9.2) 39 (49.4) 66 (26.9)
Lack of time 0 (0.0) 34 (26.1) 29 (36.7) 63 (25.7)
Lack of vaccine information 5 (13.9) 22 (16.9) 11 (13.9) 38 (15.5)
Partner opposed 11 (30.6) 8 (6.1) 12 (15.2) 31 (12.6)
Transport cost 0 (0.0) 6 (4.6) 20 (25.3) 26 (10.6)
Not in town (travelling) 0 (0.0) 24 (18.5) 0 (0.0) 24 (9.8)
Daughter opposed 3 (8.3) 7 (5.4) 13 (16.5) 23 (9.4)
Family/friends opposed 1 (2.8) 4 (3.1) 13 (16.5) 18 (7.3)
Forgot 0 (0.0) 10 (7.7) 0 (0.0) 10 (4.1)
Never considered it 9 (20.0) 0 (0.0) 0 (0.0) 9 (3.5)
Percentages may add up to over 100% due to multiple answer options.
* open question.
**open and closed question.
doi:10.1371/journal.pone.0109353.t005
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51.2% of the women stated that their daughter did not receive the
vaccine even though they had wanted to have her vaccinated. This
may have been caused by poor promotion since the main reason
for not vaccinating was a lack of invitation (i.e. not knowing where
and when they were expected (29.8%)), and 15.5% requested
more information on the vaccination. Interestingly, other longi-
tudinal studies have also reported a low coverage due to the
absence of doctors’ recommendations, [45,46,48] and many have
pointed out the importance of outreach by health staff to inform
and encourage HPV vaccination. [14,49] Other reasons for non-
uptake include time constraints and forgetting or simply not
considering the option of vaccinating. Thus the participants
indicated that cervical cancer vaccination was not considered a
priority, which reaffirms the need for HPV vaccine promotion.
School-based vaccination, which has proven to be more efficient,
could further facilitate vaccination as it solves practical problems
for the family. [14,50]
A remarkable result from this study is that, besides refusers,
participants with vaccinated daughters also feared side effects
(49.4% and 41.7%, respectively). This was somewhat surprising:
Gerend et al. showed that people with a high intention mainly
report ‘‘practical barriers’’ and those with a low intention report
‘‘global barriers’’, including side effects. [51] Considering mothers
with vaccinated girls as participants with a high intention, side
effects were not expected to be their main concern. It is of course
possible that the type of health consequences they feared were less
severe, and thus more easy to overcome, as opposed to those from
refusers. However, we did not determine which health conse-
quences participants exactly referred to, so we cannot demonstrate
this. In addition, women whose daughter received the vaccine
might have feared side effects at the moment they were actually
confronted with the vaccine. This would also explain why those
whose daughter did not receive the vaccine even though they had
wanted to were hardly bothered by side effects (9.2%): while
encountering other, more practical barriers, they were not actually
confronted with a final decision or with the vaccine, and hence
with the possibility of side effects. Finally, experiencing side effects
after receiving a dose might also have caused concerns for the
following vaccinations. More detailed information regarding
different types of side effects and when these concerns arise would
shed light on the translation of intention into real behavior.
With regard to predicting uptake, acceptance was positively
related in bivariate analysis; however in multivariate analysis,
being well-informed about the program and baseline awareness of
cervical cancer were stronger correlates, again confirming the
importance of health education. Women who grew up in rural
areas were less likely to have their daughter vaccinated. While this
may result from less knowledge regarding cervical cancer – a
correlation (AOR: 0.52; 95%CI:0.31-0.87), but no interaction was
found with baseline awareness – these women might also have less
power or means to translate intentions into action. Including socio-
psychological factors, such as self-efficacy or perceived control, in
future research may provide more in-depth explanations. The
importance of such variables is also reflected by the fact that
participants whose daughter was vaccinated encountered obstruc-
tions from their partner or the daughter but were able to either
convince them or to vaccinate without the partner’s consent. This
further demonstrates that cervical cancer vaccination is discussed
among family members. Moreover, opposition of vaccinated girls,
perhaps due to becoming weary after one or two doses, is a no
Table observation and emphasizes the importance of targeting the
sensitization messages to them as well. Cervical cancer prevention
campaigns should thus always address all community members,
including men and young girls. [37,52,53]
In addition, the weight of the partner’s decision is observed
through the strong correlation with baseline acceptance: foreseeing
a partner’s objection significantly lowered acceptance. Perceiving
the daughter as too young was also negatively related, but the
daughter’s actual age did not influence acceptance or uptake. In
general, few demographic variables explained baseline acceptance,
which might be due to the small sample size and the homogeneity
among participants. Including rural areas and participants of a
higher economic status (e.g. with daughters in private schools)
could reveal more clear distinctions. Similarly, our results suggest
that Muslims accepted the HPV vaccine less (although uptake was
not lower among them); however, the number of Islamic
participants in our study is limited. Future research should
investigate if there are indeed underlying concerns causing non-
acceptance. Once clarified, different promotional messages,
tailored to the needs of each group, might enhance uptake. [30,54]
Our study contains some limitations. First, 39% of the mothers
invited at baseline did not participate in the survey, which can be
the result of, amongst others, girls not delivering the invitation or
of disinterest in health services and cervical cancer prevention
among the women. This might have induced overestimation of
baseline acceptability due to the inclusion of women with higher
health interests. In addition, social desirability might have moved
participants towards accepting the vaccine. Nonetheless, other
acceptability studies have found an equally high interest in the
HPV vaccine. [9,10,16,18–28] Secondly, the daughter’s vaccina-
tion status was based on the participant’s report only. We are
however confident that we collected reliable estimates given that 1)
many participants indicated that their daughter did not receive the
vaccine, so overestimation of uptake is unlikely, and 2) girls could
only receive the HPV vaccine with consent of an adult caregiver,
so it is very likely that the mother accompanied them and thus
knows the number of doses received. However, future studies
might also rely on vaccination cards or on medical records of the
vaccination program itself to verify the girls’ vaccination status.
Finally, our study only presents how women with a daughter in
one of the ten initially targeted schools experienced the HPV
vaccination program and does not include data from the program
itself or from other people in the community.
In conclusion, even if the HPV is accepted, the uptake is largely
determined by obtaining appropriate information, including
practical information about HPV vaccination opportunities. Given
the weight of social influences on decision-making, vaccination
messages should target broadly and emphasize the vaccine’s safety
at all times. Finally, outreach strategies, such as school-based
vaccination, might diminish organizational challenges for those
willing to vaccinate.
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Table 1. Baseline characteristics, perceived barriers and acceptance of the HPV vaccine; comparing respondents and non-respondents of the
follow-up study.
TOTAL BASELINE
(n = 287)
FOLLOW-UP RESPONDENTS
(n = 256)
NON-RESPONDENTS
(n = 31)
BASELINE CHARACTERISTICS
Median (IQR) Median (IQR) Median (IQR) p-
value
Participant age at baseline 35 (32–40) 35 (32–40) 35 (39–40) 0.43
Range (years) 21–59 21–59 23–56
Age of daughter at baseline 12 (11–14) 12 (11–14) 12 (11–13) 0.68
Range (years) 8–18 8–18 8–17
Years of education of participant 8 (7–12) 8 (7–12) 8 (6–11) 0.35
Range (years)* 0–13+ 0–13+ 0–13+
Housing characteristics** 5 (4–5) 5 (4–5) 5 (4–6) 0.04
Range 1–7 2–7 3–7
n (%) n (%) n (%) p-
value
Marital status of participant 0.85
With partner 217 (75.6) 194 (75.8) 23 (74.2)
Without partner 70 (24.4) 62 (24.2) 8 (25.8)
Religious affiliation of participant 0.48
Protestant 226 (79.3) 204 (80.3) 22 (71.0)
Catholic 46 (16.1) 39 (15.3) 7 (22.6)
Muslim 13 (4.6) 11 (4.3) 2 (6.4)
Origin of participant*** 0.98
urban 171 (60.2) 153 (60.2) 18 (60.0)
rural—outside Kenya 113 (39.8) 101 (39.8) 12 (40.0)
Ever heard of cervical cancer? 0.37
No—don’t know 117 (40.9) 102 (40.0) 15 (48.4)
Yes 169 (59.1) 153 (60.0) 16 (51.6)
BASELINE BARRIERS: if you would decide not to vaccinate, why would that be?
Need more information? 0.40
(strongly) disagree 98 (34.6) 84 (33.3) 14 (45.2)
neutral 17 (6.0) 15 (5.9) 2 (6.4)
(strongly) agree 168 (59.4) 153 (60.7) 15 (48.4)
Doubt the vaccine works? 0.36
(strongly) disagree 197 (70.1) 174 (69.6) 23 (74.2)
neutral 24 (8.5) 20 (8.0) 4 (12.9)
(strongly) agree 60 (21.3) 56 (22.4) 4 (12.9)
Fear of side effects? 0.26
(strongly) disagree 149 (52.5) 129 (51.0) 20 (64.5)
neutral 27 (9.5) 26 (10.3 1 (3.2)
(strongly) agree 108 (38.0) 98 (38.7) 10 (32.3)
Fear of interference with fertility? 0.43
(strongly) disagree 171 (60.4) 149 (59.1) 22 (71.0)
neutral 45 (15.9) 41 (16.3) 4 (12.9)
(strongly) agree 67 (23.7) 62 (24.6) 5 (16.1)
Afraid of unsafe administration? 0.07
(strongly) disagree 203 (71.7) 177 (70.2) 26 (83.9)
(Continued)
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Table 1. (Continued)
TOTAL BASELINE
(n = 287)
FOLLOW-UP RESPONDENTS
(n = 256)
NON-RESPONDENTS
(n = 31)
neutral 17 (6.0) 14 (5.6) (9.7)
(strongly) agree 63 (22.3) 61 (24.2) 2 (6.4)
It might encourage unsafe sex 0.94
(strongly) disagree 238 (84.7) 212 (84.8) 26 (83.9)
neutral 23 (8.2) 20 (8.0) 3 (9.7)
(strongly) agree 20 (7.1) 18 (7.2) 2 (6.4)
Daughter is too young for vaccine against an
STI?
0.91
(strongly) disagree 250 (88.3) 222 (88.1) 28 (90.3)
neutral 9 (3.2) 8 (3.2) 1 (3.2)
(strongly) agree 24 (8.5) 22 (8.7) 2 (6.4)
Partner won’t approve? 0.70
(strongly) disagree **** 221 (78.4) 196 (78.1) 25 (80.6)
neutral 30 (10.6) 28 (11.2) 2 (6.4)
(strongly) agree 31 (11.0) 27 (10.8) 4 (12.9)
Vaccination takes a lot of time 0.75
(strongly) disagree 275 (96.8) 245 (96.8) 30 (96.8)
neutral 6 (2.1) 5 (2.0) 1 (3.2)
(strongly) agree 3 (1.1) 3 (1.2) 0 (0.00)
Inconvenience of 3 doses needed 0.08
(strongly) disagree 265 (96.0) 236 (96.3) 29 (93.5)
neutral 6 (2.2) 6 (2.4) 0 (0.0)
(strongly) agree 5 (1.8) 3 (1.2) 2 (6.4)
BASELINE ACCEPTANCE
Would you vaccinate your daughter against
cervical cancer?
0.69
very unlikely 6 (2.1) 6 (2.3) 0 (0.0)
unlikely 3 (1.0) 3 (1.2) 0 (0.0)
neutral 25 (8.7) 21 (8.2) 4 (12.9)
likely 80 (27.9) 73 (28.5) 7 (22.6)
very likely 173 (60.3) 153 (59.8) 20 (64.5)
IQR = interquartile range
*13+: those who studied in higher education i.e. college (middle level) and/or university
**housing: continuous variable constructed by scoring aspects of the living place: material of the roof, walls and floors, and toilet and water facilities
*** women were asked where they had lived for most of the time up to 12 years of age
**** includes participants without a relationship
doi:10.1371/journal.pone.0117761.t001
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Table 2. Bivariate logistic regression with acceptance and uptake of the HPV vaccine as outcomes.
VARIABLE BASELINE ACCEPTANCE UPTAKE
n Acceptance
(%)
AOR [95% CI] n Uptake (%) AOR [95% CI]
BASELINE CHARACTERISTICS
Participant age at baseline 286 1.05* [1.01–1.08] 254 1.01 [0.97–1.04]
Age of daughter at baseline 285 1.14 [0.85–1.54] 253 1.03 [0.86–1.23]
Years of education of participant 279 0.10 [0.88–1.23] 247 1.05 [0.99–1.11]
Housing 287 0.81 [0.61–1.08] 255 1.12 [0.74–1.70]
Marital status of participant 287 255
With partner 188/217 (86.6) 57/193 (29.5)
Without partner 65/70 (92.9) 0.53 [0.15–1.84] 22/62 (35.5) 0.75 [0.43–1.32]
Religion of participant 285 253
Protestant 202/226 (89.4) 58/203 (28.6)
Catholic 41/46 (89.1) 1.07 [0.23–4.88] 17/39 (43.6) 1.92* [1.19–3.09]
Muslim 8/13 (61.5) 0.20 [0.04–1.09] 4/11 (36.4) 1.42 [0.48–4.18]
Origin of participant 284 253
Urban 155/171 (90.6) 56/153 (36.6)
Rural—outside Kenya 96/113 (85.0) 0.61 [0.19–1.94] 22/100 (22.0) 0.48 [0.21–1.10]
Ever heard of cervical cancer? 286 254
No—don’t know 107/117 (91.4) 24/102 (23.5)
Yes 145/169 (85.8) 0.55 [0.22–1.37] 55/152 (36.2) 1.93* [1.16–3.19]
BASELINE BARRIERS: if you would decide not to vaccinate, why would that be?
Need for more information? 283 1.00 [0.84–1.20] 251 1.02 [0.89–1.17]
Doubt the vaccine works? 281 0.75* [0.59–0.97] 249 0.98 [0.76–1.26]
Fear of side effect? 284 0.69* [0.52–0.91] 252 1.00 [1.76–1.31]
Fear of interference with fertility? 283 0.71* [0.53–0.96] 251 0.94 [0.71–1.25]
Afraid of unsafe administration (i.e. using unclean
needles)
283 0.76** [0.64–0.91] 251 1.04 [0.78–1.40]
It might encourage unsafe sex 282 0.80 [0.53–1.20] 250 0.81 [0.52–1.26]
Daughter is too young for vaccine against an STI? 283 0.54** [0.38–0.76] 251 0.94 [0.61–1.43]
Partner won’t approve?° 282 0.44*** [0.31–0.61] 250 0.87 [0.68–1.09]
Vaccination takes a lot of time 284 0.51 [0.24–1.12] 252 0.86 [0.60–1.21]
Inconvenience: 3 doses needed 276 0.67 [0.36–1.24] 244 0.94 [0.57–1.55]
ACCEPTANCE—WELL-INFORMED
Would you vaccinate your daughter? (Baseline) 255
neutral—(very) unlikely 5/30 (16.7) -
(very) likely 74/225 (32.9) 2.57* [1.11–5.94]
Were you well-informed about the cervical cancer
vaccination program? (at follow-up)
235
No 10/88 (11.4) -
Yes 68/147 (46.3) 6.37** [2.21–18.36]
AOR: adjusted odds ratio—CI: confidence interval
° participants without a relationship are included in category ‘strongly disagree’
* p<0.05
** p<0.01
*** p<0.001
doi:10.1371/journal.pone.0117761.t002
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Table 3. Multivariate logistic regression with acceptance and uptake of the HPV vaccine as outcomes.
ACCEPTANCE—AOR [95% CI] UPTAKE—AOR [95% CI]
Model 1 Model 2 Model 3 Model 1 Model 2 Model 3 Model 4
n = 270 n = 278 n = 280 n = 239 n = 246 n = 247 n = 227
ACCEPTANCE—WELL-INFORMED
Would you vaccinate your daughter? (at baseline) 3.36
(very) likely (ref: neutr.–(very) unlikely) [0.80–14.1]
Were you well-informed about the vaccination program? (at follow-up) 6.37**
Yes (ref: No) [2.24–18.1]
BASELINE CHARACTERISTICS
Age of participant at baseline 1.06* 1.003
[1.00–1.12] nw [0.96–1.04] nw
Age of daughter at baseline 1.05 1.088
[0.77–1.44] nw [0.86–1.37] nw
Years of education of participant 0.98 1.051
[0.89–1.08] nw [0.97–1.14] nw
Housing 0.90 nw 0.972
[0.64–1.26] [0.60–1.56] nw
Marital status of participant
Without partner (ref: with partner) 0.56 0.689
[0.15–2.00] nw [0.37–1.29] nw
Religion of participant. (ref: protestant.)
Catholic 1.35 1.416
[0.28–6.42] [0.57–3.50]
Muslim 0.078** 1.171
[0.02–0.38] nw [0.42–3.26] nw
Origin of participant
rural—outside Kenya (ref: urban) 0.49 0.546 0.48* 0.53*
[0.15–1.62] nw [0.21–1.42] [0.23–0.99] [0.29–0.97]
Ever heard of cervical cancer? (at baseline) 0.43 0.46 1.610* 1.84* 2.07*
Yes (ref: No–don’t know) [0.17–1.11] [0.17–1.30] [1.09–2.38] [1.04–3.26] [1.18–3.63]
BARRIERS AT BASELINE
Need for more information 1.21 0.99
[0.86–1.71] nw [0.83–1.18] nw
Barriers inherent to vaccination° 0.86 1.06
[0.56–1.33] nw [0.68–1.63] nw
It might encourage unsafe sex 0.94 0.82
[0.57–1.53] nw [0.49–1.37] nw
Daughter is too young for vaccine against an STI? 0.72 0.67* 0.99
[0.48–1.10] [0.45–0.99] [0.57–1.69] nw
Partner won’t approve? 0.50** 0.47*** 0.89 0.83 0.99
[0.33–0.74] [0.32–0.71] [0.68–1.16] [0.67–1.03] [0.74–1.32]
Barriers related to time constraints°° 0.68 1.00
[0.27–1.69] nw [0.57–1.74] nw
Cons 9.86 103.60** 138.38*** 0.20 0.68 1.07 0.06*
(Continued)
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Table 3. (Continued)
ACCEPTANCE—AOR [95% CI] UPTAKE—AOR [95% CI]
Model 1 Model 2 Model 3 Model 1 Model 2 Model 3 Model 4
n = 270 n = 278 n = 280 n = 239 n = 246 n = 247 n = 227
F-statistic (p) 410.3 (0.04) 14.15 (0.01) 13.93 (0.00) 2.661 (0.44) 0.304 (0.91) 5.916 (0.02) 4.443 (0.06)
Model 1: including baseline characteristics; model 2: including barriers perceived at baseline; model 3: including baseline characteristics and barriers
obtained by stepwise backward regression—model 4: model 3 + acceptance and being well-informed about the HPV vaccination program
AOR: adjusted odds ratio—CI: confidence interval
°average of: doubt the vaccine works, fear of side effects and interference with fertility, and afraid of unsafe administration; alpha = 0.90
°° average of: vaccination takes a lot of time and 3 doses are inconvenient; alpha = 0.79
nw: not withheld in backward stepwise regression
* p<0.05
** p<0.01
*** p<0.00
doi:10.1371/journal.pone.0117761.t003
PLOSONE | DOI:10.1371/journal.pone.0117761 March 5, 2015 6 / 6
108
Chapter 7
Uptake of the Human
Papillomavirus Vaccine in
Kenya: testing the
Health Belief Model
through structural
equation modeling on
Cohort Data
Paper 2: Testing the Health Belief Model In this second pa-
per, again determinants of HPV vaccine acceptability and uptake,
and the association between these two constructs, were identified.
This time this was done using the HBM as theoretical framework:
the model and various adapted versions were tested through struc-
tural equation modelling. More particularly, the predictive value of
the models was evaluated.
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Given the result of the first paper, i.e. that adequate promotion
of the HPV vaccination programme was crucial for HPV vaccine up-
take, we added the variable to verify its impact on the predictability
of the model. The variable, which was collected at follow-up and
defined as 'feeling well-informed about the programme', allowed us
to estimate the influence of the quality of the programme's promo-
tion perceived by the participants. As such, a factor reflecting not
only personal characteristics but also implementational issues was
incorporated. In next steps, also the added value of a precursor of
behaviour was tested as well as of various socio-demographic vari-
ables.
Structural Equation Modeling SEM is a statistical method to
test and refine theoretical models attempting to explain or predict
social or behavioural phenomena. It is mostly used as a confirm-
atory analysis rather than an exploratory and can be implemented
with cross-sectional as well as with longitudinal data. The two main
advantages are 1) the possibility to include latent, unobservable vari-
ables, and 2) the inclusion of several multiple regressions simultan-
eously. In fields such as health behaviour research or psychology,
where many outcomes have several determinants and many determ-
inants lead to more than one outcome, SEM offers the possibility to
investigate how variables behave in each other's company enabling
us to test more complex models.
The techniques behind SEM are factor analysis and general linear
regression: In a first step, a measurement model is build, allowing
to identify unobserved, latent, variables by confirmatory factor ana-
lysis. In other words, different items of a questionnaire are loaded
into new constructs with factor loadings reflecting the degree of as-
sociation between the items and the latent variable (between -1 and
1). Based on a theoretical or empirical model, the researcher decides
which items tap into which constructs (factors); most loadings will
be fixed to zero indicating that certain items do not reproduce a
certain construct. The measurement model is then established by
estimating the parameters and can be modified or fine-tuned if the
estimated covariance or correlation matrix does not reproduce the
matrix of the sampled data. Finally, several goodness-of-fit indices
can indicate whether the model is supported by the data.
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In the second step, the structural model (or path model) is cre-
ated, examining the relationships between constructs (both observed
and unobserved). Through path analysis, multiple regression mod-
els can be combined and estimated simultaneously. As such, vari-
ables can take up the position of both exogenous (cfr. independent
variable) and endogenous variable (cfr. dependent variable). More
specifically, SEM allows to verify more complex relations between
variables such as indirect effects, mediation chains, i.e. variables in-
fluencing an outcome variable through another variable (X→ M→
Y), and moderating variables, i.e. variables affecting the direction
and/or strength of the relation between 2 other variables (cfr. in-
teraction). Consequently, pathway analysis is more parsimonious,
has a reduced type I error rate and will yield more precise estimates
(smaller standard errors) compared with for example 2 sequential
regressions X→ M and M→ Y [246][248].
For this second paper, SEM was chosen due to the technique's
flexibility in terms of identifying different types of associations. The
first step was however not implemented, i.e. the measurement model,
since the goal of the research was not measuring the cohesion between
several items but testing the Health Belief Model. We did check for
internal consistency by applying Cronbach's alpha. Other possible
techniques such as multilevel analysis were considered but an inter-
class correlation coefficient for clustering of vaccine uptake at school
level was calculated and was not considered high enough. Moreover,
all of the other included variables are at personal level, while for the
variable `adequate promotion', which can be considered a personal
validation of the promotion activities, a variable at school level, was
created in order to include the fact that vaccine promotion was done
at school level (i.e. the average of `adequate promotion' per school
was calculated).
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ABSTRACT 
Background: Many studies investigate HPV vaccine acceptability, applying health behavior 
theories to identify determinants; few include real uptake, the final variable of interest. This 
study investigated the utility of the Health Belief Model (HBM) in predicting HPV vaccine 
uptake in Kenya, focusing on the importance of promotion, probing willingness to vaccinate 
as precursor of uptake and exploring the added value of personal characteristics. 
Methods: Longitudinal data were collected before and after a pilot HPV vaccination program 
in Eldoret among mothers of eligible girls (N=255). Through Structural Equation Modeling, 
associations between vaccine uptake and the HBM constructs, willingness to vaccinate and 
adequate promotion were examined. Adequate promotion was defined as a personal 
evaluation of promotional information received. Finally, baseline cervical cancer awareness 
and socio-demographic variables were added to the model verifying their direct, mediating or 
moderating effects on the predictive value of the HBM.  
Results: Perceiving yourself as adequately informed at follow-up was the strongest 
determinant of vaccine uptake. HBM constructs (susceptibility, self-efficacy and foreseeing 
father’s refusal as barrier) only influenced willingness to vaccinate, which was not correlated 
with vaccination. Baseline awareness of cervical cancer predicted uptake.  
Conclusions: The association between adequate promotion and vaccination reveals the 
importance of triggers beyond personal control. Adoption of new health behaviors might be 
more determined by organizational variables, such as promotion, than by prior personal 
beliefs. Assessing users’ and non-users’ perspectives during and after implementing a 
vaccination program can help identifying stronger determinants of vaccination behavior. 
  
Key words:  
HPV vaccination  - Health Belief Model – Cohort – Kenya - Structural equation modeling  
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BACKGROUND 
Cervical cancer poses a high burden on women’s health in Kenya due to its high incidence 
and the poor prognosis of most patients.  This elevated incidence rate is related to the high 
prevalence of HIV, the low screening coverage in Kenya (only 3.2% of all women are 
screened every 3 years), and the absence of the Human Papillomavirus (HPV) vaccine in the 
national vaccination program. [1] If the HPV vaccine becomes available in Kenya, it would 
provide women on-going protection against several high-risk HPV types. [2-4]  
However, before adding the HPV vaccine to a national vaccination program, a situation 
analysis is valuable to prepare the introduction of the vaccine in terms of costs and 
infrastructure but also to assess readiness among the population. [5, 6] Worldwide, many 
studies have investigated girls’ caregivers’ willingness to vaccinate, often before the vaccine 
was introduced. While acceptability is usually high, doubts about the safety and efficacy of 
the vaccine are common. [7-11] In certain subpopulations, there is also the belief that the 
vaccines might promote promiscuity although past research does not support these claims. 
[12, 13]  
Frequently, these acceptability studies apply (health) behavior theories that include a variety 
of factors (e.g. attitudes, beliefs, perceived barriers) which are believed to influence the 
likelihood of a certain action. [14, 15] By investigating these theories’ constructs, researchers 
aim to identify determinants of vaccine uptake and refusal to incorporate them in vaccination 
strategies. An example of such theory is the ‘Health Belief Model’ (HBM), an established 
model often used to identify determinants of vaccination behavior. [14, 16] The original HBM 
indicates that in order for an individual to take action (e.g. to vaccinate your daughter), this 
person would have to (1) perceive the disease at least as ‘moderately severe’; (2) perceive a 
susceptibility or vulnerability to the disease; (3) believe that there are benefits in taking the 
preventive action; and (4) not perceive major barriers obstructing the action. [17] 
Additionally, the HBM is often extended with two more constructs: (5) self-efficacy, 
indicating the ‘expectancies about one’s own competence to perform the behavior’ and (6) 
cues to action (CTA), i.e. ‘the specific stimuli necessary to trigger the decision-making 
process’. [18-20] Through a review of HPV vaccine acceptability studies in the USA, Brewer 
et al. showed that the abovementioned constructs influence people’s willingness to vaccinate 
against cervical cancer. However, they do caution for overreliance on the results: since almost 
all studies included were cross-sectional no causal relations could be identified. [14]  
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It is generally agreed upon that there is a need to further test health behavior theories as to 
justify their use in promotion and vaccination interventions and to verify their applicability in 
different settings. It is known that the utility of the HBM varies according to the type of 
behavior that is predicted (preventive versus curative) and the health condition to be tackled 
(prevalence, morbidity and mortality of the disease in the study setting). Furthermore, cultural 
or socio-demographic variables might affect the predictive value of the model. [21, 22, 19] 
According to Janz and Becker, socio-demographic characteristics can have both direct and 
modifying effects on the (associations between) HBM constructs. [19] With regard to HPV 
vaccination, characteristics such as cervical cancer knowledge, age of the daughter or 
conservative thinking often affect acceptability. [14, 15] However, there is no clear 
description on which are most important and there is no agreement on how such personal 
characteristics fit the HBM (e.g. directly, mediated, or moderating effects).  
Similarly, CTA are poorly studied. In theory, two types are distinguished: internal cues, such 
as symptoms, and external cues, such as advice from others or a promotional campaign. While 
these conventional definitions seem straightforward, measuring CTA remains a challenge 
given that “a cue can be as fleeting as a sneeze or the barely conscious perception of a 
poster”. [20] In addition, to truly be a factor that influences behavior, the trigger does not 
only have to reach the person, it also needs to prompt adoption of the behavior. [23] So 
depending on an individual’s perception, a certain cue might be interpreted as a trigger or not. 
Therefore, we propose to include a personal assessment of a cue such as promotion, 
expanding CTA to receiving and personally evaluating the motivator, e.g. ‘did you receive an 
invitation and was this appealing to you?’. 
Finally, another point of discussion about the operationalization of the HBM is the outcome 
measure. While the original HBM had actual behavior as outcome (e.g. ‘vaccine uptake’), 
many studies apply the HBM to identify factors influencing acceptability or intention, 
considering these intervening variables as a precursor of behavior. [15, 14, 21] However, 
attitudes and intentions do not always translate into health behavior. [24] Research should 
therefore not only include antecedents but also the actual behavior as to distinguish factors 
that influence willingness versus those that inhibit or drive true behavior. Moreover, theories 
should be tested through longitudinal studies in which the influence of past behavior – often 
the biggest predictors of future behavior – is, if possible, excluded. [22, 21] Given that HPV 
vaccination in Kenya is not yet widespread, a pilot vaccination program offered the 
opportunity to measure the predictive value of the HBM constructs in this context and to 
explore the additional value of innovative variables.  
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The purpose of the present longitudinal study was to examine the applicability of the HBM to 
predict HPV vaccine uptake in Kenya. This general aim is specified into three underlying 
research objectives. First, we examined whether the HBM constructs predicted vaccine 
uptake, including a subjective evaluation of promotion. Second, we evaluated the validity of 
adding willingness to vaccinate to the HBM as mediator of uptake. Lastly, a hypotheses 
generating component was added, examining the direct- and modifying effects of personal 
characteristics on the (associations between the) HBM constructs.  
 
 
METHODS 
Pilot HPV vaccination program 
Through the Gardasil Access Program (GAP), Moi Teaching and Referral Hospital (MTRH – 
Eldoret) received 9000 doses of the HPV vaccine. Ten out of forty-two public primary 
schools in Eldoret Municipality were randomly selected to participate in this pilot vaccination 
program. All girls in classes 4 to 8 of these schools (i.e. around 4000 pupils, approximately 9-
13 years old), were eligible to receive three free doses of the quadrivalent vaccine. The 
vaccination was provided in MTRH, located in the center of Eldoret, while promotion was 
organized at school: health care providers informed the teachers who then passed on the 
information to students and parents. Implementation of such promotional activities differed 
from school to school, from parents meetings at school to teachers asking their pupils to 
notify their parents about the vaccination opportunity. The baseline and follow-up study took 
place in March 2012 and May 2013 respectively, i.e. right before and after the pilot program, 
which ran from May 2012 till March 2013. [25, 26] 
Participants and Procedures 
For this study, a random selection of girls eligible for vaccination were given an invitation 
letter for the face-to-face baseline interview, addressed to their mother. The number of girls 
per school was in proportion to the size of the school. Contact information requested at 
baseline was used to make an appointment for the follow-up interview: participants were 
contacted by phone, or the interviewers went looking for them at the description of the living-
place or at school. If those contacted by phone were not able to participate in the complete, 
face-to-face follow-up interview, they were invited to answer by phone whether or not their 
daughter had received the HPV vaccine. (Figure 1) The women were interviewed in Swahili 
or English, depending on their preference.   
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During the baseline interview, mothers were given basic information and had the opportunity 
to ask questions regarding cervical cancer, HPV vaccination and the upcoming program in 
order to enable them to make an informed decision. More detailed information about the 
planned vaccination effort was meant to be provided to all parents of all eligible girls by 
promotional activities at school. To achieve consistency in the interviews, standard guidelines 
for introductions, interviews, and informed consent requests were practiced. [25, 26]. 
-- Figure 1. Flow diagram of the recruitment and response of study participants.-- 
Measures 
Outcome variable uptake: The main outcome of the study was the actual behavior, i.e. HPV 
vaccine uptake, reported by the participants during the follow-up survey (i.e. when the pilot 
HPV vaccination program had closed). Uptake was reported per dose but assessed as a 
dichotomous variable (0 = received no HPV vaccine doses, 1 = received one or more doses of 
the HPV vaccine) given that few vaccinated girls had not completed the required scheme of 
three doses. 
HBM constructs: All constructs were measured at baseline (before the pilot HPV vaccination 
program started). Perceived severity, susceptibility and three barriers (‘foreseeing father’s 
refusal’, ‘doubting vaccine efficacy’ and ‘perceiving lack of information’) were assessed 
directly, while other HBM constructs (self-efficacy, trusting the health benefit of the vaccine 
and the two barriers ‘having safety concerns’ and ‘foreseeing time constraints’) were 
measured through several items (Table 1). All items were derived from the literature, and 
benefits and barriers were chosen based on previous research in similar contexts [15, 27, 28, 
7, 29].  
Mediator willingness to vaccinate: This variable was composed of the sum score of 2 
baseline items, i.e. ‘Would you vaccinate your daughter against cervical cancer?’, and, ‘Will 
you let your daughter get vaccinated against cervical cancer through this program?’. (Table 1) 
Adequate promotion: During the follow-up interview, people were asked whether they had 
heard of the HPV vaccination program through school after the baseline interview and if so, 
whether they felt well-informed regarding the cervical cancer vaccination program. Through 
this we assessed if promotional activities had reached the women (cfr. CTA) and how the 
messages were perceived. Adequate promotion was thus a subjective evaluation of outreach 
messages. Since promotion differed among schools, we created a variable reflecting the level 
of adequate promotion in each school (i.e. the average of being well-informed at personal 
level for each school). This variable captured the ‘school effect’, i.e. the different levels of 
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promotion among the different schools, while the original variable measured being well-
informed at personal level. (Table 1) 
Means, standard deviations, and correlations across HBM constructs, willingness to vaccinate, 
adequate promotion and vaccine uptake are provided in the Supplementary Material (SM 
Table I). 
--Table 1. Complete list of items used to assess Health Belief Model (HBM) constructs. -- 
Personal characteristics: We included ten personal factors and socio-demographic variables 
to explore their potential direct and modifying effects on the HBM constructs, willingness and 
uptake: (1) age of the participant; (2) age of the daughter; (3) class of the daughter; (4) marital 
status of the participant; (5) number of children (< 18 years) in the household; (6) ever heard 
of cervical cancer (awareness participant); (7) years of schooling of the participant; (8) origin 
of the participant: whether the participant grew up in an urban or rural area; (9) religion of the 
participant; (10) socio-economic status (SES): a scale representing the quality of the building 
materials used for the house. All these factors were obtained from the baseline survey. [25] 
For some of the items (marital status, origin, and religion) answer options in the questionnaire 
were merged based on preliminary analysis and to facilitate interpretations.  
Statistical Analyses 
To compare participants who completed versus participants who did not complete the follow-
up survey, we performed an univariate analysis of variance (ANOVA). Cronbach’s alpha was 
calculated to check for internal consistency of constructs’ items (>0.75 was considered 
acceptable). [30] Personal characteristics with less than 5% missing data were imputed using 
the expectation maximization method (EM), after establishing that the data were missing 
completely at-random (Little’s MCAR χ2(259) = 257.583, p = .513). If a background 
characteristic had more than 5% missing values, only data from participants without missing 
values was used to build models including that variable. Structural equation modeling (SEM) 
was applied to investigate the three specific research objectives. 
The first research objective, evaluating whether the HBM predicts HPV vaccine uptake in a 
Kenyan context, was examined with two models: Model 1, containing the HBM constructs 
measured at baseline (perceived severity, susceptibility, benefits, barriers, and self-efficacy) 
and Model 2, adding adequate promotion, measured at follow-up, as predictor for uptake.  
The second research objective, assessing the validity of adding willingness to vaccinate to the 
HBM as mediator of uptake, was examined with Model 3. This model contained all the 
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predictors of Model 2. However, the baseline HBM constructs were specified to predict 
willingness, and willingness and adequate promotion to predict uptake.  
Finally, we examined the direct and modifying effects of all ten personal characteristics on the 
(associations between the) HBM constructs. To do so, we applied an exploratory modeling 
procedure. First, all factors were independently added as direct (e.g. heard of cervical cancer 
→ uptake), mediated (e.g. religion → severity → willingness), or moderating effect (e.g. age 
of the daughter → willingness, with barrier ‘father’s refusal’ moderating the effect) in Model 
3 (ESM Table II). Next, Model 4 was fitted containing all significant effects from this 
exploratory procedure in addition to the predictors specified in Model 3. To correct for 
multiple testing we applied a more conservative critical p-value of 0.01.  
Models were fitted using the weighted least-squares estimator with mean and variance 
adjustment (WLSMV; because of the dichotomous primary outcome variable (uptake)). [31] 
To ensure reliable interpretation of the results, the underlying assumptions of SEM were 
checked for all variables included in the models (multicollinearity, linearity in the logit, 
missing data, and outliers). Furthermore, the nine baseline HBM constructs were allowed to 
correlate in all models. In addition, all models were evaluated by assessing the efficacy of 
each model in predicting willingness and uptake (R
2
). Since uptake is a dichotomous variable, 
R
2
 is estimated assuming that the categorical indicator is a coarse categorization of a normally 
distributed underlying dimension. Furthermore, the fit of the path models (Model 3-Model 4) 
was assessed with the chi-square overall goodness-of-fit statistic (CHISQ), the comparative fit 
index (CFI), the root-mean-square error of approximation (RMSEA), and the weighted root 
mean square residual (WRMR). RMSEA values <.06, CFI >.97, and WMSR<1.0 indicate 
close fit. [32, 33]  
Sample size 
The necessary sample size was calculated for a previous study and data analysis. [25] With 
255 observations, the data set is however also adequate for SEM (i.e. minimum 200 
observations). [32]  
Ethics, consent and permissions 
The Institutional Research and Ethics Committee of Moi Teaching and Referral Hospital, and 
the Ethical Committee of Ghent University Hospital approved this study (approval numbers 
FAN:IREC 000771 and B670201212980-B670201317007, respectively). Written informed 
consent was requested before the baseline interview, and this was verbally confirmed before 
the follow-up interview. Participants received no incentives for participation in the baseline 
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survey, while a financial compensation of 200 Kenyan Shilling (US $2.34) was given for the 
time and effort they invested in a second face-to-face interview. [25] 
 
 
RESULTS 
Participation  
A flow diagram of recruitment and response of participants within this longitudinal research 
design is presented in figure 1. Of the 472 invited participants, only 287 agreed to participate 
in the baseline survey (61%), while 256 of them (89%) agreed to participate in the follow-up 
survey. Non-completers (n = 31) were similar to completers (n = 256) on all HBM constructs 
and personal characteristics with only one exception. Compared to completers, the non-
completers scored slightly lower on self-efficacy (t(285) = 2.547, p = 0.011). 
Of the 256 participants of the follow-up survey, 8% (n = 20) only provided the information 
about their daughter’s vaccination status through the short telephone survey; data on adequate 
promotion is missing for them. One participant was deleted from analysis because she did not 
report whether her daughter was vaccinated (Nanalyses = 255).  
The baseline HBM constructs did not have any missing values and Cronbach’s alpha was 
found to be acceptable (>.75) for all HBM constructs (table 1). [30]  
Descriptive analysis 
Of the 255 participants included in the analyses, the average willingness to vaccinate was 4.4 
(range 1-5). This positive attitude towards the HPV vaccine was reflected in the baseline 
measured HBM constructs: the average perceived severity was 3.8 (range 1-5), average 
perceived susceptibility was 3.7 (range 1-5), average perceived health benefits was 4.6 (range 
1-5). Furthermore, proposed barriers were not often agreed on. The average scores on the 
barriers (range 1-5) were: lack of information 3.5 (range 1-5), doubting vaccine efficacy 2.4, 
time constraints 1.4, safety concerns 2.6, and father’s refusal 1.5. Lastly, the average score of 
mothers’ self-efficacy was 4.3 (range 1-5). (ESM Table I) 
In the follow-up survey, 37% of the participants mentioned they had not been well-informed 
about the program (adequate promotion=0). However, the average percentage of people 
mentioning this lack of promotion fluctuated per school (18% - 83%). By the end of the 
program, 31% had their daughter vaccinated against cervical cancer with one dose or more 
(72% of them had received 3 doses). 
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Of all personal characteristics, 4 had less than 5% missing values (age of the daughter, age of 
the participant, cervical_cancer_awareness and origin_of_the_participant) and one had more 
than 5% (years of schooling of the participant). The characteristics of the participants can be 
summarized as follows: the average age of the mothers was 36 (range 21-59); the average age 
of the daughter was 12 (range 8-18); the average class of the daughter was 6 (range 4-8); 76% 
of the participants had a partner (married or living together) while the remaining 24% was 
either separated, widowed or never had a partner (i.e. currently single); 4.5 (range: 1-7) was 
the average number of children in the household; 60 % had at least heard of cervical cancer 
(awareness); the average years of schooling of the participant was 8.4 (range: 0-16); 60% of 
the participants grew up in a Kenyan city, 38% were originally from the countryside and 1% 
was from outside Kenya (the latter 2 were grouped for analysis); 80% of the participants 
indicated to be Protestant, 15 % Catholic, 4% Muslim, 1% other or no religion (for analyses 
this was combined into Muslim (4.3%) vs. non-Muslim (95.7%)); and the average score of the 
quality of the building materials of the house was 4.6 (range 2-7).  
The Health Belief Model 
Research objective 1: Application of the HBM  
First, to examine how the nine HBM constructs measured at baseline predicted uptake, we 
fitted Model 1 (figure 2.a). The nine predictors only accounted for 8% of the variance in 
uptake. The only significant predictor of uptake was self-efficacy (standardized path 
coefficient self-efficacy β = .31).  
In Model 2 (figure 2.b) it was examined whether addition of the two adequate promotion 
variables increased the explained variance of uptake. The two included adequate promotion 
variables, adequate promotion at the individual level (β = .33) and adequate promotion at the 
school level (β = .49), increased the explained variance of uptake to 49%. None of the other 
predictors were significantly related to uptake.  
-- Figure 2. Health Belief Model to predict the HPV vaccine uptake without adequate 
promotion (a. Model 1) and with adequate promotion (b. Model 2) -- 
Research objective 2: Willingness as a predictor for uptake 
Model 3 (Figure 3) assessed the validity of adding willingness to vaccinate to the HBM as 
mediator of uptake. In Model 3, the nine baseline HBM constructs were specified to predict 
willingness, and willingness and adequate promotion to predict uptake. Model 3 provided a 
close fit to the data [CHISQ(11) = 7.276, p = .776 ; RMSEA = .00; CFI = 1; WRMR = 0.51]. 
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Overall, 47% of the variance in uptake and 41% of the variance in willingness was explained 
by predictors in the model. Willingness was not significantly associated to uptake. In contrast, 
adequate promotion at the individual level (β = .34) and at the school level (β = .46) were 
significantly related to uptake. Susceptibility (β = .25), the barrier ‘foreseeing father’s refusal’ 
(β = -.15), and self-efficacy (β = .41) were significantly related to willingness.  
-- Figure 3. Health Belief Model to predict the HPV vaccine uptake mediated by willingness 
(Model 3). – 
Research objective 3: Influence of personal characteristics in the HBM  
Finally, in Model 4 we examined the direct and modifying effects of personal characteristics 
on the (associations between the) HBM constructs. A priori, an exploratory modeling 
procedure was applied examining the effects (1. direct, 2. mediated, 3. moderating) of each 
personal parameter individually. Of the direct effects of the characteristics, only cervical 
cancer awareness was found to be significantly (p < .01) related to uptake. Next, the effect of 
religion (i.e. being Muslim) on willingness was found to be significantly mediated (p < .01) 
by: severity, susceptibility, self-efficacy, ‘trusting the health benefit’, and the barriers  
‘foreseeing time constraints’ and ‘ foreseeing father’s refusal’. Furthermore, the age of the 
daughter was found to have a significant (p < .01) effect on the relation between barrier 
‘foreseeing father’s refusal’ and willingness. Lastly, marital status and SES had a significant 
(p < .01) effect on the relation between susceptibility and willingness. (ESM table II) 
In Model 4 (figure 4) we added all these significant effects of the personal characteristics to 
Model 3. To avoid estimation errors, only the strongest of the interactions with susceptibility 
(i.e. susceptibility*marital status) was incorporated in the model. The predictors in the model 
explained 48% of the variance in willingness and 52% of the variance in uptake; willingness 
was not significantly associated with uptake (p=0.185). Religion was found to be significantly 
(p < .05) related to severity (β = -.23), susceptibility (β = -.13), self-efficacy (β = -.15), 
‘trusting the health benefit’ (β = -.20), and the barriers ‘foreseeing time constraints’ (β = .19), 
and ‘foreseeing father’s refusal’ (β = .24). Next, susceptibility, the barrier ‘foreseeing father’s 
refusal’, and self-efficacy were related to willingness (β = .46, β = -.63, β = .39 respectively). 
Furthermore, two interactions were significantly related to willingness:  marital 
status*susceptibility (β = -.27), and age of the daughter*barrier ‘foreseeing father’s refusal’ (β 
= .40). Lastly, in addition to adequate promotion at individual level (β = .30) and at school 
level (β = .51), baseline cervical cancer awareness was significantly related to uptake (β = 
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.20). Acceptable goodness of fit was obtained with Model 4 (CHISQ (85), p=.0001, RMSEA 
= .052; CFI = 0.920; WRMR = 0.910). 
-- Figure 4. Health Belief Model to predict the HPV vaccine uptake with modifying personal 
characteristics (Model 4). -- 
 
 
DISCUSSION 
The Health Belief Model is an established health theory often used as framework to develop 
health interventions. In this model, constructs concerning severity, susceptibility, benefits, 
barriers and self-efficacy are considered important determinants of the health related 
behavior. [17-20]  This study examined whether the HBM can be applied to predict HPV 
vaccine uptake in Kenya, a country with little research on HPV vaccine acceptability and 
uptake.  
 
Research objective 1: Application of the HBM, including adequate promotion 
A first remarkable result of this study was the large difference between Model 1 and Model 2: 
adding adequate promotion, at both personal and school level, increased the predictive value 
from 8% to 49%. The strong correlation between adequate promotion and HPV vaccination is 
not surprising since many studies have stressed the importance of triggers such as health 
provider’s recommendation. [34, 35, 16, 36] Our results might, however, overestimate the 
strength of the association because of two reasons: 1) Unlike the other HBM constructs, 
adequate promotion is measured at follow-up, i.e. when uptake was also recorded, which 
means the direction of the correlation is indeterminable, and 2) adequate promotion reflects 
the quality of the promotion from the perspective of the participant. This means that two 
participants who received the same information through the same channel, might report 
adequate promotion differently, most possibly in agreement with the vaccination status of 
their daughter. Nevertheless, the strong correlation cannot be overlooked: whether or not the 
daughter received the vaccine was highly associated with obtaining sufficient information. 
Furthermore, it is important to mention that before adequate promotion was added to the 
model, self-efficacy was the only HBM construct found to have a positive correlation with 
vaccine uptake. This clearly shows that besides an external trigger, participants still need to 
perceive themselves capable in performing the action, i.e. taking their daughter for a 
vaccination, and therefore justifies addition of this construct to the HBM.  
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The fact that none of the other HBM constructs predicted uptake is surprising, yet there are 
several explanations possible. First of all, threat (severity and susceptibility) and ‘trusting the 
health benefit’ are very skewed, making it more difficult to identify relations. All participants 
considered cervical cancer as a very severe disease which their daughter was (very) likely to 
get, and they all were driven to protect their daughter’s health. Given that cancer is perceived 
severe and deathly worldwide, it is a not a startling ascertainment that also in Kenya, where 
treatment remains inaccessible for many people, cervical cancer is considered a serious 
disease. Moreover, severity has often been identified as a construct with less predictive value, 
definitely with regards to preventive behavior. [37-39, 19] With regard to susceptibility, one 
can wonder how well parents are capable to estimate future (sexual) behavior and well-being 
of their daughter. Do they overestimate their daughter’s vulnerability because of concern and 
anxiety? Such emotions clearly also influence decision-making yet they are not included in 
cognitive theories. [20, 40] Finally, the current HIV epidemic, affecting all layers of society, 
might have increased their sense of vulnerability regarding sexual transmittable infections.  
Barriers are very often among the strongest predictors of behavior [19, 38], but in our study 
none were associated with uptake. Again, little variance was found: almost all participants 
trusted the efficacy and safety of the vaccine and worried little about time boundaries or 
objection of their partner. Social desirability and poor assessment skills of the participants 
might be at the base of these highly pro-vaccine statements. On the other hand, other studies 
found similar results and the worldwide success of childhood vaccination might also 
encourage Kenyan women to truly trust and welcome the new HPV vaccine, as other studies 
have also found. [7-9] Future studies can explore this more in-depth e.g. by applying more 
multiple item measures, since they have better predicting power, or by assessing users’ and 
non-users’ perspectives during and after program implementation. While this latter approach 
would not contribute to identifying causal relations it could help to explore and identify other 
determinants than the HBM constructs given that in this study we found little or no support 
for the HBM in the current context of cervical cancer vaccination in Kenya. 
 
Research objective 2: Willingness as a predictor for uptake 
Adding willingness to vaccinate as mediator of uptake lowered the predictive value of the 
HBM from 49% to 47%. Moreover, willingness had no effect on vaccine uptake, while 
adequate promotion remains highly associated. These results raise the issue of control, i.e. to 
what extent are people truly in control of vaccination behavior if they are depending on 
providers’ motivation and initiation? As stated by Sheeran P. (2011), the gap between 
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intention and behavior is caused by those with high intention who don’t act (inclined 
abstainers) and those with low intentions who do act (disinclined actors). [24] In the case of 
this HPV vaccination pilot program, it seems that many participants are inclined abstainers as 
a result of poor promotion, i.e. they wished to vaccinate their daughter against cervical cancer 
but were not well enough informed to do so. On the other hand, we need to ask ourselves the 
question how well people can express their wish and predict their behavior in this context. 
Again, socially desirable answers may have caused overestimation of willingness, but there 
are many other factors [24] that may have led to expression of high interest and/or low 
uptake. Most participants had never heard of the HPV vaccine and 40% had never heard of 
cervical cancer. For them to process all information received during the baseline interview 
and immediately report acceptability and intention to vaccinate might have been difficult or 
unreliable (cognitive variables). [24, 40] In addition, the time-lapse between the first 
interview and the start of the pilot program, might have given participants time to overthink 
(temporal stability) and discuss cervical cancer vaccination with friends and family 
(subjective norms). As a result, some participants might have changed their opinion and 
preferred not to act. [35, 41, 24] Finally, other important activities (competing intentions) 
might have inhibited participants from taking the time to let their daughter get vaccinated 
against cervical cancer. [24] Given the harsh living circumstances of many of our participants, 
other priorities are not unlikely. 
The nine baseline HBM constructs, which only explained 8% of the variance of uptake 
(Model 1a), explained 41% of the variance of willingness. Given that willingness to vaccinate 
was also measured at baseline (as opposed to uptake at follow-up), it was expected to detect 
more correlations among the cross-sectional data. Self-efficacy was the strongest correlate, 
but also susceptibility was positively associated. Perceived vulnerability has been previously 
related with acceptability [10, 34] and uptake of (preventive) behavior [19, 20, 18, 16], yet as 
described above, we did not find the latter correlation. Finally, participants who thought of 
their partner as somebody who would oppose to vaccinate their daughter against cervical 
cancer, were less likely to accept the vaccine. Interventions should target these characteristics 
and include all decision makers as to increase the willingness to vaccinate. 
 
Research objective 3: Influence of personal characteristics in the HBM 
Personal characteristics altered Model 3 and increased the explained variance of willingness 
from 41% to 48% and of uptake from 47% to 52%. However, given that only acceptable 
goodness of fit was achieved, we merely consider this as a sketch on how these variables are 
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related with HBM constructs, willingness and uptake as opposed to an adapted version of the 
model. For example, awareness had a direct impact on uptake which supports the importance 
of cognitive variables: participants who had heard of cervical cancer before baseline were 
more likely to vaccinate their daughter. Whether the effect is a result of knowledge of cervical 
cancer rather than the ability to process the new information regarding the vaccine more 
easily, is yet to be determined. Also, religion clearly affected the HBM constructs: Muslims 
were more likely to agree with the barriers ‘father’s refusal’ and ‘time constraints’, were less 
likely to perceive cervical cancer as severe, thought their daughter was less susceptible, had 
lower self-efficacy, and were less driven by the fact that the vaccine would protect their 
daughter’s health. The underlying reasons, e.g. a more conservative attitude or mistrust in the 
health system, are to be investigated more in-depth. Finally, the positive effect of 
susceptibility on willingness was higher for single mothers, and the negative relation of 
perceiving the father as a barrier for willingness weakened when the daughter was older. 
While the former interaction might reveal a kind of freedom to express intentions among 
women without a partner, the latter hints that even though a partner may object, mothers of 
older girls still intended to vaccinate, maybe without his consent. Our results suggest that 
personal characteristics influence vaccination differently in different circumstances, 
demonstrating the complexity of the decision-making process regarding cervical cancer 
vaccination. Further research is necessary to define whether or not some of these variables 
would have an added value to the HBM. 
 
 
CONCLUSIONS 
We found little support for the HBM in the context of HPV vaccination in Kenya and neither 
was willingness a good predictor for uptake. Due to pro-vaccine attitudes at baseline and low 
vaccination rate (31%) at follow-up, our study may have lacked power to find associations. 
However, other longitudinal studies have equally showed that attitudes, health beliefs and 
intentions are not always strong correlates of HPV vaccination. [36, 35, 42] Reiter et al. 
proclaim that “beliefs and attitudes may not be important determinants in the early adoption 
of behaviors that are not well understood by most individuals”. [35] In the same light and 
based on the strong correlation between adequate promotion and vaccine uptake, we 
hypothesize that supportive important others, motivation by health providers and general trust 
in the health system may be of extreme importance to counteract knowledge gaps and doubts. 
Therefore, we recommend to further study whether interpersonal variables and variables at the 
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level of community or health system are important determinants of new (preventive) health 
actions in addition to personal beliefs, and in which contexts. [43, 40] By monitoring future 
HPV vaccination programs and by assessing users’ and non-users’ perspectives these 
variables could be more explored and if deemed appropriate added to the HBM. Furthermore, 
such research could help identifying specific components of promotion interventions 
necessary for the target group to perceive promotion as adequate. Finally, our results also 
encourage the examination of modifying effects of personal characteristics since they might 
boost the predictive value of the HBM. Identification of such determinants might then help to 
increase the efficacy of future promotion campaigns and as such, create awareness, consensus 
and support for HPV vaccination at the community level.      
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Table 1. Complete list of items used to assess the health belief model (HBM) constructs 
and willingness. 
CONSTRUCTS 
baseline/ 
follow-upa 
Item wording (response options) # items αb 
Severity baseline How serious would it be if your daughter would have cervical cancer? (1=not serious at 
all–5=very serious) 
1 n/a 
Susceptibility baseline How likely is it that your daughter would develop cervical cancer in the future? (1=very 
unlikely–5=very likely) 
1 n/a 
Benefit health baseline You would vaccinate your daughter because:  3 .888 
  The vaccine will protect her health. (1=strongly disagree–5=strongly agree)   
  The vaccine will protect her reproductive health. (1=strongly disagree–5=strongly agree)   
  The vaccine will prevent her from having cervical cancer. (1=strongly disagree–
5=strongly agree) 
  
Barriers baseline You would not vaccinate your daughter because:   
Lack of information  You need more information first (1=strongly disagree–5=strongly agree) 1 n/a 
Doubt vaccine efficacy   You doubt that the vaccine will truly prevent cervical cancer and genital warts 
(1=strongly disagree–5=strongly agree) 
1 n/a 
Time constraints  You think vaccination always takes a lot of time. (1=strongly disagree–5=strongly agree) 2 .791 
  You think it’s inconvenient that she needs 3 doses. (1=strongly disagree–5=strongly 
agree) 
  
Safety concerns  You think it might have unknown future side effects. (1=strongly disagree–5=strongly 
agree) 
3 .882 
  You think it might interfere with her fertility. (1=strongly disagree–5=strongly agree)   
  You’re afraid the vaccine will not be administered safely (clean needles). (1=strongly 
disagree–5=strongly agree) 
  
Father’s refusal  You think your partner or her father won’t approve it. (1=strongly disagree–5=strongly 
agree – 0=no current relationship) 
1 n/a 
Self-efficacy baseline Are you confident that you could let your daughter get vaccinated if you wanted? (1=not 
confident at all–5=very confident) 
2 .762 
  For you, if you want your daughter to be vaccinated against cervical cancer, that would 
be. (1=very difficult–5=very easy) 
  
Adequate promotionc follow-up    
Personal level  Did you feel well informed regarding the cervical cancer vaccination program? (0=no, 
1=yes) 
1 n/a 
School level  School average of adequate promotion at personal level 1 n/a 
Willingness to 
vaccinate 
baseline Would you vaccinate your daughter against cervical cancer? (1=very unlikely–5=very 
likely) 
2 .901 
  Will you let you daughter get vaccinated against cervical cancer through this program? 
(1=very unlikely–5=very likely) 
  
a Measure obtained from baseline or follow-up interview. 
b Cronbach’s alpha (α) indicating the reliability.  
c Participants were asked if that had heard about the HPV vaccination study at the hospital after being informed during the baseline interview. If yes, they 
were asked whether or not they had felt well-informed. 
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Figure 1. Flow diagram of the recruitment and response of study participants. 
 
 
 
 
 
 
 
 
 
 
  
Random sample of girls 
Primary school girls (n = 472) of classes 4-8 were 
randomly selected using class lists from 10 randomly 
selected public schools within Eldoret Municipality. The 
number of  girls per school was in proportion to the size 
of the school. The mothers received an invitation for the 
baseline study via their daughters.  
Completed baseline survey 
Face-to-face interviews (n = 287) 
Invited for follow-up survey 
By phone or through visiting school or through going to 
the description of their living-place (n = 287) 
Data available for analyses 
Face-to-face baseline and follow-up interviews (n = 235) 
Face-to-face baseline interview and follow-up interview 
by phone (n = 20) 
Lost to follow-up  
Participants who could not be found, passed 
away, moved, or who were not able or 
willing to participate again (n = 31) 
One participant who did not know the 
vaccination status of her daughter (n=1) 
Non-participation  
Not responding to the invitation (n = 185) 
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Figure 2. Health Belief Model to predict HPV vaccine uptake without adequate 
promotion and with adequate promotion. 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 2. Health Belief Model to predict HPV vaccine uptake without adequate promotion (a. Model 1) and with 
adequate promotion (b. Model 2). Numbers represent the significant (p<.05) standardized parameters (β). Thin lines 
without numbers represent non-significant parameters in the model. R
2
 represents the explained variance of the dependent 
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Figure 3. Health Belief Model to predict HPV vaccine uptake fully mediated by 
willingness to vaccinate. 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 3. Health Belief Model to predict HPV vaccine uptake fully mediated by willingness to vaccinate (Model 3). 
Numbers represent the significant (p<.05) standardized parameters (β). Thin lines without numbers represent non-significant 
parameters in the model. R
2
 represents the explained variance of the dependent variable. (N = 255) 
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Figure 4. Health Belief Model to predict HPV vaccine uptake including personal 
characteristics and mediated by willingness. 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Health Belief Model to predict HPV vaccine uptake including personal characteristics and fully mediated 
by willingness to vaccinate (Model 4). Numbers represent the significant (p<.05) standardized parameters (β). Thin lines 
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 represents the explained variance of the dependent 
variable. (N = 255) 
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Supplementary Material 
Table i. Correlations, means, standard deviations, and ranges of Health Belief Model constructs.   
Variable  1 2 3 4 5 6 7 8 9 10 11 12 13 
Correlation coefficients:              
1. vaccine uptake 1.00             
2. Willingness to 
vaccinate 
.13* 1.00            
3. Severity .00 .25* 1.00           
4. Susceptibility .02 .38* .21* 1.00          
5. Benefit health  .08 .34* .31* .06 1.00         
6. Barrier lack of 
information  
.02 .02 .06 -.09 .22* 1.00        
7. Barrier doubt vaccine 
efficacy 
-.01 -.15* .03 -.14* -.07 .38* 1.00       
8. Barrier time 
constraints  
-.03 -.21* -.18* -.08 -.29* -.02 .10 1.00      
9. Barrier safety 
concerns  
.00 -.15* .03 -.17* .02 .37* .79* .10 1.00     
10. Barrier father’s 
refusal  
-.08 -.39* -.09 -.28* -.13* .09 .26* .19* .29* 1.00    
11. Self-efficacy .18 .54* .27* .15* .56* .11 -.03 -.32* -.02 -.32* 1.00   
12. Adequate 
promotion: individual 
.36* .14* .03 .05 .04 -.07 .06 -.05 .05 -.17* .11 1.00  
13. Adequate 
promotion: school 
.36* .16* .07 .07 .09 .02 .09 -.07 .10 -.08 .15* .42* 1.00 
Meana 31% 4.43 4.82 3.79 4.60 3.51 2.37 1.38 2.55 1.54 4.33 62% .62 
SD .46 .86 .59 1.03 .58 1.47 1.35 .56 1.29 1.43 .81 .47 .20 
Range 0/1 1-5 1-5 1-5 1-5 1-5 1-5 1-4 1-5 0-5 1-5 0/1 .18-.83 
N = 255.  
a Means of dichotomous variables are replaced by proportions of ones observed. 
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Table ii. Direct, mediated, and moderating effects of socio-demographic variables (xsdv) on Health Belief Model constructs (xhbmc), willingness and 
vaccine uptake: unstandardized path coefficients (β). 
 Socio-demographic 
variable (xsdv) 
Na 
Direct effect of 
xsdv on Uptake
b 
By xHBMc mediated 
effect of xsdv
c  
Moderating effect of xsdv on the 
relations in Model 3d 
Direct effects of 
interaction termse 
1.  Age of participant   255 -- -- -- -- 
2.  Age of daughter  255 -- -- Age daughter * Barrier father’s 
refusal- Willingness 
Age daughter –
Willingness        - 
    0.049 (0.015)* 0.047 (0.039)* 
     Barrier father’s refusal 
-0.689 (0.179)* 
3.  Class of daughter 255 -- -- -- -- 
4.  Marital_status of 
participant (single vs.  
255 -- -- Marital_status * Susceptibility-
Willingness 
Marital_status-
Willingness           
with partner)    -0.267 (0.086)* 1.543 (0.321)*  
Susceptibility- 
     Willingness           
0.385 (0.072)* 
5.  Number of children 
in household  
255 -- -- -- -- 
6.  Heard of cervical 
cancer 
255 0.664 (0.213)* -- -- -- 
7.  Schooling of 
participant  
236 -- -- -- -- 
8.  Origin of participant 
(urban vs. rural)   
255 -- -- -- -- 
9.  Religion of 
participant (non- 
255 -- Severity   -0.661 
(0.086)* 
-- -- 
Muslim vs. Muslim)    Susceptibility         -
0.628 (0.239)* 
  
   Benefit health       -
0.558 (0.113)* 
  
   Barrier time constraints   
0.505 (0.104)* 
  
   Barrier father’s refusal 
1.036 (0.275)*        
Self-efficacy  
  
   -0.523 (0.153)*   
10.  Socio-economic 
status (SES) f 
255 -- -- SES*Susceptibility-Willingness-
0.116 (0.038)* 
SES-Willingness 
0.419 (0.130)* 
Susceptibility- 
     Willingness  
     0.716 (0.157)* 
*p <.01; -- = indicating that no significant (direct/moderated/mediating) effects were found for the socio-demographic variable; standard errors are in 
parentheses. 
a If a background characteristics had more than 5% missing values, models, verifying the direct, mediated of moderated effect of the variable, were 
compared using only data from participants who had no missing values.  
b Direct effects were examined through specifying a direct effect of the personal characteristic on vaccine uptake within Model 3. 
c Mediated effects were examined through specifying direct effects from the personal characteristic to the ten predictors in Model 3.  
d Moderating effects on the relations in Model 4 were examined for all personal characteristics separately . 
e Direct effects of the variables in the moderation on dependent xHBMc. 
f A score representing the quality of the building materials of the house.  
 
 
 
 
Chapter 8
Implementation of an
HPV vaccination
program in Eldoret,
Kenya: results from a
qualitative assessment by
key stakeholders
Paper 3: Evaluating the HPV vaccination programme The
last paper reflects on the HPV vaccination programme from a dif-
ferent angle: qualitative data is presented (versus the quantitative
results in the first two papers), collected among several stakeholders
(as opposed to the mothers of girls). By assessing the perspectives
of fathers, teachers and vaccinators, we complemented the previous
results with insights at family as well as community and organiza-
tional level. Since the FGD were organized after the HPV vaccin-
ation programme had taken place, we were able to capture users'
perspectives as opposed to hypothetical attitudes towards the HPV
vaccine. Furthermore, barriers identified in the longitudinal study
could be explored more in-depth.
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Implementation of an HPV vaccination
program in Eldoret, Kenya: results from a
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Abstract
Background: Cervical cancer strikes hard in low-resource regions yet primary prevention is still rare. Pilot projects
have however showed that Human Papillomavirus (HPV) vaccination programs can attain high uptake. Nevertheless,
a study accompanying a vaccination demonstration project in Eldoret, Kenya, revealed less encouraging outcomes:
uptake during an initial phase targeting ten schools (i.e., 4000 eligible girls), was low and more schools had to be
included to reach the proposed number of 3000 vaccinated girls. The previously conducted study also revealed
that many mothers had not received promotional information which had to reach them through schools: teachers
were sensitized by health staff and asked to invite students and parents for HPV vaccination in the referral hospital.
In this qualitative study, we investigate factors that hampered promotion and vaccine uptake.
Methods: Focus group discussions (FGD) with teachers (4) and fathers (3) were organized to assess awareness and
attitudes towards the vaccination program, cervical cancer and the HPV vaccine, as well as a FGD with the
vaccinators (1) to discuss the course of the program and potential improvements. Discussions were recorded,
transcribed, translated, and analyzed using thematic analysis In addition, a meeting with the program coordinator
was set up to reflect upon the program and the results of the FGD, and to formulate recommendations for future
programs.
Results: Cervical cancer was poorly understood by fathers and teachers and mainly linked with nonconforming
sexual behavior and modern lifestyle. Few had heard about the vaccination opportunity: feeling uncomfortable to
discuss cervical cancer and not considering it as important had hampered information flow. Teachers requested
more support from health staff to address unexpected questions from parents. Non-uptake was also the result of
distrust towards new vaccines. Schools entering the program in the second phase reacted faster: they were better
organized, e.g., in terms of transport, while the community was already more familiarized with the vaccine.
Conclusions: Close collaboration between teachers and health staff is crucial to obtain high HPV vaccine uptake
among schoolgirls. Promotional messages should, besides providing correct information, tackle misbeliefs, address
stigma and stress the priority to vaccinate all, regardless of lifestyle. Monitoring activities and continuous
communication could allow for detection of rumors and unequal uptake in the community.
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Background
In Kenya, cervical cancer has the highest incidence and
is the most lethal cancer among women, after breast and
esophagus cancer. Yearly, almost 5000 women are diag-
nosed while close to 2500 die. East Africa is indeed one
of the most affected regions of the world, with age stan-
dardized incidence and mortality four times as high as
in more developed regions [1]. This health inequality
gap is not only the result of limited screening and treat-
ment options, also awareness of the disease and its
symptoms is insufficient [2, 3]. If uptake of preventive
measures remains inadequate, and taking into consider-
ation the present population growth, the burden of cer-
vical cancer could exponentially increase with over 50 %
more new cases and deaths over the coming years [4].
Primary prevention through HPV vaccination has the
potential to significantly reduce the incidence of cervical
cancer and to eliminate cervical cancer disparity. The
vaccines currently on the market are likely to prevent up
to 70 % of cervical cancers, i.e., those caused by HPV 16
or 18 [5–7]. National vaccination programs are already
rolled out in over 39 - mostly high-income - countries.
In less wealthy regions, where the vaccines can have
most impact, large scale vaccination efforts are still
scarce [3, 4, 8]. Through demonstration projects, many
low- and middle income countries have however gained
experience regarding the introduction of the HPV vac-
cines. Results are very promising: high uptake is
achieved (>70 %) and drop-out rates for second and
third doses are low [9–14].
A longitudinal study linked with a demonstration pro-
gram in Eldoret, Kenya, revealed however a different
outcome: although the majority of mothers of eligible
girls had expressed a wish to vaccinate their daughter
before the start of the program (88 %; 253/287), only
31 % (79/254) of those who entered the follow-up study
reported to have eventually done so. The main reason
for non-uptake was lack of information on where and
when the vaccination took place [15]. Poor promotion
might thus have hampered the program. Other pilot
programs already showed that thorough formative re-
search followed by sensitization, especially through com-
munity influencers, is indeed key for success [11, 16, 17].
But as Kane et al. pointed out, one cannot expect similar
results without investing a considerable amount of time
and money to promotional activities [4]. Another reason
for the noted difference in coverage might be a variation
in the definition of uptake, and more particularly the tar-
geted population (i.e., the denominator). Ladner et al.
presented uptake rates of 21 demonstration projects; all
achieved over 75 %. However, these figures might be
overestimations for two reasons, as reported by the au-
thors: 1) it is not clear what data was used in each study
to calculate the target population which means the
denominator might have been unreliable, and 2) programs
might have targeted and recruited more girls than originally
planned [10]. Post-vaccination studies could provide clarifi-
cation. In the case of the program in Eldoret, it remains im-
portant to further investigate why coverage was insufficient
and why people were ill-informed. By interviewing several
stakeholders, further insight can be obtained and findings
of the abovementioned study, in which women’s perspec-
tives were assessed, can be triangulated. Including the male
guardian, for example, helps clarifying whether women dis-
cuss cervical cancer prevention with their partner and
whether they involve them in the decision (given that male
partners often have decisive power [15, 18]). Also teachers
are deemed important since they had an important task in
this program, i.e., promotion of the vaccine, which was not
well perceived by the women in the longitudinal study. Giv-
ing the teachers a voice enables us to understand how they
experienced the program. Finally, the vaccinators them-
selves as well as the program coordinator can give insights
regarding the organization and can reflect on the course of
the program. The latter was in charge of promoting the
HPV vaccination program among the teachers.
Many studies have already provided important insights
from pilot vaccination projects. Through monitoring and
evaluation, barriers are recognized, underserved popula-
tions are detected and effective sensitization and delivery
strategies are identified [9, 11, 17, 19–25]. In general,
internationally more attention is going to implementa-
tion research and process evaluations in order to im-
prove and understand effectiveness of programs.
Additionally, there is a call for a close follow-up of vac-
cination strategies: “Introducing new vaccines and ensur-
ing they reach all people for whom they are intended is
a challenging task, and the science related to implement-
ing interventions effectively, efficiently, and with equity
and high fidelity has received inadequate attention, par-
ticularly in African and Asian countries where overall re-
search capacities are limited” [26].
In light of this, the aim of this study was to evaluate
the implementation of the HPV vaccination demonstra-
tion program in Eldoret. In order to do so, three specific
objectives were identified: 1) to verify whether fathers
and teachers were aware about the program and had
supported it, 2) to assess barriers in promotion, such as
the level of understanding of cervical cancer and atti-
tudes towards HPV vaccination, and 3) to gather recom-
mendations, among fathers, teachers, vaccinators and
the program coordinator, to contribute to the improve-
ment of future HPV vaccination programs in Kenya.
Methods
The study context
The pilot HPV vaccination program - From May 2012
till March 2013, an HPV vaccination program was rolled
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out in Eldoret, Kenya. With support from the GARDA-
SIL Access Program (GAP), Moi Referral and Teaching
Hospital (MTRH) was able to vaccinate 3000 girls
against cervical cancer. The vaccines were administered
for free in the hospital on Wednesdays and Saturdays.
Promotion took place in a pool of ten randomly selected
schools as to avoid over-demand in the community.
Through this, 4000 eligible girls, i.e., girls from class 4 to
8 (9–14 years old), were targeted. Health care providers
went to the schools to inform the teachers who were
then asked to promote the vaccine among the students
and their parents. Each time, two pieces of information
had to be passed: 1) basic information on cervical cancer
and the HPV vaccine, and 2) practical information on
the whereabouts of the vaccination program. However,
due to poor response after three months, the program
opened up to all other schools in the community, public
and private.
Acceptance and uptake of the HPV vaccine – We
assessed HPV vaccine acceptance among a randomly se-
lected sample of women with eligible daughters in the
ten initially included schools using a structured ques-
tionnaire (March 2012). During the interview, all women
received basic information about cervical cancer and the
upcoming HPV vaccination program. Once the program
was completed, a follow-up survey was conducted to
collect data regarding vaccine uptake (May 2013). Des-
pite high baseline acceptance, reported uptake at follow-
up was low. Main reasons for not receiving the vaccine
were not feeling well-informed, fear of side effects and
lack of time. In addition, women also reported that they
had been confronted with opposition from people
around them, among others their partner. More details
about the program and the longitudinal study are de-
scribed elsewhere [15].
Recruitment of participants
The organization of the focus group discussion (FGD)
was a stepwise process during which schools were ran-
domly selected, asking the head teacher permission to
set up a FGD in the school with either teachers or fa-
thers. Each time a school was selected for a discussion,
it was excluded from the pool (i.e., the ten schools that
were targeted during the first wave of the vaccination
program) to avoid two FGD in one school which could
otherwise result in receiving the same information from
both teachers and fathers regarding the organization of
the program at school. Schools were invited until satur-
ation was reached.
Once a school agreed to participate, the team set up
the ideal date and time with a teacher, appointed by the
head teacher, and participants were invited: 1) Fathers -
Partners of the women who participated in the above-
mentioned longitudinal study were invited, hence they
had a daughter who went to one of the targeted schools
and had been eligible for vaccination. They were con-
tacted by phone since contact information of the house-
holds had already been gathered during the cohort study
[15]. 2) Teachers – The team invited all teachers present
the day when permission to organize a FGD was asked.
In addition, information letters were left behind inviting
also other teachers to participate.
Recruitment of the vaccinators was done by contacting
the head nurse responsible for the team, who then in-
vited the other nurses for a FGD in the hospital. All
FGD took place in May 2013. Finally, the program co-
ordinator was directly invited by phone to meet in a
place selected by him (October 2014).
Procedures
All interviews were audio-recorded; FGD with fathers
and teachers were moderated by researchers of the local
team, who have considerable experience in conducting
qualitative interviews regarding medical topics in the
community. The discussion with the vaccinators and the
validation meeting with the program coordinator were
led by the first author of this paper. Before the start of
the discussion, respondents were explained that partici-
pation was voluntary, that they could choose not to an-
swer or leave the discussion at any point. Also signed
consent forms were requested from all participants.
Interview guidelines for teachers and fathers were very
similar and addressed awareness of the HPV vaccination
program and whether or not they had participated in it.
In addition, knowledge regarding cervical cancer and
prevention was assessed, followed by a short, standard-
ized informative session to provide correct information.
The discussion ended by asking for recommendations
on how future programs should be organized. During
the FGD with teachers, extra attention was paid to their
role as promoters and to their willingness to discuss cer-
vical cancer prevention with their students.
The vaccinators were interviewed about two topics:
their tasks during the program and whether they felt
prepared, and how they thought the program could have
been improved. Finally, a validation meeting with the
program coordinator was organized to reflect on the
vaccination program and the results of the FGD.
Analysis
The interviews with the teachers and the vaccinators
were in English, while the interviews with the fathers
were in Swahili. English discussions were transcribed
verbatim while Swahili sessions were translated and
transcribed simultaneously, providing final transcripts in
English. Transcription was done by local team members
who at all-time could discuss interpretation of Swahili
among each other. The transcripts were coded by two
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independent researchers, initially based on a list of codes
deducted from the interview guidelines, focusing on
awareness and perception of the HPV vaccination pro-
gram, cervical cancer knowledge and attitudes towards
the HPV vaccine. These codes were then gradually
adapted and grouped into emerging themes [27]. Finally,
results and conclusions of this analysis were discussed
with the program coordinator to place them in the spe-
cific context of the HPV vaccination program and to for-
mulate recommendations for future programs.
Ethics statement
The study protocol was approved by the ethical boards of
Moi University and Ghent University. All participants of
FGD received a small compensation (200 KES, i.e., approxi-
mately 1.5€) to cover their time and transport cost. Written
informed consent was obtained from all respondents.
Results
Characteristics of the participants
Seven schools were included given that saturation was
reached after four FGD with teachers and three with fa-
thers. In total, 67 teachers and fathers participated. FGD
with teachers consisted of more female than male re-
spondents and always included a mix of teachers of class
4 to 8, i.e., the classes targeted by the HPV vaccination
program, and teachers of younger students. As there
were no male vaccinators, the FGD with the nurses only
included women (Table 1).
The HPV vaccination program
Knowledge about the program
Few fathers had heard about the past HPV vaccination
program and when they had, it was mostly through their
children and wives. When asked if they had discussed it
with others, they explained that it was difficult given that
it is taboo to openly discuss such topics. In addition,
even if cervical cancer was brought up in conversations
participants considered it a far-flung event, far removed
from their own personal lives.
Father (FGD 7): I heard of it from my children, that
they are supposed to go and get checked.
Father (FGD 7): I only talked to my wife, not to other
people. When talking about private parts to other
people, they start drawing away from you.
Father (FGD 6): This is a new thing so we haven’t
talked about it so much. Even if we hear about it, we
don’t take it seriously….We’ve famous people like
[name 1] being affected by cancer and went for
treatment abroad….[name 2]….But to us it is a new
thing.
Similarly, not all teachers had received information
about the HPV vaccination program or if the promotion
had reached them, they “took it lightly” or “didn’t pay so
much attention”. It was clear from all FGD with teachers
that the health care providers had never sensitized the
entire teacher corpse but rather a subset of teachers,
appointed by the head teacher or those responsible for
classes 4 to 8. As a result, in none of the schools an
overall campaign or program was set up which led to
misunderstandings and distrust.
Teacher (FGD 4): They [the health care providers] met
just some of the teachers, only those who were
concerned with the… or those who had been given the
duty of taking the children, because us we didn’t hear.
Table 1 Characteristics of participants of FGD
FGD Participants Number of participants Teachers’ class
# Men Women Total Class 1-3 Class 4-8a Missing
1 Teachers of school 1 2 6 8 1 4 3
2 Teachers of school 2 2 10 12 - 9 3
3 Teachers of school 3 3 9 12 1 5 6
4 Teachers of school 4 4 7 11 1 3 6
5 Fathers of school 5 6 - 6 NA NA NA
6 Fathers of school 6 7 - 7 NA NA NA
7 Fathers of school 7 6 - 6 NA NA NA
8 Vaccinators (nurses of MTRH) - 5 5 NA NA NA
TOTAL 30 37 67
agirls targeted for vaccination, approximately 9–14 years old
In total, 10 schools were enrolled in the first phase of the vaccination program. Later the program opened up to the entire community due to low uptake in the
initial phase
FGD: focus group discussion; MTRH: Moi Teaching and Referral Hospital; NA: not applicable
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A last reason why the program had not been discussed
among participants was that cervical cancer, and health in
general, concerns only women. Therefore, male teachers
and fathers had not felt part of the vaccination activities.
Teacher (male) (FGD 2): I think the name should be
changed. You know, when I pass and I find a poster
talking of cervical cancer. It bothers me less, I feel that
I'm not of that part.
Teacher (female): To draw the attention of men.
Teacher (male): Men look at it and they see women’s
issues.
Participation in the program
Simply not being aware of the program or lack of informa-
tion were the main reasons why not all teachers had coop-
erated in the program. Those teachers who had been
involved, explained that they had just quickly passed prac-
tical information or invitation forms to their students, as
opposed to also inform them about HPV and cervical can-
cer and encourage them to get vaccinated. Some teachers
also remembered that parent meetings had been orga-
nized during which HPV vaccination was discussed.
Teacher (FGD 2): I think that time we only mentioned.
We were told [by health care providers] 'you tell these
children to take their forms to the parents, those who
are interested can go to MTRH for this'.... It was just
as simple as that. We didn't think much about it.
Teacher (FGD 4): They [health care providers] came
but there was a room which was organized for just the
mothers, the parents of the girls who had accepted, so
they talked to them and they went away.
In terms of vaccination, some fathers and teachers re-
ported having their girls vaccinated but most had not
done so.
Father (FGD 7): I took my children to all the three
vaccinations.
Teacher (FGD 1): Yeah, I have heard about it, I even
took my daughter.
Father (FGD 6): We didn’t take them.
Father (FGD 6): We didn’t know the importance of the
vaccine but now we know.
Barriers of promotion: knowledge of cervical cancer and
attitudes towards HPV vaccination
Given that the program was poorly known, we searched
for reasons why promotion had failed and found two
major reasons. First of all, due to a limited understand-
ing of cervical cancer, prevention had not been consid-
ered a priority and many participants had not felt
comfortable enough to discuss it. By providing correct
information, participants did however welcome the HPV
vaccine. Secondly, the new vaccine had instilled safety
doubts which made people feel insecure to promote it.
Cervical cancer knowledge
Cervical cancer was poorly understood by fathers and
teachers. For some of them, it was the first time they
heard about it while other participants had problems
with differentiating several types of cancer or distinguish-
ing cervical cancer from other reproductive health condi-
tions, such as fibroids or pelvic inflammatory disease.
Father (FGD 7): I had heard about cancer but I didn’t
know that there is cervical cancer. I always knew
cancer is that which is caused by smoking. That’s what
I knew.
Teacher (FGD 4): I think also when one is not clean
maybe it can result into pelvic inflammatory disease,
which can also lead to cancer, of the cervix.
When asked about the causes of cervical cancer, many
possibilities arose, yet HPV was rarely mentioned as a
primary cause. Moreover, ‘cancer’ was interpreted in vari-
ous ways: depending on the participants’ perception of
causality, cervical cancer could be a wound, a rupture,
an abnormal growth or swelling, a combination of dis-
eases, an inflammation or an inherited condition. In
turn, the ‘cancerous wound’ had many causal pathways,
such as early sexual intercourse, coils (IUD), infectious
diseases, (in)consistent use of contraceptives (pills or in-
jection), unsafe abortion, accumulated dirt, rough sex
and the use of sex toys.
Father (FGD 5): I think when a girl engages in sex
when young, if she develops a wound in the
reproductive system and the wound takes long to heal,
it might be the onset of cancer.
Father (FGD 5): Ok, I think a child is born while ‘fresh’
but when one becomes sexually active….in the process
of coming into contact with several diseases especially
the STIs…If the diseases are not treated, they block the
reproductive organ which leads to something like
cancer because I think cancer is nothing but a
combination of several diseases.
Teacher (FGD 1): I think there might be, [a relation
with bad hygiene] because if there is some dirt, let us
say the accumulation, if it accumulates and
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accumulates and there is no attention taken to it or
there is no cleanliness, that accumulation may stay
there for long and it may cause, maybe, a wound and
then from there a problem can develop.
In general, participants either brought up risk factors
related with sexual practices or with lifestyle. Sexual ac-
tivities different from a monogamous, heterosexual rela-
tionship were mostly linked to cervical cancer. Examples
of such practices are starting to be sexually active at
young age, having sex during menstruation, having sex but
not conceiving, masturbating (with dirty hands or objects),
using and sharing sex toys, having multiple partners and
having intercourse too soon after giving birth.
Teacher (FGD 3): Also, when a mother is giving birth
and then she gets an injury (pauses) and she goes for
sexual intercourse before healing.
Teacher (FGD 2): We also have these habits that have
cropped up nowadays. Eh, there is a practice of
lesbianism and even sometimes they use sex toys. I
don't know what standard of hygiene they reach to
keep those things clean for them to share.
Teacher (FGD 3): Yes, I had a point… it is not only the
machines they use. When you go to these children in
boarding schools most of them use bananas and carrots.
Teacher: and the fingers
Teacher: and their fingers …They might be infected,
they might be dirty.
The majority of the fathers and teachers, yet not all,
also thought ‘bad hygiene’ was potentially harmful, but
this could be defined as either a lack of personal care,
using dirty toilets or again engaging in certain sexual ac-
tions, such as masturbation or sex during menstruation.
Teacher (FGD 1): When you have different sexual
partners and you don’t pay attention to hygiene, you
can get it.
Teacher (FGD 1): I think there might not be [a
relation with bad hygiene] because I understand there
are areas in Kenya where access to water is an issue
and these people do not suffer from these diseases. But
in urban areas, like here in Eldoret, in town so many
people have such disease while these are the people
who know how to wash, who know how to use even the
vaginal soaps and still they are getting it.
Furthermore, participants had different opinions whether
or not cervical cancer was sexually transmitted. Similarly,
heredity was also questioned by both fathers and teachers.
Father (FGD 6): According to what my friend said that
it is sexually transmitted, I don’t think it is true…. I
had an aunt who was suffering from cervical cancer
and died. The husband is still alive and he doesn’t
seem to be having any problem.
Teacher (FGD 2): It is [inherited] because a new-born
has directly inhaled everything from the parents. So even
the blood of the parents who are cancerous, at least that
kid would take some blood, which is cancerous.
With regard to lifestyle, taking up ‘new or modern’
habits, whether it concerned smoking, food, cosmetics,
medicines, contraceptives, using microwaves or exposure
to X-rays, these behaviors were very often mentioned as
‘cancerogenic’. Especially contraceptives and food were
of major concern, more particularly canned, packed or
processed food or food exposed to fertilizers and chemi-
cals. This resulted mostly out of the impression that cer-
vical cancer, and cancer in general, is a disease of the
rich, urban population. However, some teachers coun-
tered this and started to reflect on lack of diagnoses in
remote areas. Likewise, one teacher questioned the rela-
tionship with contraceptives given that older women,
who have never used such methods, are also affected.
Father (FGD 6): A woman could plan with the man
when to get a child but nowadays they use pills and
injections. As days pass by they forget to go for the
injection or to take the pills consistently. When this
happens, they might cause a growth in the womb or
they become toxic and cause cervical cancer.
Teacher (FGD 1): There are some older women who
have suffered from cancer who have never used
contraceptives, but their story is that they have had
multiple partners, sexual partners earlier on when
they were young, but they didn’t use contraceptives
those days, it might not be, in my opinion it might not
be a real reason.
Teacher (FGD 2): I’m just on the side of the food eaten
by different people. People should …use indigenous
food. Some of this food … The food colours, the
chemicals they mix with this food. They facilitate
different types of cancers. So people should turn to the
indigenous food, the original African food.
Teacher (FGD 2): If you go in town, you’ll find that
this is very common in town. As compared to the
village and the remote areas. Why? Because, while in
town, people eat different foods. Because of the living
standards of the people, the living standard is high.
People eat different food. Somebody can eat meat for
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six days in a week and a poor person can have meat
maybe twice in a year.
Teacher (FGD 4): Many Africans are poor so most of
us are dying, because of these things, so we are dying
because of cervical cancer without knowing. Whenever
we hear of it, it’s from those people who are able,
maybe they go to London for checkups so you hear, ‘she
was sick with cervical cancer’, and that is why we
relate it to the rich. Otherwise we are dying without
knowing it is the disease which is killing us.
Finally, cervical cancer was perceived severe, affecting
one’s fertility, and deadly; treatment was just too expen-
sive. Preventive methods suggested by the participants
were mostly abstinence of all aforementioned activities
or products that could cause cancer. However, awareness
was specified as the best prevention of all. One teacher
even went further and mentioned that “ignorance itself
causes cancer”.
Father (FGD 6): When one hears the term cervical
cancer especially when your child has it, you get
scared. You then ask yourself whether she will ever
give birth…Because when she has cervical cancer, she
might not give birth and will finally die, so a parent
loses hope.
Teacher(FGD 1): I have seen someone who suffers from
it and was in a lot of pain and bleeding from the
inside - where exactly, I don’t know, but somewhere in
the uterus; it was very painful and was not curable.
Teacher (FGD 3): Ignorance of the ways of preventing
cancer itself can produce cancer.
Moderator: can you give an example?
Teacher: When you use the gels [lubricants] for
example, suppose they cause cancer…You see what has
caused cancer is not the gel but ignorance.
Attitudes towards HPV vaccination: drivers and barriers
Once participants were fully informed about cervical
cancer and HPV vaccination, they were all accepting the
vaccine. “Prevention is better than cure” was frequently
brought up as main driver, together with the fact that
the disease is deadly and cures are either unavailable or
unaffordable. Fathers were especially in favor since it
would protect their daughters’ fertility and therefore her
future life as a mother. In general, foreseeing the girls’ fu-
ture task such as providing grandchildren or taking care of
the parents were reasons to consider HPV vaccination.
Teacher (FGD 1): Now that you have taught us about
it I think it’s good.
Father (FGD 6): If the father refuses to take his
daughter - yet we are being told the disease can be
prevented - he will be ruining his daughter’s life….she
will not have children and may be unhappy in her
marriage.
Some teachers also pointed out a certain necessity for
their pupils to be protected against cervical cancer. More
particularly, they considered the students’ home situation
or sexual activities as unsafe hence the need for prevention.
Teacher (FGD 4): I can add, it is okay because we are
living in a slum where the trend of prostitution is very
high, and children are seeing those things going on and
some of them are involved because of the status of
their home, so I think it is ok.
Teacher (FGD 1): And I think it’s okay, and what
should be done is that even our children should be
taught, they should be sensitized, so if they are aware
even this matter of having sex at an early age is not
good because it gives rise to other diseases.
Respondents also reported reasons why the vaccines
could have been refused or why they themselves had not
supported them. Several barriers concealed a certain
level of distrust, towards vaccines in general or towards
the HPV vaccine specifically. Bad experiences or rumors
about other vaccines (polio and asthma especially) were
brought up as to indicate the possible danger of vac-
cines, and the fact that this vaccine was new implied a
potentially hidden experiment. Surprisingly, while pro-
tecting a girl’s fertility was a driver for accepting the vac-
cine, the same vaccine generated fear in terms of
harming the girl’s fertility. In addition, several teachers
thought that parents might have feared that vaccination
would enhance sexual activity among the children.
Father (FGD 6): There are parents who still have
traditional beliefs and don’t believe in complementary
medicine.
Teacher (FGD 4): Others think it is the disease of the
rich (laughter); you know these chronic diseases, they
think they are for the rich [after the moderator asked
reasons to refuse the vaccine].
Teacher (FGD 1): We have not heard about people
who have been vaccinated so we think they are
starting with our children, they are used as guinea pigs
or something, people try to see if it can work.
Father (FGD 6): There was a time we were told that
when one is vaccinated, she might be unconscious for
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half an hour….I heard it somewhere and it prevented
me from taking my daughter….
Father: Yes, I heard it somewhere. It scared me
because I thought that was very dangerous.
Teacher (FGD 4): She [a mother of a student] was
telling me that it is going to make our girls
infertile, or maybe they will become sexually active,
she said ‘me I refused my child to go for it’, but I
didn’t ask anything more about it, so I left it at
that. I was also of the belief that it has negative
effects but now, I am for it.
Finally, certain religious groups were known for rejecting
all vaccines so participants mentioned them as refusers.
Father (FGD 5): Religion is a very important factor.
There are some religions which do not agree to
treatment or vaccine.
Moderator: Which religion? Please give me examples.
Father: There is this church at our place with a red
cross, Holy Spirit Church
Moderator: Yeah Holy Spirit Church
Father: Legion Maria and Wakorino
During the short informative session and in the course
of the remaining discussion, moderators often had to re-
explain cancer-related issues or answer questions of par-
ticipants. It was clear that once they had received the basic
information, they started to interpret the obtained know-
ledge, each according to his or her capacity and according
to his or her understanding of health and disease. For ex-
ample, the fact that cervical cancer is sexually transmitted
led to additional questions. Particularly male participants
started wondering why boys were not targeted, given that
they are “carriers of the virus”.
Teacher (male) (FGD 4): Excuse me, somebody has
talked about it being transferred from one woman to
another by men, so men are carriers, I think also men
should be vaccinated.
Also eligibility was a topic of discussion. The moderator
had to explain carefully that targeting young girls, in this
case from class 4 to 8, was just a strategy to obtain girls
who are not yet sexually active. Especially teachers were
concerned about what would happen if a sexually active
girl would receive the vaccine and whether or not they
truly had to know which girls were already sexually active.
Recommendations for future programs
Clearly, more information was requested by all partici-
pants, combined with facilitating HPV vaccination for par-
ents, e.g. through school based vaccination. Furthermore,
a stronger collaboration between health workers and
teachers seemed essential for successful HPV vaccination.
Fathers and teachers
A first and very clear request from all participants was
more sensitization, and any place or any channel would
do: at churches, market places, schools, through radio,
through community elders, etc. Everybody was welcome
to help and spread information about cervical cancer
vaccination but surprisingly, while churches were con-
sidered good venues, religious leaders themselves were
not always seen as the correct source given that they
have no medical background. Furthermore, fathers
expressed the wish to be more included in health programs
given that they considered themselves, often together with
their spouse, the main decision taker regarding vaccination.
Teacher (FGD 3): If people or ladies or girls or
communities, if all people in general are taught about
this cancer, let people know first about cancer and
what brings cancer…Once they have the
understanding of it, then they are going to take
caution in the right way. But so many people don’t
know about cancer. So let people learn about cancer,
teach people about cancer! In schools, villages or
where, wherever they can get the information….
Moderator (FGD 6): What about religious leaders, do
they talk about it?
Father: Whenever they try we tell them they are not
doctors.
Secondly, the participants recommended to vaccinate
at schools, as it would be more convenient for many
parents. Moreover, some distrust towards hospitals or
the health system in general was revealed which could
be diminished by bringing the vaccines to the schools.
Father (FGD 5): I heard about it [the vaccination
program] but I lacked transport to take my daughter
for the vaccination.
Teacher (FGD 3): Also going to the hospital will
encourage bribing so we want to avoid that by taking
it to school…because somebody tells you, bring
something small so that I attend to you faster.
Teacher: And you might not even get the right vaccine
even after giving out your bribes.
Teachers were - “now that we are informed” - very
keen to provide help and to promote the vaccines. They
suggested themselves that they indeed should be the
ones providing information given that they have day to
day contact with the children. When asked, they
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claimed to feel comfortable to discuss such a topic in
class, although some teachers showed some reluctance.
For example, some of them would remind the others
that in order to talk about it in class, it should be part
of the curriculum, while others mentioned that it would
be easier to discuss it with girls only. The latter state-
ment was often rejected and led to discussions among
participants regarding the importance to also inform
boys. In the end, teachers did acknowledge that they
wanted support by health workers to tackle difficult
questions.
Teacher (FGD 2): Teachers spent almost all their time
with the children and children really listen to the
teachers. Whatever teachers say, a child does not
doubt. They can go home and convince the parent ‘this
is what the teacher said’.
Teacher (FGD 4): I think what happens in a
class, I think it should go hand in hand with the
curriculum. I don’t see how this cervical cancer
information can come, not unless it is also included
in the curriculum.
Teacher (FGD 1): I have a different opinion. I think
both the sexes should be told because nowadays they
teach sciences about delivery, how the baby is formed
and all that. I think they should teach in the same
manner. So I think it is beneficial because they are
growing. One time they will be parents and they need
to have this knowledge.
Teacher (FGD 4): Or you can call a health worker to
come and tell the parents.
Moderator: So you think it should be the health
workers’ tasks?
Teacher: yes! Because I don’t have much experience.
They might shoot questions that I don’t know how to
answer, I may not be able to answer the questions.
Thirdly, support from local authorities and the govern-
ment was deemed essential, both in terms of assuring
the safety and effectiveness of the preventive method as
financially. Especially fathers were worried about the
cost and thought the vaccines should be subsidized.
Father (FGD 5): It shows I care about my daughters…
and as I care, the government should do the same. It
should be a national thing in schools and whatever.
The vaccine should be taken to schools, to the ground.
Father (FGD 6): I agree with my colleagues because
that amount is too high….the government should
intervene because these children are our future
leaders…He has talked of Kshs 2000 I would suggest
Kshs 100 [referring to how much the vaccine should
cost now that it was no longer available for free
through the vaccination program] . With the current
cost of living and if one has five children, it is a lot of
money…One can try to get the 100 but 2000 [Kshs] is
a lot of money.
Teacher (FGD 4): It is a good idea but I suggest, I
think the government should do a bit of educating the
masses because, if we teachers do not know what
cervical cancer is, then how about that mother in the
village, she will not accept; so education is very
important.
Finally, in all FGD people wanted to know when a next
vaccination program would be organized, or where they
could go to vaccinate their daughters given that now
they were better informed, they did not want to wait any
longer. Cervical cancer vaccination was now considered
a priority.
Program coordinator and vaccinators
Similar to the teachers and fathers, the nurses stressed the
need for information. More particularly, they stated that be-
fore the onset of the program they were unaware that cer-
vical cancer is caused by a sexually transmittable virus. A
short training before the start of the program, provided by
the program coordinator, had informed them about HPV.
Moderator (FGD 8): Before you were vaccinating the
girls, were you aware that it was a sexually
transmitted disease?
Nurse: Before that I didn’t know, until I was sensitized
about that.
In addition, the nurses also reported that they doubted
their communication skills with the girls as to inform
them about the vaccination, as well as how to address par-
ents’ questions, e.g., why boys were not eligible. How to
face these difficulties was not addressed in the training.
Nurse (FGD 8): With the guardians, we were
comfortable [discussing cervical cancer]. It is only that
we thought with the children, of course they also have
to know, but you could be wondering whether they
understand, because someone who is like 9 years may
not, in fact may not have started with reproductive or
other health subjects. I was wondering if they
understood, what we were talking about.
While the program coordinator was surprised to hear
that there were many teachers and parents unaware of
the HPV vaccination program that had taken place, he
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offered some possible explanations based on his experi-
ences. First of all, he had noticed that the attitude of the
head teacher was crucial: during the program he saw
that more pupils got vaccinated from schools with an
enthusiastic and supportive head teacher. The nurses
had perceived a similar effect. In addition, the coordinator
confirmed that the health care providers visiting schools
never spoke to the entire teacher corpse leaving it up to a
few to further inform and involve their colleagues.
Nurse (FGD 8): I think that it depended with how the
authority of the school took this message. Did they take
it with some weight, or did they just take it lightly….
So if they didn’t, then the girls would not appear. I
think it depended on the authority of the school and
how they received the message.
Secondly, in one school teachers foresaw distance and
thus transport time and cost as a major barrier for the
parents, which made them doubt the feasibility of the
program from the start. Lastly, during his contact mo-
ments with the schools he observed that two types of
promotion were implemented: while in some schools the
teachers informed the students who on their turn had to
inform their parents, other schools organized contact
moments with the parents to inform them directly. Like-
wise, some schools organized transport for the girls and
a teacher accompanied them to the hospital to receive
the vaccine. This was confirmed by the nurses.
Nurse (FGD 8): Mostly they were brought by teachers,
in groups.
Especially schools that were not included in the first
selection of 10 schools, tended to respond faster and
more organized. These were often, yet not exclusively,
private schools. The coordinator provided some possible
explanations as to why these schools handled more
swiftly: Private school teachers are considered more ac-
countable for the well-being of their pupils, making it
their responsibility to respond to vaccination efforts.
Furthermore, both parents and teachers often have a
higher socio-economic status compared with public
school settings, making it easier for them to pick up and
understand public health messages as well as to spend
time and money for preventive medicine. Regarding the
decision to open up the program to more schools, as op-
posed to, for example, revisiting the original selection,
the coordinator explained that they called the ten
schools to ask them to reinforce their promotional activ-
ities. However, teachers reported that parents were
aware of the vaccination opportunity and were maybe
simply refusing to vaccinate their daughters. As a result,
the team decided to include more schools.
Finally, both the program coordinator and the nurses
pointed out that the program knew a slow start but once
it took off, demand increased exponentially. Particularly
when the program opened up to more schools, the schools
themselves started to inform neighboring schools inducing
a type of snowball-effect.
Nurse (FGD 8): At first, the message was not received
kindly. Many people had questions, everyone had
questions about this vaccine. So in the first place, I
think it was considered like testing. Like someone
wanted to know, ‘are others taking their children?’, but
after that…most of them came and I think it was because
they saw that almost everybody else was doing it.
Nurse (FGD 8): Yeah, in the beginning of the program,
people were not willing, but towards the end, you see
most of them are now coming and ask for the vaccine.
Discussion
The results clearly show that promotional activities were
suboptimal: not all teachers were informed by health
care providers, only some schools invited the parents for
informative sessions (others relied entirely on students
passing the invitation), and there were hardly any contact
moments between health care providers and parents. Con-
sequently, several bottlenecks were induced, blocking the
flow of information from the health promoters, through
the teachers and students, to the parents .
As stated before, target groups need to receive two pieces
of information in order for them to undertake action to re-
ceive the HPV vaccine. First of all, they need to be aware of
cervical cancer and they need to understand the import-
ance of HPV vaccination. In order to achieve this, the infor-
mation provided should correspond with the needs of the
community. Secondly, potential participants need to know
how they can receive the vaccine: where and when are vac-
cination activities rolled out?
Many women who participated in the longitudinal
study, stated that none of this information had reached
them [15], which was confirmed by the fathers in this
study. However, the majority of the men also reported
that their wife had informed them neither, meaning that
many women had not shared the basic information they
had received during the baseline interview. In addition,
men are in general less informed given that they don’t
feel addressed by public health campaigns regarding cer-
vical cancer and that they find it particularly difficult to
discuss it with others. Nevertheless, in case of an HPV
vaccination opportunity they do want to discuss this
with their wife and they do feel responsible for the final
decision. Their lack of understanding might however re-
sult in vaccine refusal: opposition against the HPV vac-
cine by men was indeed reported as an important
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barrier by the women in the previous study [15]. Includ-
ing men in cervical cancer prevention strategies and en-
couraging couples to discuss this might be challenging
but seems crucial for success.
Following discussion will reflect first on the condition
of awareness and understanding in the context of this
demonstration project. Subsequently, the role of the
teachers in public health programs will be discussed,
more particularly to what extent teachers might take up
certain types of promotional messages regarding HPV
vaccination. Finally, the introduction of new vaccines
will be assessed, i.e., how some people might need more
time to gain confidence or to respond for them to adopt
the new behavior, regardless of the information they
received.
Appropriate promotional messages
Besides the fact that many participants had not heard of
the program, an equally important conclusion is that
those who had received information had not given it
thought and had not shared it with others. Fathers found
it inappropriate to talk about cervical cancer with others
while teachers stressed the need for more information
for them to feel confident. However, there might have
been other reasons. First of all, just like the fathers, some
teachers felt equally uncomfortable to share this type of
information with their colleagues or students. While
they all wish to have a better understanding of cervical
cancer, the topic causes them discomfort and anxiety.
Secondly, one might ask how participants, including
the teachers, process and interpret the received informa-
tion. How do they define viruses and transmission, what
do they consider cancerogenic and who is at risk? Dur-
ing the discussions, it became clear that some had a very
limited understanding of the human body and diseases.
So even if the correct information was passed on, the
question remains whether this newly gathered know-
ledge fitted into their vision of health and diseases and
what they perceive as important to remember. For ex-
ample, participants who knew about the cervical cancer
vaccination program, still did not mention HPV as the
main cause. Also in Vietnam and Italy, participants still
had limited knowledge about cervical cancer after the
implementation of an HPV vaccination program, even
though they themselves considered them well-informed
or had received the vaccine [20, 28].
Finally, and related with the previous argument, both
teachers and fathers might not have perceived a cervical
cancer prevention program as important: the strong
conviction that cancer in general is a disease that affects
rich people, or people with a “modern lifestyle”, pro-
vokes a certain indifference. Compared with a 2001
study from Gatune et al. (2005) in a rural area close to
Nairobi, participants now stressed much more the causal
relation with processed food or chemicals, rather than
only sexual behavior and the use of contraception [29].
Given that participants did not feel part of this modern
society exposed to those external, modern, risks, there
was a strong overall feeling that cancer strikes others.
Not observing cervical cancer among the general popu-
lation is probably a result of lack of diagnoses and not
discussing the sickness out of shame. The fact that par-
ticipants did not perceive themselves or their environ-
ment susceptible for cervical cancer is however
contradictive with previous findings where mothers re-
ported that it was very likely that their daughter would
have cervical cancer in the future [15]. The latter was of
course a more direct and quantitative question concern-
ing ones daughter which may have induced a socially de-
sirable expression of concern while the FGD were more
generally speaking.
Overall, we can conclude that translation of received
information into action remains very challenging. Be-
cause of lack of understanding or not feeling addressed
by promotional messages, people remain vulnerable for
cervical cancer since they won’t feel urged to undertake
actions to prevent it. Health messages should therefore go
beyond providing essential information and should also
address misunderstandings and rumors (e.g., cervical can-
cer is not heritable and is not linked with the use of cos-
metics), assure that the target group is properly reached (e.
g., cervical cancer occurs both in urban and rural areas),
and actively fight stigma (e.g., condom use can protect
against cervical cancer instead of having multiple partners
increases the risk of cervical cancer or cervical cancer is
not caused by bad hygiene). In order to identify the needs
and worries of the target population, formative research
should be carried out not only before the start of the pro-
gram, but monitoring activities should continuously
screen for new or evolving rumors [30]. Also, both men
and women should be approached and empowered to dis-
cuss such a sensitive topic among each other. Moreover,
support from the government and local authorities will in-
crease the credibility of the program [25].
Teachers as public health promoters
Besides receiving and sharing information, there were
clearly other factors that influenced the HPV vaccination
program. The program might have over-relied on
teachers without considering their motivation or avail-
ability. Early involvement and clear communication with
teachers regarding the design of the program was
skipped, whereby taking up promotion could be more
perceived as a favor towards the health staff instead of
an agreement or responsibility.
However, even teachers who were addressed by health
staff and had agreed on cooperation had not informed
all their colleagues nor had they set up large-scale
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promotional activities. This failure to perform, may be
caused by various factors. As in many low-income coun-
tries, Kenyan teachers might be poorly motivated due to
little job satisfaction, few material tools, low salary, etc.
[31]. Extra tasks might not be received well. Teachers
requesting to include HPV and cervical cancer in the
curriculum for them to discuss it in class, hints to the
need for approval of the ministry of education as well as
to delimiting work load. In addition, some teachers de-
scribed their pupils’ background and behavior in a rather
negative way, pointing out the worrying situation some
students find themselves in. While this might be a driver
for some teachers to help and protect the children, it
might also pull some of them down.
Finally, talking about sexual health has always been a
challenging task for teachers. Besides feeling uncomfort-
able to discuss such topics in class, some teachers might
not agree with the type of information that should be
shared or with what to promote (e.g., condom use vs.
abstinence) [32]. Indeed, teachers often discussed
whether or not boys should be informed as well, in
which type of class cervical cancer could be discussed (is
it the responsibility of the science teacher?), which age
groups should be included, etc. Others even saw it as an
opportunity to preach morality and discourage sexual
freedom (i.e., masturbation or early sexual onset), using
HPV and cervical cancer as a potential threat. Promoting
it as a cancer vaccine and not mentioning the STI-
aspect of cervical cancer was however never mentioned
as an option. Teachers expected questions from both
the students and the parents and therefore stressed the
necessity to be well informed. It is also in this light that
it becomes clear why teachers had only given their stu-
dents the message to go to the hospital for vaccination
as opposed to explaining them about HPV and cervical
cancer: they opted to share logistical information rather
than discussing prevention of a sexually transmittable
disease.
So while school based vaccination was perceived as a
good approach by all of the participants and while vari-
ous studies have showed good results of such programs
[33, 34], teachers should not stand alone when it comes
to promotion. Health systems will have to support the
schools, clearly describing and differentiating the re-
sponsibilities and messages that both parties will take
up. As showed in a study by Brabin et al., close collabor-
ation and good relationships between the schools and
the health system are important predictors of vaccine
uptake [35]. In addition, the schools might serve as a
bridge between the health care providers and parents,
whose contact is also crucial to achieve good coverage
[34, 36]. Finally, the HPV vaccine might be seen as an
opportunity to roll-out school health programs, includ-
ing e.g., sexuality education, addressing the large but
underserved group that are adolescents in low-income
countries [37–39].
Introducing new vaccines
New vaccines always provoke some hesitance and
doubts, which diminish after a while but might linger for
a very long time. These worries emerge from the fact
that people have not yet seen the effects of the vaccine –
or rather have not yet confirmed the absence of side-
effects - but these concerns are also fed by persistent
memories of bad experiences or rumors about other
vaccines. Kennedy et al. showed that the combined
MMR vaccine still causes worries in Scotland, after a
controversy of more than 10 years ago, and even influ-
enced decisions regarding new vaccines [40]. Likewise,
participants in this study recalled stories of the polio
vaccine and even an asthma vaccine, indicating previous
failures of vaccine efforts and health communication.
However, as reported by the vaccinators and the coord-
inator, the HPV vaccination program did eventually be-
come successful, after a first period of habituation and
trust gaining. Just like other new techniques, adoption of
a vaccine might follow a Gaussian bell-curve of a normal
distribution, representing diffusion throughout the com-
munity with early adopters setting the example while
others lag behind (Diffusion of innovations, Everett
Rogers). Indeed, people have reported a ‘wait and see’ ap-
proach when it comes to uptake of the HPV vaccine as to
evade unknown side-effects [9, 41]. However, it will be im-
portant 1) to minimize the time span between adoption by
innovators and laggards, and 2) to ensure that usage is not
delayed among already underserved subpopulations, out-
of-school youth or groups who refuse the vaccines for reli-
gious purpose. The high response noted during the second
wave of this demonstration program may thus follow from
late adopters coming round but might also reflect a differ-
ence between the ten selected schools and the newly in-
cluded. Private vs. public schools was one of the aspects
noted by the coordinator, indicating a potential threat for
reaching health equity. Studies have indeed showed that
ongoing HPV vaccination programs do not always elimin-
ate cervical cancer disparity: girls from more deprived ori-
gins tend to have less chance to be fully vaccinated and
non-school approaches may even induce more inequality
[42–46]. Similar, parents with lower socio-economic back-
ground often have less cervical cancer knowledge and
HPV vaccine awareness, which remains a first condition
for uptake, while also financial restrictions impede vaccin-
ation [47–49].
In order to enhance acceptance and to speed up vac-
cine uptake, we need not only to spread information but
we need to enter into dialogue with community mem-
bers, addressing context specific concerns. What used to
be predominantly a top-down approach, should become
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a continuous and open dialogue between all stakeholders
[30]. In addition, surveillance programs should be put in
place to assure that the HPV vaccines actually reach every-
body – timely - and that they fulfill their potential to re-
duce the health inequality gap regarding cervical cancer.
Limitations
The study has some limitations. First of all, selection of
the vaccinators was not random, given that the nurses
were invited by the head nurse. Although this might
have induced selection bias, having duty around the time
of the FGD was the major criteria for them to partici-
pate. In the end, five nurses participated in the FGD
representing almost 50 % of the entire vaccinators team
(i.e., twelve nurses).
Secondly, not all teachers who participated in the FGD
gave classes to girls in class 4 to 8, i.e., the target group
of the vaccination program. This means that these
teachers were not asked to promote the vaccine among
their students. Still, proper school based promotion
would imply inclusion of the whole teacher corpse
(maybe not in terms of active responsibilities but at least
everybody should be informed). Moreover, their partici-
pation in the study revealed clearly that the vaccination
opportunity was not discussed widely.
Thirdly, FGD with fathers were not transcribed verba-
tim in Swahili but were simultaneously translated into
English. This may have led to the loss of some nuances
or cultural specific concepts. In order to limit this type
of error, researchers experienced in qualitative research
in public health were given the task, while other local
team members were always available to assist.
Finally, our study was conducted 14 months after the
onset of the program which might have induced a recall
bias. Participants had sometimes troubles remembering
clearly what they had heard about the vaccination effort
and from whom, or which promotional activities were or-
ganized. Especially the lack of insight in how promotion
was implemented in each school limits the understanding
on which channels were more successful than others.
However, this also is a reflection of a lack of structural
organization of, and exposure to sensitization.
Conclusions
Although an HPV vaccination program had been imple-
mented, people still had poor knowledge regarding cer-
vical cancer. In general, cervical cancer prevention was
not truly prioritized given that the disease is stigmatized
through associations with non-accepted sexual activities
and highly linked with usage of modern products such
as cosmetics, contraception or processed food. Therefore
many participants did not feel addressed by the promo-
tion effort and had found it uncomfortable discussing
the topic. Teachers pointed out that support from health
staff would be essential in order for them to feel
confident to promote the vaccine among students and
parents. A closer collaboration with health care pro-
viders and schools would help to address questions of
parents as well as teachers’ own doubts. Finally, distrust
towards (new) vaccines had also hampered uptake:
small-scale vaccination projects are often confused with
trials, but also bad experiences during previous vaccin-
ation programs had reduced faith. Suspicion did however
fade away after a couple of months, once the community
was convinced about the safety of the vaccine. Also the in-
clusion of schools with higher capacities to respond to the
vaccination invitation had boosted uptake.
Health care promoters of future programs will need to
enter in dialogue with the community, as opposed to just
provide information, to increase awareness and actively
tackle misbeliefs and rumors. In addition, rolling-out HPV
vaccination programs should go hand in hand with careful
monitoring to assure that cervical cancer disparities are not
further induced by differences in HPV vaccine coverage.
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Part VII
DISCUSSION
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Chapter 9
Acceptability and uptake:
how to bridge the gap?
Conclusion 1: HPV vaccine acceptability is rather
a reflection of a desire to prevent cancer than a
predictor of uptake.
The longitudinal study found a positive relation between HPV
vaccine acceptability and uptake, yet only significant in bivariate
logistic regression. Also in the mediation analysis, willingness to
vaccinate was not a predictor of vaccination. As hypothesized, none
of the non-acceptors reported to have a vaccinated daughter while
half of the acceptors had not lived up to their own expectations. Lack
of information (regarding both the vaccine and the programme) and
being afraid of side-effects were reported as main barriers during
baseline and follow-up, as well as having a partner who opposed.
Other prospective studies regarding HPV vaccination found sim-
ilar results, i.e. relative high willingness to vaccinate compared to
the final uptake, and a positive association between the two out-
comes [210], [211], [215], [217][219], [249]. Among these studies,
some were also unable to detect a significant association when con-
trolling for other variables [217], [218] and one other study did not
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find any relation at all [216]. These mixed results reflect that while
HPV vaccination is considered the right thing to do by many people,
intentions diverge from actual actions and several factors might influ-
ence the final behaviour. Also previous reviews studying the correl-
ation between intention and other health-related behaviours demon-
strated that there is a reliable, but no perfect association between
reported intention and behaviour [250][253].
9.1 What causes the intention-behaviour
gap?
According to Sheeran (2011), there are several properties of inten-
tion that strongly determine the relation with behaviour [254]:
• Degree of intention formation: The extent to which parti-
cipants have thought through the action and the related con-
sequences.
• Temporal stability of intention: Intentions may change
over time and can therefore lose their predictive value for be-
haviour.
• Attitudinally versus normatively controlled intentions:
Whether the expressed intention is the result of one's own
attitudes or rather determined by subjective norms.
These and other factors that might have influenced the correlation
between HPV vaccine acceptability and uptake are further discussed
below.
9.1.1 Overestimation of acceptability
Socially desirable answers versus heuristic decision-making
At baseline, women reported a high willingness to vaccinate which
is similar to the findings of many other HPV vaccine acceptability
studies [158], [183]. Given however the short time between receiv-
ing cervical cancer information during the baseline interviews and
expressing acceptability towards the vaccine, the degree of intention
formation, can be brought into question. As specified by Sheeran
(2003), not taking the time to think things through might result
in poor estimation of one's own intention and thus hampers the
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intention-behaviour association. Also, as mentioned before, gauging
willingness to vaccinate in a hypothetical situation where the vaccine
is not yet available, or with limited understanding about the disease
can lead to socially desirable answers [213]. Considering that vac-
cine decisions can be seen as risk decisions - evaluating the risk of
harm due to the vaccine against the potential risk of the disease - it
is indeed remarkable that a new vaccine is so well accepted without
any previous experience with it: given that such decisions involve
more information than can easily be processed (or for which basic
knowledge is lacking), we would expect that people tend to rely on
heuristics or 'cognitive short-cuts' which result more easily in a neg-
ative opinion towards the vaccine as opposed to the measured posit-
ive one. An example of a heuristic that is applicable in the context
of HPV vaccination is omission bias, i.e. preferring not to vaccinate
given that one would feel more responsible for sickness as a result
of vaccination than for illness of a vaccine-preventable disease. Also
protected values (zero tolerance towards risk) and ambiguity aver-
sion (opting for the familiar risk instead of new or ambiguous risk)
are heuristics which people may use during the decision-making pro-
cess regarding the uptake of the HPV vaccine [255][257]. So while
people might have reported high acceptability, given that this is the
socially desirable answer, their true opinion might have been the
opposite, having relied on the above-mentioned heuristics.
Intention versus desire Another reason for the discrepancy be-
tween acceptability or willingness to vaccinate and uptake, might be
that women have expressed their desire instead of an estimation of
their intentions. In the analyses presented here, acceptability was
defined as 'would you vaccinate your daughter against cervical can-
cer', and willingness to vaccinate - used in the mediation analysis
- was a combination of acceptability and intention, i.e. 'will you
vaccinate your daughter in the upcoming programme'. It is pos-
sible that these variables have not measured direct precursors of
behaviour but actually the antecedents of intention: according to
Perugini and Bagozzi (2004), "desire is a state of mind whereby an
agent has a personal motivation to perform an action or to achieve a
goal, which is typically followed by an intention to do so. Therefore,
desire should be distinguished from concepts such as intentions, atti-
tudes and goals." [258] The concept of desire is however not present
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in the leading theories of health behaviour and also in the literature
regarding HPV vaccination there is no differentiation between desire
and acceptability or intention. However, it seems quite likely that in
some studies stated acceptability comes closer to desire as opposed
to intention, or that participants report a wish to vaccinate rather
than their true intention. When this is the case, a correlation with
vaccine uptake is rather unlikely given that reported desire might
be independent of the intention to actually perform the behaviour
[258].
Peruguni and Bagozzi (2004) propose three criteria to distinguish
between intention and desire: perceived performability, temporal fram-
ing and action-connectedness [258]. The first criteria refers to the
fact that desires can stand alone, i.e. they don't need to be feasible,
while intention contains inherently an evaluation in terms of per-
formability. This can be interpreted as either a form of self-efficacy
and confidence in carrying out the action or it can be linked to the
belief that the behaviour will lead to the underlying goal. With
regard to HPV vaccination, this means that one has to be capable
to go for vaccination and one has to belief in the protection offered
by the vaccine. The fact that self-reported efficacy was high in this
study and correlated with both willingness and vaccine uptake, in-
dicates that participants have truly expressed an intention and not
a desire. On the other hand, the poor uptake and the many par-
ticipants who reported fear of side-effects as major barrier, indeed
suggest that women reported a wish to protect their daughter from
cervical cancer without relying on the vaccine to actually provide
this protection.
Also the second indicator, temporal framing, can partially explain
the failure of finding a strong significant correlation between HPV
vaccine acceptability and uptake: temporal framing implies that
while desires are often time indefinite, intentions are to be translated
into action in the short run. The wait-and-see attitude, reported
in the qualitative component of this study, might therefore also be
considered a reflection of poor intention in the community - instead
of just distrust towards the HPV vaccine - and might be a more
correct assessment than the quantitatively reported intention by the
mothers in the longitudinal study.
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Finally, the last criterion, action-connectedness, supports the idea
that participants have expressed a desire given that it simply states
that intention has a stronger connection with behaviour than desire.
This is based on the idea that intention implies a certain readiness
and commitment, whereas desire does not.
9.1.2 Underestimation of external factors
Changing opinion towards HPV vaccination While people
might indeed have reported an overestimation of their acceptability,
felt unable to answer truthfully on the spot, or expressed a desire
rather than an intention, it is also possible that they changed opinion
afterwards: the results show indeed that some acceptors became
refusers in follow-up. Temporal stability is another characteristics of
intention that affects the link with behaviour according to Sheeran
(2003-2011) [252], [254] and there are various reasons to assume
that this might be applicable in the context of HPV vaccine decision
taking. In the aftermath of the baseline interview, participants'
feelings towards the vaccine or the programme can change due to
many external factors. In the same light, while a lot of participants
still wanted to vaccinate their daughter at follow-up they had been
unable to do so: various factors had blocked the translation of their
acceptability into behaviour.
Volitional control: blocked by others Looking at the determ-
inants reported by the women, both for acceptability and uptake,
it becomes clear that they are more related to actions or attitudes
of others than to the participants' own characteristics and feelings
towards the HPV vaccine. The main barrier, lack of information
is primarily the responsibility of the organizers of the programme
rather than of the target group and even fear of side effects can be
partly seen as a result of poor promotion. Similarly, the objection of
the father to vaccinate his daughter indicates that the participants
of the cohort study were not in control of the action to vaccinate,
meaning that in these cases not their wish but the partner's wish to
(not) vaccinate is translated into the corresponding behaviour. As
such, one can wonder to what extent HPV vaccination is the result
of each of the most important players, i.e. the parents of the girls
163
and the organizers of the vaccination programme. It is known indeed
that perceived behavioural control (PBC), a main construct of the
TPB, has an important impact on the relation intention-behaviour:
intention tends to be a weaker predictor for actions lacking volitional
control [251]. This also resembles the fact that intentions can either
be attitudinally or normatively controlled, as stipulated by Sheeran
(2011), with the latter having a negative effect on the predictive
value of intention.
Volitional control: a variety of barriers Finally, behaviour is
often blocked by community norms, hit up against inadequate or low
quality health services, or obstructed by a range of barriers such as
access to promotion, time restrictions and cost. As a result, these
factors might be stronger determinants compared with acceptability
reported among the target population.
9.1.3 Overestimation of uptake in other demon-
stration projects
Scale of promotion: creating demand Another remarkable
result in this study is the low uptake (31 percent received at least
one dose) compared with other demonstration projects (over 70 per-
cent received all three doses) [122]. Given these high coverage rates
in other settings, and the high acceptability measured in these places
where formative research has been conducted, no such discrepancy
between HPV vaccine acceptability and uptake was detected [121],
[146]. Of course, the large-scale promotional activities - going from
media attention to door-to-door sensitization - will have boosted
uptake in these programmes as opposed to the limited sensitiza-
tion activities of the Eldoret pilot programme [134]. While the
latter might have hampered the credibility of the programme, the
wide-reaching promotion of other demonstration programmes might
have led to over-demand (which can raise ethical questions). Also,
whether such wide-reaching sensitization strategies will remain pos-
sible when scaling up to national roll-out, and thus whether uptake
will continue to reflect high acceptability in these settings is yet to
be seen.
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Scale of promotion: estimating the denominator In addi-
tion, the scale of the promotion programmes implemented during
these demonstration projects is not only questionable in terms of
feasibility in future programmes, it might also have influenced cov-
erage determination. As shown by Ladner et al. (2014), some of
these pilots report over 100 percent uptake, indicating that the de-
nominator was poorly determined. This is indeed mentioned as a
limitation in the review: each programme calculated the denomin-
ator based on different sources (census or population data or school
enrolment lists, among others) of which the quality is unknown [122].
However, besides poor demographic data, certain outreach activities,
such as radio spots, also make it difficult to estimate the coverage
area and thus the denominator, which clearly leads to unreliable
coverage rates.
Defining the denominator A final explanation for the difference
in uptake lies again in the definition of the denominator and can be
clearly illustrated with the example of the demonstration project in
Kenya, as presented in the review of Ladner et al. (2014). They
define the denominator as "the number of girls targeted determined
prior to implementation based on data from available sources" (cfr.
the demographic data mentioned above). However, the denominator
they report and use in the review, i.e. 3000 girls, was the goal
established by the programme organizers in Eldoret, rather than the
girls they planned to reach through promotion - initially the 4000
eligible girls in the ten schools - or approached in the end (girls from
other schools and reached through the radio spot). It is possible
that staff of other demonstration projects has also interpreted and
reported 'targeted' differently. So besides the challenge of precisely
defining the catchment area and the eligible population in it (due
to poor demographic data), misinterpretation of 'targeted group'
might also have led to an underestimation of the denominator. The
resulting high coverage, on its turn, then creates the false impression
of a strong, positive relation between acceptability and uptake.
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9.2 When is measuring acceptability as
precursor for uptake acceptable?
It is clear that, in order to detect a correlation between a precursor
of behaviour and the actual behaviour, certain conditions need to be
fulfilled. Whether or not acceptability, for example, leads to HPV
vaccine uptake is a complex issue which may vary across time, place,
type of participants, etc. As such, it is possible that in certain con-
texts not acceptability but other (organizational) variables are more
defining for the behaviour. Before implementing formative research,
researchers should thus more carefully reflect on which and how vari-
ables need to be measured, when and among who. Below we outline
some of the steps that can help justifying measuring precursors and
their association with an action, as well as other important determ-
inants of behaviour.
Defining precursors A first condition to further understand the
predictive value of HPV vaccine acceptability is good determina-
tion and the use of validated measures: currently, concepts such as
acceptability, intention and willingness to vaccinate are not stand-
ardized resulting in non-accurate labels and thus confusing results
[143]. Also the difference between desire and other precursors needs
to be highlighted. In a next step, the relationship between these
precursors and vaccine uptake, i.e. the only true outcome variable
of interest, can be defined as well as how they relate to each other.
As such, mediation effects and thus the pathway of decision-making
will be better understood.
Repeated measurements However, even with well defined and
validated measures, other methodological challenges still remain when
determining a valid proxy of behaviour, e.g. social desirability, tem-
poral stability of constructs or limited knowledge leading to poorly-
informed decisions and heuristics. Repeated measurements of pre-
cursors and self-reported behaviours, after providing basic inform-
ation, might help in identifying and diminishing the effect of these
biases.
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Identify moderators at personal level Given that the correl-
ation determined in this study was mainly driven by non-acceptors
who did not vaccinate their daughter, future studies should further
focus on distinguishing acceptors who vaccinate from those who do
not as to identify moderating factors of the association with uptake.
Who fulfils his own prediction and who does not? It is possible
that personal characteristics define whether or not somebody is more
likely to translate desires and intention into behaviour. In this study,
baseline cervical cancer awareness was however a direct predictor of
vaccine uptake rather than a mediating or moderating factor of will-
ingness and vaccination. Other socio-demographics were not related
to uptake but should be further investigated. Educational level or
socio-economic status can clearly influence a participant's capacit-
ies to resist socially desirable answers, to process new information
rapidly or to foresee logistics barriers. Hence, in some subgroups
the relation acceptability-uptake might be stronger than in others.
More heterogeneous sampling, including a more diverse population,
can help identifying such factors. In addition, volitional control over
the action should be considered as this strongly defines the possibil-
ity to translate intentions into behaviour: only the one who is truly
in control of the behaviour can make valuable prediction [251].
Identify moderators at community or organizational level
Also the impact of external factors on the relation precursor-behaviour
should be taken into account. Different delivery platforms, such as
school-based or hospital-based vaccination obviously induce several
types of barriers and include different stakeholders who can affect
the vaccine's credibility and uptake. In addition, the roll-out should
be monitored since design and final implementation might differ or
change over time due to unforeseen circumstances. These deviations
from the original planning can affect vaccination and thus the link
between predicted and actual uptake.
Intention versus behaviour among health care providers
Finally, besides investigating the correlation between e.g. inten-
tion and vaccination behaviour among the target group, also the
health care providers' intention to promote and offer the HPV vac-
cine should be investigated. In the case of the pilot programme in
Eldoret, teachers' promises to support the project turned out to be
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unreliable or their final effort was minimum. Moreover, during the
FGD they expressed again a high willingness to cooperate in future
cervical cancer prevention programmes yet also they might bump
(again) into various barriers while trying to fulfil their promises.
A review by Eccles et al. (2006) found indeed that the variance
in behaviour explained by intention among health providers was of
the same magnitude as among non-health professionals. Given that
clinical behaviour is a form of human behaviour, the same theor-
ies and thus the same mediating and moderating variables might
cause the intention-behaviour gap regarding promotional activities
of providers [259].
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Chapter 10
Health behaviour theories
Conclusion 2: Health behaviour theories at per-
sonal level have poor predictive value in the con-
text of HPV vaccination - programmatic charac-
teristics influence uptake more.
The HBM was for the first time tested in an African context
through structural equation modelling. The relation of the con-
structs with HPV vaccine uptake was examined, as well as with
willingness to vaccinate. Overall, the HBM had low predictive value:
only self-efficacy was associated with uptake while willingness to
vaccinate was predicted by self-efficacy, susceptibility and father's
refusal. Also other longitudinal studies, in HIC, have found limited
support for the HBM in the context of HPV vaccination [210], [215]
[219], [249].
The added variable of adequate promotion, i.e. the perception
of having received sufficient information, was a strong predictor of
HPV vaccine uptake and increased the predictive value of the model.
Also socio-demographic variables such as cervical cancer awareness
at baseline influenced vaccination behaviour directly.
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These results hint to two main reasons as to why the HBM did
not proof to be very predictive: 1) the constructs are either not
taken into account when the decision regarding HPV vaccination
is taken, and 2) other factors weigh more in the decision taking
process. In any way, the usefulness of the HBM in the context of
HPV vaccination seems doubtful.
10.1 An evaluation of the constructs of
the Health Belief Model
10.1.1 Perceived severity
When is cancer not severe? The HBM assumes that the more
serious a disease is perceived, the more likely preventive methods
are performed. A review by Janz and Becker (1984) showed however
that for preventive behaviours, the association was limited [207]. A
meta-analysis by Brewer et al. (2005) also found a limited effect for
severity, which was even diminished in case of skewed risk response
distribution [260]. Given that cancer is a serious health threat all
over the world, skewed results are very likely which jeopardizes the
relevance of the construct. On the other hand, being unfamiliar with
cervical cancer might make it difficult to estimate the impact of the
disease. Similarly, the seriousness of an HPV infection, which could
also be used to measure severity, might be too abstract. In conclu-
sion, it is unlikely that perceived severity can distinguish compliers
from non-compliers in the context of HPV vaccination.
10.1.2 Perceived susceptibility
Cervical cancer: in general a far-flung event but what if we
discuss a daughter's risk? Generally, susceptibility is defined as
the likelihood that one becomes ill. In this study, women perceived
their daughters at high risk for contracting cervical cancer in the
future, which positively influenced willingness to vaccinate but not
vaccine uptake. However, besides the likelihood of harm, i.e. the
chance to become infected, susceptibility can also be defined as an
individual's constitutional vulnerability to an illness. The first ver-
sion is represented by questions like 'How likely is it that you will
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get cervical cancer?', the second by questions like 'Are you more
likely than other people to get cervical cancer?'. [260]. So while the
general likelihood, i.e. the probability of getting infected, might be
small, your own constitution might increase the chances of becoming
ill. The other way around is of course also possible: while object-
ively the likelihood of developing cervical cancer is large, your own
chances can be lower if you do not engage in risk behaviour. As such,
women might have answered, socially desirable, that given the high
incidence of cervical cancer - which was communicated to them dur-
ing the baseline interview - their daughters too were exposed to high
risks, while in fact, they more subjectively believed that this would
not happen to their daughter. This was also more reflected in the
qualitative component of the study when participants described the
disease as something that happens to other, rich people or individu-
als with a more modern lifestyle. Finally, also other studies showed
that people rate their daughter's risk higher than their own which
means that susceptibility might relate differently with behaviour de-
pending on who's risk is estimated [183]. As such, this construct can
be interpreted differently and thorough validation seems necessary
as to define its impact on preventive behaviour designated to protect
different persons.
10.1.3 Perceived benefits
Estimating the unknown The main benefit investigated in re-
lation to HPV vaccination is of course prevention of cervical cancer,
i.e. the efficacy of the vaccine. In this study context, given the
novelty of the vaccine, participants had no previous experience with
the vaccine and thus had to hypothesize whether or not the HPV
vaccination would work. Although prospective studies investigat-
ing new behaviours are least likely to be influenced by past HPV
vaccination, which helps identifying causal relations [214], they do
induce a certain 'guesswork'. Obviously, people will rely on similar
experiences to judge, for example childhood vaccines, but in the end
it will also be a matter of 'blind trust'. This was also illustrated
in a longitudinal study from Brewer et al. (2011) in which both
HPV vaccine effectiveness and uncertainty about the vaccine were
questioned. While effectiveness was not correlated with uptake, un-
certainty was [215]. Given that trust was also a major factor brought
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up during the FGD, both towards the vaccine and the health sys-
tem in general, it might be interesting to measure specifically trust
related variables when identifying predictors of new behaviours.
10.1.4 Perceived barriers
Estimating the unknown With regard to barriers, several types
are often investigated, such as cost or time, lack of information,
fear of side effects, doubting efficacy and opposition of important
people [143], [158]. Of course, the diversity makes it more difficult
to compare results but generally, barriers are among the strongest
predictors of the HBM [207], [208]. The absence of significant associ-
ations in this study is therefore rather surprising. However, similarly
to benefits, participants needed to anticipate problems regarding an
unknown preventive action.
Volitional control Just like described above regarding the 'un-
derestimation of external factors' when discussing the intention-
behaviour gap, control can be an issue: individuals have to predict
barriers (cfr. express their intention) while they are not in control of
for example organizational aspects, which may induce time or cost
constraints, promotional activities, which may lead to information
shortage or the will of others, who may stop them from doing what
they think is best. As such, their predictions are unrelated to their
subsequent behaviour. Two main constructs of the TPB could be
very valuable here, i.e. subjective norms and perceived behavioural
control (PBC), and raise the predictive value of the HBM [251]. Also
including some personal characteristics, for example socio-economic
status as moderator for perceived financial constraints or community
embeddedness to counteract promotional failure, might improve the
predictive value of the model. However, adding factors beyond the
personal level, for example characteristics of the vaccination pro-
gramme will have an even greater impact.
Different types of barriers distinguish different types of in-
tention Besides vaccine uptake, the association between the bar-
riers and willingness to vaccinate was also investigated: except for
father's refusal, none of the measured barriers was related. Accord-
ing to Gerend's multidimensional nature of barriers (2013), global
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barriers, inherent to the vaccine (for example fear of encouraging
sexual risk behaviour), are negatively linked with intention, and
practical barriers, such as financial constraints, positively. This is
based on the assumption that people who are interested in the vac-
cine will already look for possibilities to achieve their goal and as
such identify practical barriers while those who have no interest at
all will mainly mention their concerns regarding the practice that
is discussed [261]. Given that fathers' refusal lowered willingness to
vaccinate classifies the variable as a global barrier, inherent to the
vaccine. This indicates that some women expressed their interest in
the vaccine in function of their partner's wish (normatively inten-
tion) and not their own attitudinal intention [254].
10.1.5 Perceived self-efficacy
Being able as precursor for intention Perceived self-efficacy,
the ability to perform a behaviour, was found to be positively related
to both willingness and actual vaccination behaviour. This is similar
to what was found in a meta-analysis of the TPB, which included
self-efficacy along with perceived behavioural control ([251]). While
self-efficacy resembles behavioural control, it distinguishes itself in
that it covers the ability to perform a certain action from a cognitive
perspective, based on internal factors, whereas perceived behavioural
control rather evaluates external factors. Therefore, self-efficacy is
often a strong predictor of intention (and subsequently behaviour)
given that positive intentions are especially formed for behaviours
one believes he/she can enact on. However, if unexpected, external
events change this ability, self-efficacy will loose its predictive power.
10.1.6 Cues to action
Causality issues Generally, cues to action (CTA) can be ex-
trinsic, for example receiving an invitation, or intrinsic, for example
the anxiety to become ill. CTA is however one of the less developed
constructs of the HBM and is therefore left out of meta-analyses
[207], [208]. A first problem to investigate the causal relationship
between CTA and behaviour is the fact that, especially for extrinsic
CTA, people cannot predict what cues they will receive, they can
merely say what or from whom they would like to get advice, which
173
does not imply this will actually happen. This is however how most
studies assess CTA (with a physician's recommendation as main
trigger) [95], [100], [101], [145]. On the other hand, if measured
retrospectively, it becomes more difficult to argue that one invest-
igates a causal pathway, yet it might be the closest thing to do so.
A second problem is related to the value each of us gives to differ-
ent CTA: while one person might find a poster very convincing, the
other can think the opposite. In this case, a dichotomous variable
of having received the cue, i.e. having seen the poster, will not be
able to predict correctly the uptake of a certain action.
Evaluating cues versus predicting them In this study, it was
opted to ask not only whether the participants had received inform-
ation but also if they found it sufficient. By doing so, the second
problem was avoided but of course, the estimated correlation cannot
be considered purely causal. However, the strong association with
HPV vaccination and feeling well-informed should stimulate future
research to not only ask users and non-users which cues were received
but also how they were perceived. This might give more insight in
how to trigger people, rather than asking this prospectively and
thus hypothetically ('what would encourage you to?'), even though
it would complicate measuring its predictive value in the HBM.
10.2 When to use the Health Belief Model?
As outlined above, each of the constructs of the HBM has its own
strengths and limitations, or is more or less applicable in different
situations. Consequently, the predictive value of the HBM depends
on many factors and might vary greatly. When foreseeing to ap-
ply the model as a framework to identify predictors of behaviour,
following considerations, based on own reflections, should be taken
into account:
• Interaction between threat and control - Risk perception
is an important driver to look for medical care. The predictive
value of perceived threat differs however greatly according to
who is in control of the behaviour, who is the decision taker
and who will benefit from it.
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• Hypothetical estimations versus users' perspective -
What is the value of trying to predict new, unfamiliar beha-
viour versus assessing and understanding real life experiences
of users and non-users?
• The outcome variable of interest - Do we want to identify
determinants of precursors such as desire or intention, or of
actual behaviour? And what is the impact of time on the
predictive value of these precursors.
Threat-control interaction Cognitive models, such as the HBM,
share the vision that the desire to prevent a medical condition origin-
ates from the perception of a threat that needs to be avoided (while
at the same time balancing the advantages and disadvantages of
that preventive action). Risk perception is however more import-
ant when the preventive behaviour is truly an individual choice (for
example the use of sun screen) instead of vaccination or screening,
which depend heavily on providers [260]. The predictive value of
the model depends thus heavily on the type of behaviour and the
volitional control associated with it. Given that controllability may
vary along diverse settings - for example through different levels of
access to information or to high quality care - the model's strength
may differ greatly across the world. Estimating the impact of struc-
tural factors might help in the decision whether or not the HBM is
a suitable model to rely on.
A second problem with threat as one of the main drivers of pre-
ventive behaviour is, as described above, the ability to correctly as-
sess severity and susceptibility. As such, the type of disease (e.g.
cancer versus the flu) and the person who needs protection will
highly influence the applicability of the HBM. For instance, in the
case of child vaccination, the beneficiary is not the one in charge of
the decision while the decision makers, the parents, might overes-
timate the risk as a consequence of overprotection. These factors
should thus be taken into account when the HBM is taken into con-
sideration.
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Users' perspectives Besides the level of control and the ability
to estimate threat, also the type of behaviour in terms of 'novelty'
will define the functionality of the constructs of the HBM. Ideally,
predictors of behaviour are defined without the influence of past
actions [214]. However, this induces a catch-22: without having per-
formed the action one can only guess, while through carrying out
the behaviour, perspectives are formed based on that experience. In
this case, the question is whether identifying causality is of major
interest as opposed to distinguishing users' perspectives. Ravindran
et al. (1997) advocated already in 1997 for investigating users' per-
spectives of contraceptives rather than hypothetical acceptability,
arguing that such information would not only help improving health
services but also assist potential users in assessing the appropriate-
ness of the method [213]. Constructs such as benefits, barriers and
cues to action might thus serve better in the context of evaluating
past behaviour than supposed to predicting new actions. For ex-
ample, in the longitudinal study, women who had vaccinated their
daughter did bring up fear of side effects as a difficulty they had
to overcome. Since HPV vaccination requires more than one dose,
reinforcing the safety of the vaccine might be equally important to
ensure completion of the scheme than to stimulate uptake of the first
dose among 'new users'.
Defining and timing of precursors and outcome variable
Furthermore, the HBM is supposed to predict behaviour but, as
stated by Armitage (2001) in the context of the TPB, constructs
are often closer related to desire than with intention or actual be-
haviour [251]. As such, the outcome variable of the HBM could be
evaluated and if deemed appropriate replaced by desire. If of course
the objective is to truly identify the predictive value of precursors,
time should be taken into account: given that time has a moderating
effect on the association between precursors of behaviour, such as
desire and intention [208], the constructs and behaviour should be
measured in a relatively short timespan and, if included, the pre-
cursor should be assessed with a time limit ('I intend to vaccinate
within one month'), to improve the predictive value of the model.
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Exploration of the HBM Finally, while carefully evaluating
whether or not the HBM is the optimum model in each context,
the model itself can of course also be improved in order to increase
its usefulness for predicting a diverse set of health behaviours in a
diverse set of contexts. Adding variables, such as trust or personal
and structural determinants might be one possibility, but might also
complicate measurement and analysis. Therefore, focussing on the
original constructs itself is also a useful step. Although the HBM is a
widely used theory, there are still surprisingly many knowledge gaps:
the relationship between the variables has never been spelled out and
the definitions of the constructs are ambiguous [143], [213]. Barriers
and benefits can cover somehow everything and cues-to-action has
never been properly defined, as such there is a need to specify each
construct if we want to compare research results. Additionally, the
simple four-variable additive model should be re-evaluated and pos-
sible mediation and moderator effects among the constructs should
be tested.
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Chapter 11
Introduction of cervical
cancer vaccination: the
importance of tailored
promotion and strategic
service delivery
Conclusion 3: Wide-spread tailored promotion can
diminish the importance of delivery strategies that
guarantee easy access, and vice-versa. Vaccine
uptake is the result of personal conviction and
effort combined with health system investments
and outreach. Focussing on one can take away
the need of the other, yet a balance between both
is more desirable.
The need for more information was continuously expressed by all
participants during all phases of this study. Information on cervical
cancer and the vaccine, as well as information regarding the vac-
cination programme was requested. Also indirectly it became clear
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that people were ill-informed: participants were still unaware about
the link between HPV and cervical cancer and missed the sense of
urgency to undertake action against HPV infections. The import-
ance of awareness and knowledge became however clear in the strong
correlations found of vaccine uptake with both baseline cervical can-
cer awareness and a self-reported feeling of being well-informed at
follow-up. Participants thus required some basic information and a
sense of conviction of the need for prevention, yet detailed knowledge
did not seem crucial for vaccine uptake. Also other post-vaccination
studies, in Vietnam and Italy, reported that participants who had
vaccinated against HPV could still have suboptimal knowledge, even
though they considered themselves well-informed [133], [262]. A cer-
tain level of knowledge is thus required yet it remains unclear what
type of messages are necessary and in which contexts to guarantee
successful HPV vaccination. The information people request might
also be related to the level of trust in and accessibility of the health
system, with high levels of trust and access minimizing the need for
(vaccine specific) information.
Lack of information obviously hampered vaccine uptake, but also
the choice of the vaccination venue has influenced parents' decision.
Especially during the FGD it became clear that school-based pro-
grammes were preferred over the current hospital-based programme
and also the quantitative study revealed that time constraints had
hindered women in vaccinating their daughter. Bringing the vac-
cine to the community was considered the right approach. In gen-
eral, schools are promoted as an effective place to reach the target
group and several demonstration projects have achieved good cov-
erage with this approach. However, as with outreach vaccination,
school-based programmes require movement of health staff and vac-
cines, which brings extra costs along. So while this strategy might be
more attractive for potential participants, eliminating practical bar-
riers, it does ask for more investments from the health care system
and, in addition, the schools [113], [138].
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11.1 Determinants of successful health pro-
motion
During the FGD, participants were asked what they understood
by cervical cancer and how they thought it was caused. Surprisingly,
HPV was hardly mentioned even though some of the fathers reported
having discussed cervical cancer with their wife - who had received
direct information during the baseline interview and a leaflet to take
home afterwards - and some of the teachers had been involved in
the vaccination programme that had taken place in their school. As
a result, one can doubt the adequacy of the information that was
passed (basic concepts about cervical cancer and HPV transmission
were communicated). On the one hand, the messages might not have
been adapted to the audience so more attention to health literacy
could resolve this problem. On the other hand, providers' skills
to communicate appropriately with the community, i.e. teachers
and parents, might have been sub-optimal. In that case, improving
(cultural) competency of providers should be the focus.
11.1.1 Health literacy
Evaluating the four competences of health literacy - to access, un-
derstand, appraise and apply health information (table 3.1 [191] -
in the context of the HPV vaccination programme in Eldoret, im-
plies that potential participants had to have access to information
on determinants and risk factors of cervical cancer in the first place.
Additionally, given the role that teachers were given in the promo-
tional strategy, they too had to receive adequate information: not
only to convince them to support HPV vaccination but also to en-
able them to pass the information to the students and parents. Given
that mothers and fathers who participated in the study reported to
have received insufficient information, it is clear that health care
promoters from the vaccination team should have put more effort in
spreading information, among teachers and directly among parents
(and students). However, one can also question whether the parents
themselves also had a responsibility in obtaining information. Given
that women knew, from the baseline interview, that a vaccination
effort would take place in the hospital, they could also have actively
searched for information regarding HPV vaccination.
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Secondly, even though information is spread, receivers need to un-
derstand and process the information. Were people capable to com-
prehend and evaluate messages regarding cervical cancer and HPV
vaccination? And finally, was the provided information applicable
to their vision of health and disease? Reactions of participants dur-
ing the FGD suggest that they did not always use the information
as expected or that the given information was not compatible with
their idea of cancer.
Applying Stuart Hall's theory of encoding and decoding (1980)
might help here to clarify the hampered flow of communication [263].
Encoding, defined as the process to transfer ideas and feelings into
messages, could have gone wrong if providers were not capable of
passing the information in a clear, culturally acceptable way (cfr.
cultural competence below). Additionally, there is little or no re-
search done regarding how the HPV vaccine promotional messages
are decoded, i.e. how they are interpreted and which ideas and
feelings they convoke among the target group. Studies that have
started addressing this issue, tested for example whether focussing
on either cancer, warts, or STI prevention influenced people's ac-
ceptability towards HPV preventive measures: Cancer prevention
seems to be more appealing yet more research is needed before res-
ults can be generalized [264][266]. Other studies have investigated
different communication styles, such as attribute and goal framing.
The former compares positive messages regarding the vaccine's ef-
fectiveness (able to prevent HPV types causing 70 percent of cervical
cancers) versus negative ones (the vaccine is ineffective against 30
percent of cervical cancer causing HPV types) [267], while the latter
refers to either stressing gain (benefits of the vaccine) or loss (costs
of not receiving the vaccine) [268][270]. Current results are not
conclusive but tend to favour positive goal framed messages (gain-
framed), just like a meta-analysis of Gallagher et al. (2012), evaluat-
ing the effect of messages on attitudes towards preventive behaviour,
concluded [271]. More research is necessary to better understand
why different promotion styles evoke different reactions and to dis-
tinguish the effect of personal and cultural characteristics on inter-
pretation of preventive health promotion. A study in the USA, for
example, found that goal framing had a different impact on African-
Americans and Hispanics compared to non-Hispanic whites [270]. It
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is quite likely that people with different cultural backgrounds and
frameworks of illness and disease prevention respond differently to
health messages. Definitely in Sub-Sahara Africa, where health be-
liefs might substantially differ from the Western view, the effect of
health information and how it is integrated in the existing model of
cancer needs to be unravelled. More qualitative research regarding
people's perspectives on the functioning of the body and on illness
would be a first step to do so, combined with in-depth investigation
on how messages derived from Western medicine are interpreted.
Such studies would benefit from a phenomenological approach since
this would help describing and interpreting people's experiences with
disease and preventive medicine [272]. Furthermore, these studies
are extremely timely now medical information becomes more easily
available through all sorts of media.
11.1.2 Cultural competence
In order for the general public to understand health related mes-
sages, the information needs to be tailored to the audience. But
also the health staff, who are the messengers, needs to be capable
to reach and convince the clients. In a Kenyan setting, physician-
patient communication might be hampered by socio-economic bar-
riers but also by cultural ones. First of all, Kenya is a multi-cultural
society, including many tribes (accompanied by different languages)
and religions, each with their own perspective on health and medi-
cine. Secondly, adoption of Western views by medical staff during
their training might move them away from their own and their pa-
tients' cultural background. As such, sharing the same nationality
might not be sufficient to cover the discordance between providers
and clients.
Miscommunication might especially occur when providers only
use the Western biomedical template of disease and illness rather
than applying other cultural patterns. Following Habermas' theory
of Communicative Action, Mishler (1984) identified two voices in
doctor-patient interviews: the voice of the lifeworld and the voice of
medicine. The former refers to the patient's subjective experience of
illness and prevention, while the latter is the objective, scientific ac-
count of the biological manifestations of a disease or in this case the
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efficacy of a preventive method. Barry and colleagues (2001) then
further classified several communication styles: 1) strictly medicine,
when provider and patient both use the voice of medicine, 2) mutual
lifeworld, when the physician acknowledges how the patient exper-
iences health and illness, 3) lifeworld ignored, when the physician
holds on to the voice of medicine while the patient expresses him or
herself through the voice of lifeworld, and finally, 4) when the phys-
ician does not react to lifeworld expressions [273], [274]. This study
did not determine the presence of these different voices in promo-
tional activities carried out during the HPV vaccination programme.
Future projects might need to focus on the communication styles of
providers to gauge their impact on effective vaccine promotion. In
addition, just like it is important to understand the perspective of
the patient, also the experience of the providers can learn us more
regarding vaccine counselling sessions. As such, phenomenological
studies should not only be carried out to understand the patients'
view, as mentioned above, they can also help to explore providers'
experiences with regard to vacine promotion [272].
With this in mind, providers should also be sufficiently trained
to acquire good communication skills and to enable them to recog-
nize the cultural mix they are confronted with on daily basis and
the socio-cultural barriers that might impede them to transfer mes-
sages efficiently: conscious or unconscious stereotyping shapes their
behaviour and decisions during consultations and health promotion
activities. Knowledge about particular cultural beliefs, values and
practices is important to hypothesise about an individual's perspect-
ive, as well as the capacity to assess the degree to which the indi-
vidual adheres to the cultural background. As such, cross-cultural
expertise can significantly improve providers' persuasiveness. A first
step towards a cross-cultural competent health system is however ac-
knowledgement of the importance of culture and disentangling social
factors (economic and educational status) from cultural ones [275]
[277]. Only then, models of prevention interventions can be cultur-
ally adapted, i.e. can become responsive to the cultural needs of the
community by addressing core values, beliefs and norms of the target
group's views and lifestyles. Finally, this approach also contributes
to health equality as it diminishes discrimination of subgroups [278].
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11.2 The role of the service delivery plat-
form
Communication strategies addressing all members of society are
crucial to establish an accessible health system for all. Yet, choosing
the right service delivery platform might be equally important. As
witnessed during the demonstration programme in Eldoret, which
used a hospital based approach, a certain wait-and-see approach was
adopted justified by awaiting potential side effects among the vaccin-
ated. However, discussions with the vaccination team (vaccinators
and programme coordinator) revealed that after the vaccination op-
portunity was opened up to the whole community - as opposed to
targeting only ten public primary schools initially - some schools
were capable in reacting promptly and organized transport for their
pupils to go for vaccination. This raises the hypothesis whether
school-based vaccination might be able to totally eliminate health
inequality: schools with better capacity to organize and follow-up
a vaccination programme - often private schools - will easily obtain
better results in terms of coverage and completion of the vaccination
schedule.
In general, school-based vaccination is however considered a de-
livery method through which the target group can be easily reached
(conditional on sufficiently high enrolment and attendance) [113],
[142]. But besides the above-mentioned risk of unequal uptake among
schools, there is also the question on how to reach non-school going
girls. Or, for example in South-Africa, the national programme only
includes government schools, assuming that families with daughters
in private schools can organize and pay for HPV vaccination them-
selves [279]. School programmes should be combined with community-
based or health centre-based vaccination efforts in order not to miss
out the opportunity to improve health equity regarding cervical can-
cer.
Finally, HPV vaccination might be considered as a momentum
to introduce or fortify school health or more in general, adolescent
health. Adding other important health services to HPV vaccination
could help establishing routine HPV vaccination. Several options are
possible, going from sexuality education, to de-worming or eye check-
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ups [280]. MacPhail et al. (2013) also recommended to evaluate the
local context when considering additional health services to take into
account not only local priorities but also regional resources available
[281].
11.3 Vaccine confidence, complacency and
convenience
It is clear that the synergy between communication, i.e. promo-
tional activities, and service delivery is crucial in order to obtain
high vaccine uptake. Both components need to convince the tar-
get group of the need, the safety and efficacy of the vaccine, while
limiting potential barriers. Taking in mind the three C's as cru-
cial factors for vaccination, we can reflect on the HPV vaccination
programme in Eldoret and how the promotion strategy and service
delivery influenced these three crucial variables.
Vaccine confidence: lack of trust in vaccine or provider.
There are various reasons related to confidence why participants did
not vaccinate their daughter against cervical cancer. As mentioned
before, fear of side effects was among many participants. This is
partially due to the newness of the vaccine but also the promotion
activities, i.e. teachers informing parents and students, might have
affected trust: are teachers considered a reliable source of inform-
ation? While schools might be a good venue, participants of FGD
did express the wish to be informed by health professionals. A bit
contradictory to this, is the request of participants to vaccinate in
schools, instead of health facilities, because of the low quality of ser-
vices offered in the hospital. Improving quality of care, including
communication skills of health staff, seems necessary to boost the
confidence towards the health facilities in general (definitely when
school vaccination is not an option). However, vaccine confidence
went beyond trust in medical science and health systems, as ex-
pressed by worrying about possible experiments of the pharmacy
or potential infertility. Unfortunately, these concerns derive from
a general distrust towards the West due to (past) domination and
exploitation, as well as from internal tribal conflicts where fertility
is considered necessary to maintain power. Support by important
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influencers, e.g. (local) politicians, can take away this fear yet they
also need to gain confidence in new vaccines.
Vaccine complacency: not perceiving the need, not valu-
ing the vaccine. Results regarding perceived risks were contra-
dictory: quantitatively, mothers reported that is very likely for their
daughter to develop cervical cancer while qualitatively, teachers and
fathers reported that cancer is not a disease that strikes them (as
opposed to people with a 'modern lifestyle'). Given the low up-
take, the susceptibility mentioned by the women might have been an
overestimation (due to social desirability) or the risk of the vaccine
out-reached the risk of the disease. Again, better communication
can tackle vaccine complacency but also good cancer registration
and provider-patient communication can help combating the belief
that cervical cancer is not common among the general population in
Kenya. Finally, certain service delivery operations might also affect
complacency, more particularly defining the target group. While the
quantitative study did not identify age of the daughter as a determ-
inant for HPV vaccine acceptability or uptake, including slightly
older girls in the target group might facilitate vaccination: given the
difficulty to discuss cervical cancer, older girls might eliminate this
discomfort.
Vaccine convenience: access. Participants of the qualitative
component called for 'bringing the vaccine to the community' instead
of parents taking their daughters to health facilities for HPV vaccin-
ation. School-based vaccination was one of the preferred options, but
other venues (church, markets, etc.) would do as well. From this we
can conclude that indeed the convenience for the parents - as long
as the health system reaches out to them and not the other way
around - is priority. However, when vaccine confidence is high and
complacency is minimized, people might be willing to invest more in
HPV vaccination, i.e. take on a more active attitude and responsib-
ility towards cervical cancer prevention. In this light, the question
remains to what extent sensitization, which provides understanding,
is important, and to what extent the type of delivery, which might
induce or lift up barriers, influences people's vaccination behaviour.
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11.4 Vaccine hesitancy
Given the wait-and-see approach reported by participants of this
study, it seems appropriate to consider the possibility that vac-
cine hesitancy influenced the HPV vaccination programme in El-
doret. Another observed sign of vaccine hesitancy is the measured
intention-behaviour gap: many participants were probably still in
the decision making process, hence the discordance between (over-
)expressed intention and uptake. The large group of participants re-
porting at follow-up that they had wanted to vaccinate their daugh-
ter but had not managed to do so is however worrisome, as is the
poor support of the teachers. These results hint that there are many
hesitant people in the community with little interest in vaccination
or maybe in cancer prevention in general. If they remain indifferent
towards sensitization, their reported intention might never be con-
verted in vaccine uptake. Wegwarth et al. (2014) looked into the
effect of balanced versus unbalanced messages, defining balanced
as correct (evidence-based), transparent (risk presented in absolute
numbers, providing a reference class) and complete information (i.e.
pointing out both harms and benefits of the vaccine). They found
that stated intention to vaccinate was more reliable among the parti-
cipants who received the balanced information, i.e. the information
helped them translating their intention into behaviour [282]. Com-
munication is thus a tool to eliminate vaccine hesitancy and to push
people towards action. On the other hand, if service delivery op-
erations limit the effort of the parents, for example through free
school-based vaccination requesting active opt-out, also more chil-
dren could receive the vaccine, with or without parents' conscious
decision.
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Chapter 12
Conclusions and
recommendations
12.1 Principal findings
Measured HPV vaccine acceptability is often high but does not
always reflect behavioural intentions or does not always translate
into uptake. While it is a precursor of behaviour, i.e. an essential
step in the pathway of decision-making towards vaccination, its pre-
dictive value depends on certain conditions. Indeed, many factors
moderate the relation between acceptability and uptake, or influ-
ence uptake directly. A first important determinant is awareness
and knowledge of cervical cancer and HPV vaccination. People's re-
ported acceptability will miss out stability and truthfulness if they
are not familiar with the disease or the concept of vaccination. As
such, socially desirable answers, desires or even guesses will occur
more frequently, hampering the link with vaccine uptake. Secondly,
volitional control is crucial as it determines who will be responsible
for the final decision. Assessing acceptability among those without
a certain level of freedom to act will thus also lead to a poor asso-
ciation with behaviour. Finally, many factors beyond personal con-
trol, especially organizational factors, can interrupt the intentional
behaviour if they were not taken into account or changed since the
moment of formulating the willingness to vaccinate.
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Besides the acceptability-behaviour gap, also other attitudinal
factors loose predictive power due to the above-mentioned factors.
For example, estimating the threat of an unknown disease or the
cue that would trigger an new action is challenging. And also the
outcome variable itself plays a role in the strength of the correlation:
new actions are more difficult to evaluate and rely on trust or past
experiences of similar behaviour. This should be taken into account
when health behaviour theories are chosen as to help identifying
determinants of acceptability and/or behaviour.
The failure to find strong associations between several constructs
of the pathway of decision making, and more particularly between an
antecedent and the behaviour, is mainly driven by non-compliance,
i.e. people do not fulfil their own expectations. While non-believers
primarily need information in order to be persuaded by the im-
portance and benefits of HPV vaccination, non-compliers need both
(practical) information and an accessible vaccine. Therefore, em-
phasis on promotion only versus rolling out an accessible vaccina-
tion strategy will lead to vaccine uptake among people with different
points of view and different levels of willingness to invest in vaccin-
ation: the first approach will lead to vaccination among those who
rely on information and who, once convinced, are willing to invest in
it. The latter strategy will stimulate vaccine uptake among people
who might be less interested but are willing to vaccinate given the
small effort it takes them. Ideally, vaccination programmes focus on
both components as to reach as many people as possible.
12.2 Future steps
Formative research, as has been done, has helped identifying know-
ledge gaps or gauging expected barriers, but has however mainly
focussed on vaccine acceptability. As discussed above, this con-
struct might not cover all aspects of the decision-making process
and might not always lead to vaccine uptake. Measuring vaccine
hesitancy, and its determinants confidence, complacency and con-
venience, might offer a better insight in the 'state of preparedness'
and willingness of people to vaccinate against HPV. Similarly, in
addition to investigating the constructs of the HBM in particular
and of health behaviour theories at personal level more generally,
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factors at higher levels should get more attention as to better un-
derstand vaccine uptake. Combining constructs of different theories
such as the HBM, the TPB or the socio-ecological model might lead
to stronger predictions [210].
Furthermore, implementation studies, assessing users' perspect-
ives, can contribute a lot to the understanding of uptake of pre-
ventive behaviour by identifying true benefits, barriers or cues, as
opposed to those mentioned in hypothetical situations [213]. As
such, besides preparing the introduction of a vaccine by formative
research, implementation itself needs to be carefully monitored, con-
tinuously assessing attitudes and uptake:
• Attitudes, through open communication with the community,
as to timely detect vaccination hesitance, rumours and doubts
and to tackle them with tailored sensitization.
• Uptake, through vaccine registration, as to verify if the deliv-
ery platform is reaching the entire, previously identified target
group.
In order to address specific concerns timely, surveillance sys-
tems should be put into place to measure uptake and to monitor
vaccine acceptability [230], [283] and more broadly vaccine hesit-
ancy. Therefore, validated and standardized tools are needed to
gauge vaccine hesitancy and its determinants in different settings.
A first survey measuring vaccine hesitancy has been developed by
the SAGE Working group (2015) yet it still needs to be validated
and tested [226], [284].
Finally, strategies need to be developed to, once identified, address
vaccine hesitancy. Given the complexity, there is however no single
intervention to address all types and aspects of hesitancy: tailored
interventions are necessary to cover the specific concerns of each
group. Of course, lessons learned should still be shared; a review
of interventions found that uptake was most likely to increase if
strategies either
1. directly targeted under-vaccinated populations,
2. aimed to increase knowledge and awareness,
3. improved access to vaccination,
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4. targeted specific subgroups,
5. mandatory vaccinations or sanctioned non-vaccination, and/or
6. engaged religious or other influential leaders to promote vac-
cination.
Regarding the tools that can be used, interventions can be dialogue-
based or apply incentives or reminder-recall systems. In general,
evidence for successfully increasing vaccine uptake is often still rely-
ing on traditional tools, such as passive information sharing (leaflets
or mass media campaigns), and do not fully address vaccine hes-
itancy. Especially in LMIC, carefully planned interventions with
strong evaluation components are needed to better understand and
counteract vaccine hesitancy [234], [285].
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12.3 Limitations
This research study was set up around an HPV vaccination pro-
gramme which was an independent effort from health care providers
of the referral hospital of Eldoret, Kenya. While this is also def-
initely a strength - research results are not biased by conflicts of
interest - it also brings along some limitations.
First of all, the decision of the programme makers to open up
the vaccination opportunity to more than the ten initially selec-
ted public schools, resulted in the fact that the entire target group,
the denominator, of the programme was no longer identifiable. As
such, we could only report coverage among our study participants
which is independent from the actual coverage reached by the pro-
gramme. Furthermore, by not including people who were included
in the second wave, we could not verify whether they differed from
the first group in socio-demographics or attitudes towards cervical
cancer vaccination.
Secondly, promotional activities among the different schools were
poorly recorded. The idea to track them down during the FGD with
the teachers and parents resulted also to be difficult given that so
few people had heard of the programme or remembered how it was
announced. While this is of course also an important result, it did
hamper the analysis in terms of clearly identifying which activities
and which types of messages had persuaded people to vaccinate their
daughter.
Finally, because of the fixed vaccination strategy - which was in
the context of Eldoret and the financial situation of the programme
makers definitely a justified choice - no comparison between different
delivery strategies or promotional campaigns could be made. In or-
der to identify the most cost-effective programme different variations
should be implemented and evaluated.
Another shortcoming of this study is that while we critique the
misuse of health behaviour theories and the lack of clear definitions
of constructs, we also have mixed the use of several antecedents of
behaviour, such as acceptability, intention and willingness to vaccin-
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ate. However, it was not our intention to propose new definitions
or differentiate one of the other. Rather, we aimed at showing as to
why these constructs need to be questioned and better defined.
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